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Abstract
Lipopolysaccharide (LPS: endotoxin) is an essential part of the outer membrane of
the Gram-negative cell envelope, and is recognized as one of the potent inducers of
immune responses. Endotoxin is also recognised as the main cause of the events
leading to septic shock since it is believed that a huge amount of endotoxin crosses
the intestinal barrier to reach the blood circulation. Although it is essential to try to
identify the interactions between endotoxin and the innate immune mechanisms in
particular, it is not possible to isolate these interactions from other possible
interactions with other cell wall related structures of protein or polysaccharide origin.
This was the reason for the first approach of this study in which different LPS
extraction methods were utilized to investigate the differences between them in terms
of producing proinflammatory immune response. A further application of a
repurification method was to eliminate any possible protein contaminants. These
purified LPS preparations were used for the other main approach of this study in
which different unpurified and repurified Bacteroides fragilis LPSs together with
different heat killed B. fragilis populations were examined to elucidate their Toll-like
receptor (TLR) specificity.
Four different extraction methods were chosen to extract LPS from Escherichia
coli 018K-, Pseudomonas aeruginosa Pa-Ol, Bacteroides fragilis NCTC 9343 and
Rhodobacter sphaeroides NCIMB 8253. All of these species, except of R.
sphaeroides, were able to stimulate the production of proinflammatory cytokines
TNF-a and IL-1 (3 with differences apparent between different LPS preparations
according to their extraction methods. R. sphaeroides LPS was able to inhibit the
ability of these LPSs to induce TNF-a production except for B. fragilis LPS which
was not effected by R. sphaeroides LPS. All different B. fragilis LPSs showed the
ability to exert an antagonist effect on different E. coli LPSs on production of TNF-a
or IL-1 (3 from both human monocytes and THP-1 cell lines, which indicated that
xiv
there was not such a profound effect of the extraction method in totally changing the
bioactivity of specific LPS. Moreover, unpurified or purified LPSs of B. fragilis on
the one hand and heat killed bacteria of B. fragilis from different capsular
polysaccharide populations on the other hand all showed an obvious TLR2 signalling
specificity but not TLR4 specificity. This adds further evidence that different LPS
extraction methods with or without applying a repurification procedure do not
change the TLR specificity of the B. fragilis LPS.
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1.1 General structure of lipopolysaccharide (LPS)
1.1.1 General view
One of main dissimilarities between Gram-positive and Gram-negative bacterial cell
walls is that the latter contains an inner and outer membrane. Lipopolysaccharide
(LPS) is an essential part of the outer membrane of the Gram-negative cell wall. LPS
and endotoxin are terms that describe the same molecule. LPS usually refers to the
chemically purified form of the molecule whereas it is called endotoxin when it is
found inside the host (Radon, 2006). The discovery of endotoxin by Richard Pfeiffer
in 1892, as a determinable bacterial structure, paved the way to understand how
microbes create disease (Beutler and Rietschel, 2003). According to current
knowledge, lipopolysaccharide is considered to be a fundamental structure for the
viability of all Gram-negative bacteria and one of the most powerful microbial
inducers of inflammatory immune responses (Alexander and Rietschel, 2001;
Dobrovolskaia and Vogel, 2002). However, two exceptions to this rule have been
observed. Firstly, some bacteria contain glycosphingolipids rather than LPS.
Secondly, an LPS-deficient mutant ofNeisseria meningitidis was described that has
the required viability for survival (Gronow and Brade, 2001).
Since the 1950s, techniques of extracting and purifying lipopolysaccharide have been
developed. These have been used to verify its basic structure by adapting and
applying methods linked to sugar and lipid chemistry (Caroff et al., 2002). In this
regard, it is known that each single bacterial cell contains about 3.5xl06 molecules of
LPS (Rietschel et al., 1994) and every LPS molecule has a molecular weight that
varies between 2000 to 20,000 (Caroff et al., 2002). 75% of the bacterial surface area
is assumed to be occupied by LPS molecules which represented about 10-15% of the
total molecules in the outer membrane (Lerouge and Vanderleyden, 2002). The
lipopolysaccharide structure is conceptually heat-stable, non-proteinaceous and
consists of lipid and carbohydrate (Erridge et al., 2002; Dixon and Darveau, 2005).
Having carbohydrate linked to a lipid is a general method for firmly attaching a
hydrophilic biopolymer to the outer surface of a membrane (Wilkinson, 1996). As a
general guideline, LPS represents a particular family of polymers which (a) are part
of the outer membranes of Gram-negative bacteria, (b) contain a distinctive
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phospholipid anchor "Lipid A", (c) are built according to a common and principle
design and (d) possess specific biological properties in term of endotoxicity and O
antigenicity (Wilkinson, 1996).
With regard to their general structural architecture, all forms of LPS are comparable
(Heumann and Roger, 2002). Structurally, most types of LPS are composed of three
characteristic segments: (a) a conserved hydrophobic Lipid A moiety embedded in
the membrane, (b) the core oligosaccharide, and (c) the O-specific polysaccharide
chain which is called O-antigen (Hurley, 1995a; Wilkinson, 1996; Caroff et al.,
2002; Dixon and Darveau, 2005). In a manner consistent with the general LPS
architecture, there is a huge diversity of natural structural alternatives that are mainly
due to an enormous variety in the chemical composition of the polysaccharide
region, followed by the less diverse core region and finally the reasonably conserved
Lipid A region (Alexander and Rietschcl, 2001; Dobrovolskaia and Vogel, 2002).
Conserved domains of LPS are common in bacterial species and contain essential
components which maintain either the integrity and/or preserve the whole structure
and survival of the bacterium itself. The variable domains represent those parts
which are not critical for the bacterium and lacking them does not lead to devastating
consequences. In fact, lacking of such variable domains may also have an
advantageous nature for the microbe itself.
Generally, alterations in the length of the segment within these domains can result in
simple variations of LPS. On the other hand, changing the overall chemical
construction or attached charge groups can have remarkable effects which, in turn,
can damage the overall structure (Dixon and Darveau, 2005). Nevertheless, typical
LPS containing all three segments is found in Escherichia coli and other bacterial
species related to enterobactcria and is often called smooth or S-form chemotype of
LPS (Morrison and Leive, 1975; Poxton, 1995; Wilkinson, 1996; Amor et al., 2000;
Beutler and Rictschel, 2003). On the contrary, the genus of Sphingomonas is so far
the only group of Gram-negative wild-type bacteria which do not express LPS.
Instead, the outer membranes of these microorganisms have been shown to contain
glycosphingolipids (Kawahara et al., 1991).
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1.1.2 O polysaccharide
Isolates of the families Enterobacteriaceae, Pseudomonadaceae, Pasteurellaceae and
Vibrionaceae, as well as many other Gram-negative bacteria form a smooth LPS
molecules (S-form) in which O-specific chain consists of a maximum of 50 repeating
oligosaccharide entities composed of 2-8 monosaccharide moieties in a highly
specific style (Alexander and Rietschel, 2001; Raetz and Whitfield, 2002). Bacterial
species from the Enterobacteria can synthesize O-specific domain since they have the
responsible gene cluster which is called wb or rfb. So it is unequivocal to extrapolate
that bacterial mutants having either defect in, or loss of, this locus synthesize O-
polysaccharide deficient LPS which is historically known as rough (R-form)
chemotype or deep rough mutants (Rietschel et al., 1994; Poxton, 1995; Alexander
and Rietschel, 2001).
The terms O-specific polysaccharide and O-antigen are often interchangeable in view
of the fact that the O-polysaccharide is the outermost domain of LPS thus it is a very
exposed antigen targeted by highly specific host antibody response (Erridge et al.,
2002).
It is worth mentioning the general functionality of the O-polysaccharide domains of
LPS since it gives a protective role against host antibacterial defences such as bile
acids and cationic peptides or Lipid A recognition receptor (Alexander and Rietschel,
2001).
Generally, the O-specific chain is characterized by a remarkably high structure
changeability in term of nature, ring form, sequence, substitution, and type of linkage
of constituent monosaccharides such as acetyl, ketal, and glycosyl residues
(Rietschel et al., 1994; Keenleyside and Whitfield, 1996; Caroff et al., 2002; Erridge
et al., 2002). In addition to that, such heterogeneity is observed even within a
specified bacterial species, most plausibly because of the same bacteria synthesize
different LPS molecules in term of the length of O-specific chains. In line with the
practicality of this, S-form LPS can be detected as a "ladder pattern" of repeatedly
spaced bands when examined by polyacrylamide gel electrophoresis and stained with
silver (Poxton, 1995; Wilkinson, 1996).
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This heterogeneity provided the chemical basis for the serological specificity of a
particular wild-type bacterial strains based on the surface O-antigenic properties
(Rietschel et al., 1994; Alexander and Rietschel, 2001). For example, there are more
than 170 known O-antigens of E. coli (Amor et al., 2000). Moreover, it is
documented that the O antigen variations between E.coli Ol, 07 and 018 are related
to differences in the nature of pathogenicity (Pluschke et al., 1983b; Achtman and
Pluschke, 1986).
On the other hand, the in-vitro capability of rough mutants to survive and reproduce
indicate that principally the O-chain is not essential for bacterial viability. However,
in tissues or body fluids, many pathogenic Gram-negative bacteria can only survive
by virtue of an O-specific chain which in in-vivo situations protects the bacteria from
phagocytosis and obstruct the access of serum complement to the Lipid A (Pluschke
et al., 1983a; Alexander and Rietschel, 2001; Dobrovolskaia and Vogel, 2002;
Femandez-Prada et al., 2003). Intriguingly, once the reaction between O chain and
complement occurs far away from the bacterial cell surface, complement is unable to
release its effect. By extrapolation, it could be assumed that the long O antigen has
the potential to stop host complement from exerting its ability to lyse bacterial cells.
In comparison with this situation, a short or removed O chain allow direct antibody-
antigen reaction which lead to bacterial lysis (Lerouge and Vanderleyden, 2002).
Another interesting observation obtained from the phenomenon of molecular
mimicry between O antigen from Helicobacterpylori and host antigen in which both
molecules have a close chemical relationship. This in turn, does not allow immune
cell to differentiate between them and as a result an immune response cannot occur
(Appelmelk et al., 2000). However, many studies reported LPS of wild-type species
of pathogenic Gram-negative bacteria such as N. meningitidis, N. gonorrhoeae,
Haemophilus influenzae, Bordetella pertussis or Chlamydia trachomatis as O-
specific chain deficient. These species have the specific ability to colonize the
mucosal surfaces of the respiratory and urogenital tracts. Furthermore, many of these
pathogenic bacteria have been elucidated to express different terminal
oligosaccharide domains, which closely resemble human glycosphingolipids.
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LPS from these species have also been described as low molecular weight LPS
(LMW-LPS) or lipooligosaccharides (LOS) (Preston et al., 1996; Alexander and
Rietschel, 2001; Dobrovolskaia and Vogel, 2002).
Nevertheless, the immunogenicity of O-antigen appears to be dependent on the
adjuvant effect of the lipid-A component of LPS since it is clear that O-antigen
detached from the Lipid A core is not very immunogenic and is often referred to as a
hapten (Reeves, 1995).
1.1.3 Core polysaccharide
Compared with the high variability of the O-polysaccharide region of LPS, the
heterooligosaccharide core of LPS is relatively more conserved. For example,
although there are more than 170 O-antigen for E. coli, only five distinctive
oligosaccharide cores have been determined (Rl, R2, R3, R4 and K12) (Rietschel et
al., 1994; Dobrovolskaia and Vogel, 2002).
According to the current state of knowledge, two main regions of the oligosaccharide
domain are based on sugar composition (Hoist, 1999; Erridge et al., 2002). The
relatively more variable outer core which is classically composed of neutral or amino
hexose sugars such as D-glucose, D-galactose, D-glucosamine, D-galactosamine or
N-acetyl derivatives and the inner core which is attached to Lipid A (Alexander and
Rietschel, 2001; Caroff et al., 2002; Erridge et al., 2002; Raetz and Whitfield, 2002).
The structure of the inner core is very similar between most Gram-negative bacteria
and it contains a L-glycero-D-manno-heptose (Hep) residue and at least one Kdo (2-
keto-3-deoxyoctonic acid) moiety (Schletter et al., 1995b; Nikaido, 2003).
Most intriguingly, unlike O-chain and the majority of the core which arc dispensable,
the Kdo residue is a unique component found in almost all known cores. However,
there is a derivative of D-glycero-D-talo-oct-ulopyranosonic acid (Ko) which
replaces Kdo in species such as Acinetobacter haemolyticus (Raetz and Whitfield,
2002). Kdo is usually considered to be completely vital for the bacterial viability.
Most compelling for this are two observations. The first is that a rough mutant of H.
influenzae contains the smallest saccharide component of LPS of any bacteria which
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has only one Kdo residue attached to the Lipid A (Helander et al., 1988). The second
is that Chlamydia spp have the smallest core ever known in wild type bacteria which
contains only a trisaccharide units of Kdo residue (Rietschel et al., 1994;
Dobrovolskaia and Vogel, 2002; Raetz and Whitfield, 2002).
Such observations demonstrate the importance of the Kdo region as a linkage to
Lipid A and a diagnostic indicator for LPS. In addition studies have considered
producing new antibacterial agents designed to inhibit the Kdo-assembly steps in the
synthesis of LPS (Rietschel et al., 1994; Belunis et al., 1995; Wyckoff et al., 1998).
For the whole inner core, one study on hepatocytes from mice strongly suggested the
presence of a lectin-like receptor for the LPS inner core region (heptose-Kdo region)
on the plasma membrane (Parent, 1990).
1.1.4 Lipid A
Lipid A is the vital structural element of LPS that mediates interaction processes with
the innate immune response (Cadenas and Cadcnas, 2002). It is an extraordinary
glycophospholipid that possesses exceptional structural properties (Poxton, 1995).
There had been numerous observations since the early 1950s that pointed towards
Lipid A as the "seat of endotoxicity". Clear cut evidence came from the comparison
of synthetic Lipid A with "free Lipid A" extracted from the LPS of E. coli. These
studies concluded that both are equal in term of structure and endotoxic activity
(Alexander and Rietschel, 2001; Beutler and Rietschel, 2003).
Hydrophobicity is also a feature that obstructs the complete solubility of Lipid A.
Hence, the reduction of the hydrophobic side chains increases solubility of a
synthetic lipid compound such as E5564 which is well known for being easily
purified and formulated (Rossignol and Lynn, 2002)
At the conceptual level, most bacterial Lipid A molecules have a high level of
structure stability which contributes to the almost optimal endotoxic activity.
Numerous studies established that Lipid A contains: a) disaccharide residues of ((3-
1,6-linkcd D-glucosamine) carrying two phosphoryl groups; a glycosidic (position 1)
and a nonglycosidic (position 4'), b) six acyl groups which contain fatty acids of 12
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to 14 carbons in length, c) asymmetry of the acylation distribution (4+2) (Rosner et
al., 1979; Galanos et al., 1984; Seydel et al., 1984; Tanamoto et al., 1984; Kotani et
al., 1985; Erwin and Munford, 1990; Rietschel et al., 1994; Dobrovolskaia and
Vogel, 2002; Dixon and Darveau, 2005). Nearly all other LPS molecules which
diverge from this structure result in reduced or negligible endotoxic activity.
(Galanos et al., 1985; Rietschel et al., 1994)
Accumulated evidences suggested that the receptor-binding specificity of Lipid A is
determined by its hydrophilic region (phosphorylated-D-glucosamine disaccharide).
Whereas the role in immune cell activation which follows the binding is considered
to be controlled by the hydrophobic region of Lipid A (acyl groups) (Rietschel et al.,
1994; Alexander and Rietschel, 2001).
The highly conservative level of Lipid A architecture which is comparable between
all LPS molecules may lead to conclude that they also have comparable, if not equal,
biological actions. The current state of knowledge though clearly indicated that this
assumption is far from being a general rule. Instead it is considered that dissimilarity
in the Lipid A function is the rule rather than the exception and it closely affects
Lipid A activity. These dissimilarities are based on structural domains like the nature
of hexosamine found, the extent of phosphorylation, the existence of phosphate
substituents and the nature and architecture of acyl groups (Rietschel et al., 1994;
Netea et al., 2002).
Examples of LPS structure with high stimulatory activity are those of E. coli and
many other enterobacterial bacteria such as Salmonella spp and Klebsiella
pneumoniae in addition to nonenterobacterial and enteropathogenic bacteria such as
N. meningitidis (Gronow and Brade, 2001; Netea et al., 2002; Dehus et al., 2006).
Lipid A isolated from other species varies in terms of the existence of 2,3-diamino-
2,3-dideoxy-D-glucose rather than D-glucosamine, the number of acyl groups (4, 5
or 7), chain length, symmetrical allocation (3 + 3 or 2 + 2) or replacement of
phosphate groups (Seydel et al., 2000). Many of the penta-acylated Lipid A
structures fit in this manner. For example, the LPS of C. trachomatis, Rhodobacter
sphaeroides, Rhodobacter capsulatus and Lipid A precursor la (compound 406)
have, in fact, antagonistic actions. Furthermore, some hexa-acylated Lipid A species
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like that from Legionella pneumophila display low endotoxicity because of its slight
modification of an extended acyl groups of at least 18 carbon atoms in length.
Another example of low activity Lipid A is the hyperthermophyle Aquifex pyrophilus
which grows only at high temperatures in the range of 67-95°C. The organism has
LPS characterized by a distinctive Lipid A type which entirely lacks any phosphate
group and having D-galacturonic acid linked to positions 1 and 4' as a substitute
(Alexander and Rietschel, 2001; Netea et al., 2002). Moreover, another study
demonstrated that an intracellular Gram-negative coccobacillus, Francisella
tularensis has a kind of inert LPS which act neither as agonist to stimulate
inflammatory response nor as an antagonist to inhibit other classical LPS (Ancuta et
al., 1996).
Much recent attention has focused on the observation that there is a functional
relationship between the biochemical composition of Lipid A to its three-
dimensional conformation and bioactivity (Seydel et al., 2000). The activity of LPS
molecules which have a conical conformation such as that of E. coli, is exceedingly
high comparing with a cylindrical conformation LPS such as those of precursor la
(compound 406), R. capsulatus or Chromobacterium violaceum (Seydel et al., 2000;
Netea et al., 2002). Factors like the nature, chain length, number and asymmetry of
acyl chains and number and distribution of negative charges, are responsible for such
three dimensional conformation of Lipid A (Rietschel et al., 1994; Schromm et al.,
1998; Netea et al., 2002). More intriguingly, these characteristics lead some
investigators to hypothesize consequently that 'endotoxic activity' is not an exclusive
property of endotoxin, but of any other molecule demonstrating such characteristics




























1.2 Endotoxin and immune response
1.2.1 General view of innate immunity
The basic functions of the innate immunity are recognizing pathogens, providing an
instant obtainable mode of defences without need for previous experience and
induction of the adaptive immunity (Vasselon and Detmers, 2002; Kaisho and Akira,
2006). In comparison with adaptive immunity, innate immunity was believed to be
rather naive until numerous recent studies prove the high level of complexity of the
innate immunity. Endotoxin related studies are considered to be a cornerstone of
such studies (Triantafilou and Triantafilou, 2005).
Predominantly, the innate immunity consists of three main defence categories;
mechanical, chemical and cellular. The mechanical mechanisms include events like
the physical barrier role of the epidermis and mucosa as well as the physiological
functions of cilia action, desquamation and mucus discharge. The chemical
mechanisms can easily be divided into three subcategories: soluble or cell-linked
pattern recognition receptors (PRR), proteins or peptides which have hydrolytic
effect on microbes, and cytokines and chemokines that coordinate the immune
response. The cellular mechanisms includes many types of host cells such as;
epithelial cells, mast cells, dendritic cells, macrophages, granulocytes and natural
killer cells (Basset et al., 2003).
In term of recognition machinery of the microbial product, the main dissimilarity
between both innate and adaptive immune responses relates to the nature of the
receptors. Both T-cell and B-cell receptors of the adaptive immune system are
created throughout the development of these cells, in a way that equips each
lymphocyte with a structurally unique receptor. These receptors are neither encoded
for ever nor are passed on to the next generation. In term of numbers, there are
between 1014 to 1018 different somatically generated T-cell and B-cell receptors
(Medzhitov and Janeway, 2000a).
On the other hand, the innate immune receptors are different in term of their presence
on a variety of host cell types, crucially on immune cells like macrophages, dendritic
cells, most intriguing B cells (the professional antigen-presenting cells) and specific
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types of T-cell, and even non-immune cells such as fibroblasts and epithelial cells.
(Medzhitov and Janeway, 2000a; Akira et al., 2006). Moreover, these receptors have
equal specificities when they are expressed by a particular cell type (e.g.,
macrophages) although some of which shows various degrees of polymorphism
within specific species (Medzhitov and Janeway, 2000a; Vivier and Malissen, 2005).
Moreover, these receptors generate an immediate effects rather than waiting for a
proliferation process (Medzhitov and Janeway, 2000a).
From the structural point of view, pattern-recognition receptors (PRR) contain many
families of protein molecules which include leucine-rich repeat domains, calcium-
dependent lectin domains and scavenger-receptor protein domains. In parallel with
this, the functional role of PRRs can be achieved by three main modes: secretion,
endocytosis and signalling. Mannan-binding lectin is an example of a secreted
pattern-recognition molecule which acts in an opsoninization way by attaching to
microbial cell surfaces and designating them to be recognised by the complement
system and phagocytes. Endocytic pattern-recognition receptors are found at the
phagocyte surface and play an important role in distinguishing specific, highly
conserved structures on a microbial cell and facilitating the uptake of the pathogen
into lysosomes in which they are destroyed. The Toll-like receptor (TLR) family is
one of the important examples of signalling receptors which identify specific highly
conserved microbial structures and stimulate signal-transduction cascades that lead to
the expression of a diversity of immune-response genes, including inflammatory
cytokines (Medzhitov and Janeway, 2000a).
In keeping with the participation of PRRs in detecting different microbial structure,
another functional classification has deepened our understanding of these molecules.
Thus, two functional categories of PRRs can be classified, nonsignalling and
signalling PRRs. Lipopolysaccharide-binding protein (LBP) is a good example of the
former and TLR of the signalling receptor (Kaisho and Akira, 2006).
In contrast to trying to identify every possible antigen, a relatively small number of
innate immune receptors recognize a few highly conserved structures which exist in
numerous microorganisms (Janeway, 1989; Akira et al., 2006). These
microorganism-specific structures are often called pathogen-associated molecular
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patterns (PAMP) and the innate immune receptors which are responsible for
recognizing them are PRRs (Janeway and Medzhitov, 1998). There are many well
known examples of PAMP in the microbial kingdom such as bacterial
lipopolysaccharide, pcptidoglycan, lipoteichoic acids, mannans, bacterial DNA,
double-stranded RNA (Medzhitov and Jancway, 2000a).
Although different examples of PAMPs vary in their chemical composition, they
have three main characteristics in common. Firstly, PAMPs are only considered to be
a microbial structure not present with host molecules or cells. Secondly, PAMPs are
usually vital for either the pathogenicity or the survival of a particular microbe.
Finally, PAMPs of a given microbial class are usually consistent and common within
the entire microbial class (Medzhitov and Janeway, 2000a; Beutler, 2004b; Akira et
al., 2006; Horner, 2006). Being vital for the survival of the microbe provides a
theoretical assurance in keeping the mutation rates at a diminutive level which does
not allow PAMPs to escape from immune recognition (Teixeira et al., 2002; Beutler,
2004b). Noticeably, PAMPs are not exclusive molecules for pathogens but are also
found on non-pathogens such as normal gut flora (Horner, 2006). Therefore, it seems
more accurate to identify them as microorganism-associated molecular patterns
(Cohen, 2002; Kaisho and Akira, 2006).
1.2.2 Functional role of endotoxin
Most Gram-negative bacteria have a mixture of amphiphilic molecules within the
outer membrane. Of these molecules, endotoxin is considered to be of
microbiological and immunological importance as a principal surface antigen (Dixon
and Darveau, 2005). From the host part, the presence of endotoxin, as a PAMP,
distinctly signifies the presence of Gram-negative bacteria as no other PAMP from
other types of organisms can do (Medzhitov and Janeway, 2000b; Medzhitov and
Janeway, 2002).
Basically, endotoxin contributes to the outer membrane of the Gram-negative
bacteria, structurally as a supportive macromolecular domain of the cell envelope
and functionally as is highly anionic and acts as selective permeability barrier to
molecules of either negatively charged and/or hydrophobic domains (Horn et al.,
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1996; Lerouge and Vanderleyden, 2002), adsorption receptor of some bacteriophages
and more obviously is its toxicity and immunogenicity to many higher organisms
(Leive et al., 1968; Morrison and Leive, 1975).
It has been recognized for a long time that highly purified bacterial endotoxin is very
toxic when it is injected systemically and its consequent effect is a pathophysiologic
condition similar to the septic shock condition seen in Gram-negative bacteraemia
(Rietschel et al., 1994; Horn et al., 1996). Furthermore, the capability of endotoxin to
stimulate host responses is not inactivated at very high temperature. For example, it
is only considered to be inactive after 4 hours at 160°C (Radon, 2006). In this regard,
there is a general agreement that endotoxin functions as a molecule that provides
awareness to the immune system of the presence of Gram-negative bacteria within
the body (Horn et al., 2000).
Some early doubts about the way endotoxin might interact with host cells in a
specific way, had been clarified by the substantial progress that has been achieved in
the field of identifying the molecules responsible for sensing of, and interacting with
endotoxin. These studies established the idea of endotoxin recognition via specific
host receptors (Schletter et al., 1995b; Beutler and Poltorak, 2001). So, it is scientific
to postulate that any substance which generates a biological effect at very low
concentration often does so by connecting with a precise receptor that works as a
signal-amplifier (Beutler and Rietschel, 2003).
Unlike many protein exotoxins which act by killing host cells or by inhibiting
cellular functions, endotoxin instead acts non-intrinsically and fundamentally via its
Lipid A moiety. As a prototypical cell inducer, it is capable of stimulating a potent
inflammatory immune response which is entirely conferred by the host itself (Alving,
1993; Rietschel et al., 1994; Bcutler and Poltorak, 2001). Nevertheless, bacterial
components other than endotoxin arc acknowledged to be endotoxic-like biological
inducers such as bacterial exotoxins, lipopeptides, peptidoglycan, lipoteichoic acid
and double-stranded (ds)RNA (Beutler and Rietschel, 2003). Most of the time, the
usual outcome is successful antimicrobial protection rather than lethal toxicity.
On the other hand, low doses of endotoxin showed a beneficial role in term of
stimulate immune response and enhance resistance to infections and malignancies
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(Rietschel et al., 1994; Schletter et al., 1995b). However, in a situation like
endotoxin hypersensitivity, even low doses may be harmful. Bacterial exotoxins,
chronic infection and tumors are considered as a contributing factors for endotoxin
hypersensitivity (Rietschel et al., 1994).
Macrophages are of fundamental importance to the immune response against
endotoxin (Michalek et al., 1980; Freudenberg et al., 1986). Basically, because they
are the main source of tumor necrosis factor alpha (TNF-a) obtained by endotoxin
induction in vivo (Mannel et al., 1980). However, endotoxin can stimulate other host
cells such as endothelial cells, smooth muscle cells and neutrophils, to produce and
release mediators of endogenous origin. These include bioactive lipids (e.g., platelet-
activating factor and thromboxane A2), reactive oxygen species (e.g., nitric oxide),
and, in particular, proteins such as interleukin-l(IL-l), IL-6, and TNF-a. As a rule,
the more endotoxins are released, the more of these mediators are released in a
consequential pattern of the pathophysiological reactions (Rietschel et al., 1994;
Schletter et al., 1995b; Beutler and Poltorak, 2001). TNF-a, is one of the main
contributors to the lethal consequence of endotoxin exposure and its production has
been considered as a biologically significant endpoint of the endotoxin response. For
this reason, macrophages are the most suitable target for the study of endotoxin
effect (Beutler et al., 1985; Poltorak et al., 2000).
In both health and disease, endotoxin is in a continuous dialogue with the host which
develops several mechanisms to deal with various amounts of endotoxin. These
responses depend on physiological, biochemical and biophysical approaches with
the aim of diminishing or removing endotoxin effects. Trying to understand each
individual strategy in isolation from the others is problematical since they evidently
overlap, whether they take place extracellularly or intracellularly (Elsbach, 2000).
As a free or complexed form, endotoxin is released from Gram-negative bacterial
cell either at multiplication or after dying (Darveau, 1998). Consequently, interaction
events take place between endotoxin and the host immune system via a cascade of
molecules either at the site of local inflammation or systemically in the bloodstream.
Some of these molecules are located outside the cell helping in recognition of
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endotoxin while the other are found inside the host cell leading to the activation of
inflammatory immune response (Antal-Szalmas, 2000).
Most of the rest of this section, will concentrate on the extracellular events that occur
either outside or on the host membrane which include a receptors complex (discussed
below) and finally contribute to the inflammatory immune response.
1.2.3 LBP
Lipopolysaccharide binding protein (LBP) is proposed to be the first host receptor
involved in LPS recognition leading to inflammatory immune response (Schumann
et al., 1990).
Lipopolysaccharide binding protein is a 50-kDa polypeptide mainly produced by
hepatocytes and is released as a glycoprotein into the blood circulation (Schumann et
al., 1990). Other LBP producer cells have been recognized including; epithelial cells
of the skin, the lung, the intestine and human gingival tissues in addition to the small
muscle cells of the lung arteries, heart muscle cells and renal cells (Su et al., 1994;
Dentener et al., 2000).
Various human cell line and animal models provide clear evidence that LBP is a
secretory class 1 acute-phase protein (Zweigner et al., 2006). It is considered to be a
member of the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family
which also include bactericidal permeability increasing protein (BPI), the cholesteryl
ester transfer protein (CETP) and the phospholipid transfer protein (PLTP). The
basic activity of these molecules involves their ability to bind both specific lipid
substrates and interact with bacteria and/or lipoproteins (Zweigner et al., 2006).
LBP is principally present in human serum at concentrations of 5-15 (lg/ml (Froon et
al., 1995; Zweigner et al., 2001). This concentration of LBP is increased by 50-100
fold in inflammation status as a result of either the introduce or presence ofmicrobial
stimuli (Schumann et al., 1990; Schletter et al., 1995b; Tobias et al., 1999).
Basically, LBP acts as an amplifying system that alerts host immune cells to the
presence ofminute quantities of LPS (Elsbach, 2000).
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At physiological concentrations, LBP fundamentally enhances the close contact
between LPS molecules, in either free or aggregated form, and other recognition
molecules either in the serum, such as high density lipoprotein (HDL) and soluble
CD14, or on cells, such as membrane CD14 (Yang et al., 1998; Freudenberg et al.,
2001).
The potential consequences for such close contact include cell activation via CD 14
or neutralization of LPS by means of HDL. Accordingly, the way the host responds
to LPS is determined to some extent by the rate of either process. Kinetic studies
revealed in particular that LPS/LBP complexes combine with CD 14 more rapidly
than LPS transfers to HDL . This observation proposes a probable priority situation
in which LPS initially triggers immune cells earlier then it is neutralized in order to
avoid over-stimulation of the response (Heumann and Roger, 2002).
The presence of LBP in a serum-free cell system increases the endotoxin-mediated
stimulation of CD14-positive cells 100- to 1000-fold. It has been shown that LBP
transfers LPS to sCD14 and this can lead to the activation of mCD14-deficient cells
such as endothelial and epithelial cells (Zweigner et al., 2006).
One study assumed that a single LBP molecule has an ability to transfer hundreds of
LPS molecules to CD14 without being consumed by this reaction (Tobias et al.,
1995). Another recent study showed that LBP acts as an integral part of stable
trimolecular complexes in which it interacts with LPS and CD 14. This enables
monocytes, for example, to respond to concentrations of LPS as low as 10 pg/ml
(Thomas et al., 2002).
In laboratory animals, removal or reduction of LBP levels leads to almost complete
elimination of LPS-induced toxicity which shows the need for LBP to transfer LPS
to its receptor complex in vivo. Many studies have shown that compared with normal
wild type mice, LBP-deficient mice were unable to generate a successful early
inflammatory response to Gram-negative bacteria such as S. typhimurium, Klebsiella
pneumoniae, and E. coli as a result of increased lethality because of bacterial
overgrowth (Opal et al., 1999; Branger et al., 2005). In the same context, one study
found that anti-LBP antibodies provide protection for mice from low LPS dose to
endotoxaemic shock (Gallay et al., 1994). Nevertheless, the highly elevated level of
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LBP may display protective effects against LPS by way of reduction of the
monocytes responsiveness to LPS (Freudenberg et al., 2001; Zweigner et al., 2001).
One study showed that introducing recombinant LBP in a high dose of lOOpg per
mouse improved the survival rate of mice injected with either fatal amounts of LPS
or live E. coli 0111 :B4 (Lamping et al., 1998).
There are potential inhibitory mechanisms of LBP that could be mentioned; one is
that LBP has the capability to neutralize bioactive LPS molecules by transferring
them to plasma lipoproteins (Wurfel et al., 1994; Vesy et al., 2000). The second
probable mechanism is that although sometimes LPS-LBP complexes are
internalized by mCD14, they contribute to diminshcd LPS signalling since the
complexes are aggregated in large forms (Gegner et al., 1995). Another inhibitory
mechanism came from a recent study revealing that LBP can dissociate the
attachment between LPS and membrane-bound CD14 (mCD14) to inhibit monocyte
responses to LPS (Thompson et al., 2003). Therefore it is tempting to speculate that
there is a concentration-dependent style for LBP activity in which LBP can mediate
signalling of LPS at all LBP concentrations. Whereas, the inhibitory effects need
rather high LBP concentrations to be significant (Thompson et al., 2003).
In addition to the binding of LBP to LPS, two studies provide evidence that LBP has
an additional ability to bind intact bacterial cells of Salmonella spp. and K.
pneumoniae leading to the clearence of these bacteria via phagocytosis (Wright,
1989; Fan et al., 2002). Although LBP was traditionally regarded as a binding
receptor committed to Gram-negative bacteria (Tobias et al., 1986), recent studies
indicated that LBP has the capability to attach to other bacterial compounds leading
to stimulation of innate immune response. Most of these compounds were found to
be amphiphilic in nature, such as glycolipids or lipoproteins, lipotcichoic acid (LTA)
of different Gram-positive bacteria and LTA-like glycolipids isolated from
spirochaetes. Apparently, since there are different sources of LBP in tissues such as
lung and intestine and due to the soluble character of LBP, it has the ability as an
important defence molecule to distinguish a diversity of bacterial pathogens prior to
the establishment first contact with the immune mechanisms (Schroder and
Schumann, 2005). These observations suggested that apart form the classical role of
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LBP in binding and transfer LPS to the immune cells, it has a more complex
immunomodulatory capability at high concentrations (Zweigner et al., 2006).
In regard to the structural-functional features of LPS, the early evidence that different
LPS conformations interrelate in different ways with specific receptor complexes
came from investigations related to LBP. These investigations revealed that the E.
coli conical shape LPS which has a Lipid A structure consisting of six acyl groups in
an asymmetrical model, attaches firmly to LBP, whereas a more cylindrically formed
LPS, such as that of P. gingivalis with five asymmetrically dispersed acyl groups,
attaches weakly to LBP (Cunningham et al., 1999). For example, LPS from both
Helicobacter pylori and Porphyromonas gingivalis are bound by LBP with low
affinity, less than 10-100 times than E. coli (Cunningham et al., 1996).
1.2.4 CD14
CD 14, formerly known as a monocytc-specific antigen (Van Amersfoort et al.,
2003), is an important receptor since once LBP-LPS complex is accomplished, it is
transferred to either soluble or membrane-bound CD 14 (sCD14 or mCD14).
Therefore, binding to CD 14 is most likely to be the second step in the LPS-signalling
process (Dixon and Darveau, 2005).
In fact, forming a complex of CD14-LPS radically decreases the necessary
concentration of LPS to mediate signalling by 100 to 1000 fold compared to LPS
alone (Landmann et al., 2000). However, CD 14 does not show identical affinity for
all kinds of LPS. For example, one interesting binding study demonstrated that P.
gingivalis, H. pylori and E. coli LPSs bind to CD 14 in different way, and the amount
of P. gingivalis LPS needed to gain half-maximum binding to CD 14 was about 10-
fold more than that ofE. coli LPS (Cunningham et al., 1999).
CD14-deficicnt cell lines like 70Z/3 which is unresponsive to LPS, regain its ability
of sensing LPS after being transfected with human or rabbit CD14 (Lee et al., 1992).
Furthermore, genetically CD14-deficient human monocytes showed low affinity for
LPS binding (Couturier, 1991).
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CD 14 appears to work via concentrating-LPS in a manner which provides a kind of
charged surface which promotes LPS interactions in an electro-static manner
(Wright, 1995). This carrier role of CD 14 is far from being able to distinguish
between different microbial ligands (Delude et al., 1995; Wright, 1995; Cunningham
et al., 1999). Indeed, it seems to be a step of the collection of sufficient LPS for
recognition by a second receptor (Funda et al., 2001). To date, much of the
accumulating evidence indicate that CD14 can not activate the LPS-cell signalling
since it is not a transmembrane protein therefore it does not have an intracellular tail
to deliver the signal (Beutler and Rietschel, 2003; Marshall, 2005).
In addition to LPS, CD14 can bind to a broad spectrum of diverse microbial
structures, suggesting the potential central role ofCD14 as a PPR (Pugin et al., 1994;
Freudenberg et al., 2001). Although it is far from accurate to speculate that this sheds
light on the fact that the clinical picture of sepsis is very similar whether it is caused
by Gram-negative or Gram-positive bacteria, or even by fungi, it indicates that CD14
is probably a common receptor for many different microbial structures (Landmann et
al., 2000). In keeping with this notion, CD 14 functions as a lectin-like receptor to
potentially identify a variety of sugar or glycolipid patterns in microorganisms
(Heumann and Roger, 2002).
CD 14 is also considered as a receptor for pcptidoglycan of Gram-positive cell wall
(Pugin et al., 1994). Not only that, but a recent report indicated the distinctive
importance ofmCD14 as a sensor for fimbriae from P. gingivalis (Hajishengallis et
al., 2006). Recently, other functional roles for CD 14 apart from endotoxin signalling
have been established. These include the recognition and phagocytosis of apoptotic
cells, stimulation of B cells and control ofT cell activity (Jacque et al., 2006).
In a manner consistent with the structural effects of endotoxin on the signalling
process, one interesting study shows that both fully acylatcd LPS and cnzymatically
deacylated LPS (dLPS) can interact efficiently with CD14-LBP complexes but only
the former can go further to mediate effective LPS signalling while dLPS can not
(Kitchens et al., 1992). This observation suggests that the different effects of these
types of LPS takes place subsequent to the CD14-LPS interaction where dLPS can
not stimulate signalling since it is missing the required structural information
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(acyloxyacyl groups) (Kitchens et ah, 1992). In the same context, data from two
studies indicated that neither human nor murine CD 14 have the ability to
discriminate between different Lipid A molecules. This supports the suggestion that
this kind of species-dependent discrimination of Lipid A structures happened at a
step beyond LPS/CD14 interaction (Delude et al., 1995; Muroi et al., 2002).
Nevertheless, epitope-mapping studies demonstrated that CD14 selectively binds E.
coli, P. gingivalis and H. pylori LPSs via hydrophilic domains of the amino-terminal
region of CD 14 and the differences in CD14-affinity might be attributable to the fact
that II. pylori and P. gingivalis Lipid As are monophosphorylated and have few but
longer-chain fatty acids (Cunningham et al., 2000).
Moreover, studies with LPS isolated from E. coli, S. abortus ss equi, S. minnesota, P.
aeruginosa, N. meningitidis, Bacteroides fragilis, and Rhodobacter sphaeroides
illustrated that the presence ofO-antigen, six acyl chains in the Lipid A, and two Kdo
units are important requirements for CD14-dependent responses since wild-type
LPSs which lack an O-antigen and including a short core and one Kdo or even a
phosphorylated Kdo stimulate responses independent of CD 14 (Gangloff et al.,
1999). In keeping with this, recent study has shown that there are a significant
differences between CD14+/+ and CD 14" " mouse macrophages in their ability to bind
smooth E.coli LPS and its various partial structures which do not have an increasing
amounts of carbohydrate. In CD14+/+ cells, sensitivity to different partial structures of
LPS declines in as far as 500-fold below that to smooth LPS. Whereas CD 14" " cell
are incapable to differentiate between smooth LPS and its partial structures.
Additionally, CD14 " macrophages are 150,000-fold less sensitive than CD14+/+
macrophages to smooth E.coli LPS. A comparable capability to discriminate between
different LPS structures of other bacteria such as Bacteroides fragilis and Salmonella
abortus are observed for CD14+/+, but not CD14~/_, macrophages. This would
probably make CD14 a highly specific receptor in term of sensitivity and ability to
distinguish between various LPS ligands (Gangloff et ah, 2005)
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1.2.4.1 Membrane CD14 (mCD14f
mCD14 is a 55-kD glycosyl-phosphatidylinositol (GPI) anchored membrane protein
(Lee et al., 1992; Lee et al., 1993). Numerous host cell types express mCD14 on
their surface. It is found mainly on myeloid cells such as monocytes, macrophages,
polymorphonuclear but it is also present on nonmyeloid cells such as B cells,
gingival fibroblasts, mammary cells, placental trophoblasts, dendritic cells,
respiratory epithelial cells, cornea, ciliary body epithelial cells, uroepithelial, smooth
muscle cells and pancreatic islet (3 cells (Sugawara et al., 1998; Antal-Szalmas, 2000;
Funda et al., 2001; Bas et al., 2004; Jersmann, 2005). Furthermore, human intestinal
epithelial cells have the ability to either express mCD14 or liberate sCD14 (Funda et
al., 2001). The expression of mCD14 on the host cells listed above was shown by
many investigators to be through endogenous production rather than transient
expression by the virtue of sCD14 adsorption (Jersmann, 2005). In term of mCD14
molecules presence, there are an estimated 30,000 - 45,000 mCD14 molecules per
single monocyte based on monoclonal antibodies binding to the same epitope on
human monocytes (Van Voorhis et al., 1983; Vasselon et al., 1997). However,
another very thorough analysis using both reference beads and scatchard analysis
estimation study reported the CD 14 number to be about 110,000 molecules per
monocyte (Antal-Szalmas et al., 1997).
Apart from its role in LPS-signalling, another function of mCD14 is its role as a
signalling receptor for Interleukin 2 (IL-2) in monocytes. This distinctive functional
role has been clearly revealed by using the CD14-deficient human U937
promonocyte cell line which is unresponsive to IL-2. These cells gained the ability
to respond to IL-2 after being transfected with the gene for human CD 14 (Bosco et
al, 1997).
Several studies have confirmed that mCD14 also acts as an uptake receptor for LPS
internalization (Schiff et al., 1997; Kitchens et al., 1998; Poussin et al., 1998; Latz et
al., 2002). In the same context, anti-CD 14 murine monoclonal antibodies (anti-CD 14
mAb) inhibit LPS-LBP complexes from binding to CD 14 in mice experiment and
lead also to the low production of different proinflammatory cytokines (Leturcq et
al., 1996). However, it is observed that specific anti-CD14 mAb can inhibit LPS-
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signalling process without affecting the LPS-internalization whereas other anti-CD 14
mAb inhibit LPS-internalization without altering LPS-signalling effects (Gegner et
al., 1995). Needless to say this means CD14 has a potential dual role in two different
immune mechanisms (as a receptor in signalling process and as a scavenger in
internalization process) otherwise the first impression may give a false conclusion
that CD 14 has two a slightly opposite functions at the same time (Heumann et al.,
2003).
1.2.4.2 Soluble CD14 (sCD14I
Two forms of sCD14, a 56-kDa and a 48-kDa molecule, have been identified in
normal human circulation based on both the molecular weight and mobility (Antal-
Szalmas, 2000). sCD14 serum concentrations vary between 3-6 mg/ml (Bazil et al.,
1986; Schletter et al., 1995a). It is thought that sCD14 has a considerable ability to
mediate the LPS-induced activation of mCD 14-deficient cells such as endothelial
cells (Kirschning et al., 1998; Furst-Ladani et al., 1999; Bas et al., 2004).
Seemingly, sCD14 works in parallel with LBP in the same concentration-dependent
manner. As with mCD14, lower concentrations of sCD14, which apparently are
found in extravascular fluids, mediate a beneficial inflammatory immune response.
On the other hand, moderate to higher concentrations of sCD14 in blood circulation
are found to prevent LPS-induced systemic inflammation (Thompson et al., 2003). In
the latter inhibitory function, sCD14 can challenge mCD14 in a competitive way to
bind LPS which can reduce the endotoxin activity in the end (Landmann et al., 2000;
Bas et al., 2004).
Furthermore, sCD14 acts in a similar way to LBP by enhancing LPS transfer to HDL
to neutralize the LPS. This suggests that both LBP and sCD14 may function as
shuttle molecules for LPS, mediating both stimulatory and inhibitory effects by the
use ofmCD14 and HDL, respectively (Heumann and Roger, 2002).
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1.2.5 Toll like receptors
Although the complete and exact molecules that recognize endotoxin have yet to be
identified, the discovery of Toll-like receptors (TLRs) stand as the main conduit of
the endotoxin transduction mechanism (Beutler and Rietschel, 2003). Not only that
but the discovery of TLRs has had an equal impact on immunology as the
importance of early discoveries of the receptors that serve adaptive immune
response, namely the immunoglobulins and the T-cell receptors (Beutler, 2004a). In
light of this, it is needless to say that TLR immunobiology currently creates a centre
of huge attention more than any immuology research area at the present time (Pandey
and Agrawal, 2006).
TLRs are a family of PRR which consist of type 1 integral transmembrane
glycoproteins which consist of leucine rich repeat (LRR) units in the pathogen-
binding ectodomains (ECD). Signal transfer occurs via intracellular structural
components including an almost identical structure in TLR and IL-1 receptor family
members, called Toll/IL-1 receptor homologous (TIR) domain which represent the
cytoplasmic end. Both ends are linked by a single transmembrane helix (Akira et al.,
2006; Kaisho and Akira, 2006; Pandey and Agrawal, 2006). Moreover, the conserved
TIR domain is found in many transmembrane and cytoplasmic proteins in plants,
worms, arthropods and even bacteria. Interesting all these molecules are found to
have a function in host defence, the feature that makes TIR one of the earliest
signalling domains known (Aravind et al., 1999).
Up to date, 13 mammalian TLR have been recognized, of which, 11 arc known to be
expressed in humans (TLRs 1-11) and 12 are expressed in mice (TLRs 1-9 and 11-
13). Human TLRs are so called because they have a common sequence similarity
with toll protein in Drosophila (Zhang et al., 2004; Kaisho and Akira, 2006). (see
Figure 1.2)
Drosophila toll contributes to both dorsal-ventral patterning in fly embryos and fly
immunity against fungi. Domain similarity in the cytoplasmic area among
Drosophila toll and mammalian IL-1 receptor drove the research efforts to discover a
human Toll which was later designated to be TLR4 (Medzhitov and Janeway, 2000a;
Kaisho and Akira, 2006; Pandey and Agrawal, 2006). Although murine TLR provide
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a very useful tool in this field, there are a number of reasons why care should be
taken into account when comparison are made between human and murine TLRs in
term of functionality and regulatory role. First, there are several variations between
humans and mouse strains in their response to specific PAMPs, like LPS for
example. Second, the regular use of tumour cell lines as a model of TLR regulation
does not show as close a correlation with what happens in primary cells in vitro and
in vivo. Third, even for a specific cell line from a specific species, laboratory
experimental conditions may add an additional limit to cross-species comparison
(Rehli, 2002).
According to both size and inner structure of the ectodomains, human TLR can be
divided into two main groups: TLR1-TLR6 and of TLR7-TLR9 (Chuang and
Ulevitch, 2000; Du et al., 2000). Additionally, TLRs can be divided according to
their cellular location. For example, TLR1, TLR2 and TLR4 are expressed on the
extracellular surface, as verified by positive staining cell with surface antibodies.
Whereas, TLR3, TLR7, TLR8 and TLR9 have been demonstrated to have an
intracellular expression in cellular components such as endosomes (Takeda and
Akira, 2005; Akira et al., 2006).
Identification ofmany of the TLR ligands was revealed via screening experiments of
different kinds of PAMPs in human embryonal kidney (HEK293T) cells which had
been transfected with different TLRs. HEK293T cells are a very useful tool in this
regard since they do not express any of the TLRs (Janssens and Beyacrt, 2003). In
light of this it has become clear that TLRs have the ability to recognize a wide range
of PAMP ligands varying from protozoa, to bacteria, to fungi and to viruses (Beutlcr,
2004a). Those ligands can be divided into three categories based on their structure:
lipid, protein, and nucleic acids (Kaisho and Akira, 2006). For example, TLR1, 2 and
6 recognise PAMPs of lipid or protein origin and TLR7, 8 and 9 recognise nucleic
acids (Akira et al., 2006).
In addition to microbial molecules and non-self ligands, TLRs have the capability to
recognize several endogenous ligands as well. Among these are hyaluronic acid,
fibrinogen, fibronectin, heat-shock proteins, beta defensins and heparin sulphate
(Akira et al., 2006; Kaisho and Akira, 2006; Pandey and Agrawal, 2006)
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However, according to the current picture from different studies regarding the
relation between TLR and their ligands, it is plausible to conclude that there is no
exclusive single TLR dedicated to one group of pathogens. For example, PAMPs of
Gram-negative origin can be recognized by both TLR2 and TLR4. In addition, one
TLR can be signalled by different unrelated PAMPs from different groups of
pathogens. For example, both viral components and Gram-negative LPS are
recognised by TLR4 (Janssens and Beyaert, 2003).
Two main regulatory functional roles of TLRs are currently recognized, the
stimulation of innate inflammatory response and the establishment of adaptive
immunity (Kaisho and Akira, 2006; Pandey and Agrawal, 2006). TLR2 and TLR4
have received the most attention due to their relationship with bacterial endotoxin
(Schaub et al., 2006). These two receptors are discussed below in details.
1.2.5.1 TLR2
Although the picture of the functional role of TLRs is far from being completed,
TLR2 has an extraordinary position among other members of the human TLR family
since it has the capacity to identify a wide range of PAMPs from different kind of
microorganisms including those from Gram-positive bacteria, Gram-negative
bacteria, mycobacteria, fungi, viruses and parasites (Raetz and Whitfield, 2002;
Texereau et al., 2005). Examples of the range of PAMPs recognized by TLR2
include lipoproteins/lipopeptides, pcptidoglycan, lipoteichoic acid,
lipoarabinomannan from mycobacteria, glycosylphosphatidylinositol from
Trypanosoma cruzi, a phenol-soluble modulin from Staphylococcus epidermis,
zymosan from fungi and glycolipids from Treponema maltophilum (Takeda and
Akira, 2005).
Furthermore, the way that TLR2 is distributed through the human body indicates its
central role as a very first line of antimicrobial defence. The cells of hematopoietic
origin especially peripheral blood leukocytes such as monocytes, macrophages,
granulocytes and dendritic cells exhibit the highest expression level followed by cell
populations from the spleen and lung and other kind of cells that have a role in acute
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There are several proposals for the way TLR2, as a single molecule, has the
distinctive capacity to identify a broad range of PAMPs. One explanation proposes
that TLR2 is considered to form a multi-signalling TLR receptor complex by
heterodimerization with other TLRs such as TLR1, TLR6 or other TLRs (Ozinsky et
al., 2000; Takeda and Akira, 2005; Texereau et al., 2005; Triantafilou et al., 2006).
One piece of evidence supporting this mechanism is the observation that TLR6-
deficient mice do not exhibit any inflammatory activity against diacyl lipopeptides of
Mycoplasma (Takeda and Akira, 2005). Although, the same kind of cells
demonstrated normal inflammatory response towards triacyl lipopeptides of Gram-
negative bacteria (Takeuchi et al., 2001). The vice versa situation is applicable, in
which TLR1-deficient mice demonstrated a normal response to the diacyl
lipopeptides and weakened response to the triacyl lipopeptides (Takeuchi et al.,
2002). This shows the potential functional association between TLR1 and TLR6 on
one hand and TLR2 on the other in a way that allow the formation of such
heterodimcr complex to differentiate between diacyl or triacyl lipopeptides (Takeda
and Akira, 2005). Moreover, TLR1 shows its capacity to be involved in the
signalling process against outer surface lipoprotein of Borrelia burgdorferi
(Alexopoulou et al., 2002). The other potential mechanism of TLR2 activity is
demonstrated by the model in which TLR2 act in collaboration with unrelated
receptors other than TLR to recognize different PAMP structures (Gantner et al.,
2003; Triantafilou et al., 2006). The observation that a receptor such as CD36 can
assist TLR2 activity in response to diacylated lipoproteins supports this notion
(Triantafilou et al., 2006). In addition, other observation have shown TLR2 in
collaboration with one of a lectin family receptor, dectin-1, in the recognition of (3-
glucan, a fungal cell wall component (Takeda and Akira, 2005).
To simplify the continuous debate of whether TLR2 or TLR4 is the physiologically
significant LPS receptor, it is important to evaluate every experimental approach in
this regard in terms of cell type used and LPS source (Tapping et al., 2000).
Primarily, TLR2 was acknowledged as an LPS receptor by the result of
overexpression experiments where TLR2 was stimulated with commercial
preparations of LPS (Kirschning et al., 1998; Yang et al., 1998). These findings were
confirmed by several studies (Aliprantis et al., 1999; Brightbill et al., 1999;
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Hirschfeld et al., 1999; Means et al., 1999a; Schwandner et al., 1999; Flo et al.,
2000). In view of such an approach, THP1-CD14 cells that have a significantly high
expression level of TLR2 compared with TLR4, were found to demonstrate high
sensitivity to impure commercial preparations of LPS (Tapping et al., 2000).
Nevertheless, two important studies have demonstrated that this kind of TLR2
activity is attributable to impurities in the LPS that were revealed to be protein or
lipoprotein contaminants. LPS re-extraction methods eliminate the LPS signalling
through TLR2 and confer a TLR4 response (Brightbill et al., 1999; Hirschfeld et al.,
1999; Hirschfeld et al., 2000). At the same time these findings shed more light on the
capacity of TLR2 to recognize LPS-contaminated endotoxin protein (Takeuchi and
Akira, 2002). Although the contribution of TLR2 as a signal transducer for such
LPS-contaminants protein or microbial lipoproteins in general does not exclude the
contribution of other TLR family members in term of combined-TLR signalling
(Brightbill et al., 1999). In the same context, Chinese hamster ovary (CHO) cells
which are known for their sensitivity to LPS (Golenbock et al., 1993; Delude et al.,
1995; Heine et al., 1999), have a nonfunctional version of TLR2 and they showed a
normal response to LPS isolated from Salmonella minnesota R595 (Heine et al.,
1999; Takeuchi et al., 2002).
On the other hand, it is well documented that TLR2 has the capability to recognize
LPS structures from bacterial species other than Enterobacteriaceae such as
Leptospira interrogans, Porphyromonas gingivalis, Helicobacter pyroli (Hirschfeld
et al., 2001; Werts et al., 2001; Smith et al., 2003), Rhizobium species Sin-1,
Legionella pneumophila (Girard et al., 2003), Bacteroides fragilis NCTC-9343,
Chlamydia trachomatis LGV-1 and Pseudomonas aeruginosa PAC-611 (Erridge et
al., 2004b). It was also observed that LPS from Bacteroides fragilis and
Pseudomonas aeruginosa were able to produce a signal in TLR4-deficient
macrophages isolated from C3H/HeJ mice (Delahooke et al., 1995; Girard et al.,
2003). In general, these organisms have different structural features from that of
classical LPS, such as that of E.coli (see section 1.1.4), which is shown to be
recognized by TLR4 instead. These variations, which include the number and the
distribution of acyl chains in the Lipid A component, seemingly lead to a different
recognition style (Netea et al., 2002). The multiplicity of a functional role of the
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conformation types of LPS have shown that conical and cylindrical types of LPS
might attach to and signal different receptor complexes. This was revealed by the
findings that P. gingivalis LPS of cylindrical shape signals cells via TLR2 but not
TLR4, while E. coli LPS of conical shape use TLR4 as a signal transducer
(Hirschfeld et al., 2001; Netea et al., 2002). Intriguingly, LPS obtained from P.
gingivalis is abnormal and highly heterogeneous, containing both tetra- and penta-
acylated Lipid A structures (Darveau et al., 2004a; Reife et al., 2006). Some reports
introduced this LPS as an agonist for TLR2 (Bainbridge and Darveau, 2001;
Hirschfeld et al., 2001; Martin et al., 2001) and other reports provided evidences of
its ability to be either antagonist (Darveau et al., 2002; Hajishengallis et al., 2002b;
Yoshimura et al., 2002; Coats et al., 2003) or even agonist for TLR4 (Tabcta et al.,
2000; Ogawa et al., 2002)
Ofmuch interest, LPS of N. meningitidis appears to signal via both receptors TLR4
and TLR2. Although, N. meningitidis LPS resembles the classical LPS of E.coli in
which it has six acyl chains, these acyl structures are dispersed equally between the
two hexose groups (i.e 3+3 not 4+2). This situation gives it a kind of intermediate
conformation between the conical and cylindrical forms, which, hypothetically,
could provide the opportunity to attach to either TLR2 or TLR4. This is evident by
the findings that high concentration of ultra pure meningococcal LPS still has the
capacity to stimulate macrophages of TLR4-deficient C3H/HeJ mice to produce
TNF-a but at a level lower than that of control C3H/HeN macrophages. This
signifies that both TLR4-dcpendent and -independent signalling pathways arc used
(Netea et al., 2002).
Most recent studies have revealed another dimension to the function of TLR2 as one
of PPR of the innate immunity. Sutmuller and others have demonstrated that TLR2
has an additional function in controlling the activity of regulatory T cells which are
essential cells belong to the adaptive immune system (Sutmuller et al., 2006).
1.2.5.2 TLR4
Many investigators speculated before the discovery ofTLRs that there was a receptor
which was central to LPS signalling, different from CD 14 and expressed on both
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CD14-positive or -negative cells (Kitchens et al., 1992; Pugin et al., 1995; Schletter
et al., 1995a; Vita et al., 1997; Heumann and Roger, 2002). The current main pieces
of evidence supporting the role of TLR4 in signalling the presence of bacterial LPS
are as follows. First, the loss of the LPS response due to specific mutant in Ips locus
in mouse. Second, the finding that the Ips locus is identical to tlr4 and they code for
TLR4. Third, re-extraction of LPS to remove protein contaminants eliminated the
ability of LPS to stimulate cells from the LPS non-responder strain of mice,
C3H/HeJ. Fourth, none of the human or murine TLR2 transfected cell showed
response to either repurifed LPS or protein-free synthetic Lipid A. Finally, the
unresponsiveness of TLR4-deficient mice to LPS challenge (Poltorak et al., 1998a;
Poltorak et al., 1998b; Hoshino et al., 1999; Hirschfeld et al., 2000; Heumann and
Roger, 2002). In general, evidence is accumulating to suggest that, different species
of animals may use different Toll like receptor as a signal transducer for LPS (Heine
et al., 1999; Takeuchi et al., 1999). In the same context, a TLR4 mutation
Asp299Gly that affects the extracellular domain of the receptor and renders it
unresponsive to LPS has been transfected into THP-1 human cell line. However,
human primary airway epithelial cells or alveolar macrophages from individuals with
the Asp299Gly mutation recovered their responsiveness towards commercial LPS
when these cells were transfected with the wild-type allele of TLR4 (Arbour et al.,
2000). Nevertheless, monocytes from another group of individuals with the
Asp299Gly mutations showed LPS response almost identical to that from monocytes
from normal individual when they are both challenged with a panel of seven different
purified LPS preparations (Erridge et al., 2003). Two possible explanation to resolve
this apparent contradiction between these two studies are: first, it may be due to the
difference in TLR4 expression between monocytes and airway tissues. Second, it
may be due the purity of LPS preparations since the former study used a commercial
LPS which is assumed to have a lot of protein contaminants while the later study
used a re-purified LPS preparations (Erridge et al., 2003).
In parallel with this, another study found that the TLR4 knockout mice were
hyporesponsive to a limited, but not all, set of LPS preparations (Takeuchi et al.,
2000). The extracellular domains of both human TLR4 and mouse TLR4 show only
53% similarity, while their cytoplasmic domains are identical by 83% (Anderson,
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2000). Moreover, the LD50 (defined as the quantity of a substance that causes death
of 50% of the animals) for virulent E. coll in C3H/HcJ mice, which have a non¬
functional TLR4, is not more than ten organisms, whereas the LD5o for wild-type
mice is 10 000 organisms. Accordingly, TLR4 seems to contribute to the protection
against septic shock, as a severe complication of an unwanted immune response,
more than acting as a cause of it (Brunn and Piatt, 2006). Although TLR4 mutations
are rare in humans they have been shown to be over-expressed in patients with
meningococcal meningitis or septicaemia (Smirnova et al., 2001; Smirnova et al.,
2003). In a similar study, the most severe symptoms were seen in 91 patients with
septic shock who were genotyped to reveal that they had TLR4 mutations,
Asp299Gly and/or Thr399Ile (Lorenz et al., 2002a).
Two kinds of LPS-hyporesponsive mice are known to be tlr4-gene deficient.
C3H/HeJ mice have a point mutation within the tlr4 gene and C57BL/10ScCr mice
which displayed total absence of the tlr4-gene (Poltorak et al., 1998a; Qureshi et al.,
1999). These two TLR4 deficient mice are well known as LPS-hyporesponsive
(Hoshino et al., 1999). Moreover, mice which have a critical mutational defect in the
Tlr4 locus arc noticeably vulnerable to Gram-negative infections. This indicates how
the recognition of LPS is so beneficial for the host (O'Brien et al., 1980;
Rosenstreich et al., 1982). Functionally, TLR4 acts as the actual signalling piece of
the LPS recognition complex to recruit adapter proteins via intracellular Toll/IL-1
receptor domain which lead to the expression of inflammatory gene transcription
(Marshall, 2005).
Moreover, recent studies suggested that TLRs tend to be expressed during the
immune response event sequentially and in a collaborated order during the course of
an infection such as those caused by Salmonella and respiratory syncytial virus
(RSV). These two pathogens arc initially recognized by TLR4 to activate
inflammatory responses. After a specific period, the TLR4 activation is down-
regulated. At the same time both TLR2 and TLR3 are up-regulated due to the
presence of bacterial lipopeptide, and viral dsRNA, respectively (Haeberle et al.,
2002; Weiss et al., 2004). Furthermore, recent studies have raised the possibility that
the actual number of TLR4 molecules that arc engaged is essential in determining the
type of signal which is going to be triggered (Visintin et al., 2003; Triantafilou et al.,
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2004). This seems that a minimum number of TLR4 molecules are required to attach
to the receptor complex in order to introduce the maximum cellular activation. If this
minimum number of TLR4 is not reached, as in the situation of the LPS antagonists,
a decreased activation is observed (Triantafilou and Triantafilou, 2005).
One of the mechanisms suggested to explain the relation between different
components of the LPS recognition system, postulates the presence of a so-called
proteolytic system between CD 14 and TLR4. In this system a polypeptide signal is
created as a response to the connection between LPS and CD14, and consequently
mediate a response via TLR4 (Wright, 1999). However, this model has high level of
uncertainty since CD14 is not known to have proteolytic activity (Beutler, 2000).
As mentioned earlier, the biophysical properties of LPS molecules are proposed to
play a role in TLR signalling. Many investigators have suggested that the typical
hexa-acyl LPS structure from enterobacteriaceae which have a conical conformation,
is the most favorable structure for TLR4 activation, whereas the penta-acyl LPS of a
cylindrical conformation have a tendency to signal through TLR2 (Schramm et al.,
2000; Netea et al., 2002). It is also found that a tetra-acyl domain of Lipid A alone
does not signal human TLR4, while Lipid A does. The situation is quite different
with mouse TLR4 which is signalled by both intact Lipid A and tetra-acyl Lipid A
(Poltorak et al., 2000). It has been postulated that human TLR4, but not mouse
TLR4, is able to "read" the LPS structure, evaluate the nature of acyl chains and
finally distinguish between Lipid A and tetra-acyl Lipid A (Poltorak et al., 2000).
Moreover, uncommon LPS molecules like Lipid A analogues lipid IVa and
Rhodobacter sphaeroides Lipid A contribute to this TLR4 species-specific variation
in which they both abolish the LPS effects in human cells but show LPS- like activity
in Chinese hamster ovary fibroblasts expressing CD 14 (Lien et al., 2000).
In regard to species-dependent discrimination, two studies found that TLR4 has its
own capacity to differentiate between tetra-acylated Lipid A precursor (also called
compound 406 or lipid IVa) and R. sphaeroides Lipid A. The other explanation for
this phenomenon is the ability of TLR4 to distinguish between the conformation of
CD 14 molecules when they bind different Lipid A molecules (Lien et al., 2000;
Poltorak et al., 2000).
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Noticeably, many of the studies investigating TLR4 as a LPS-signal transducer
picked only classical kind of LPS (sample or control) which are known to signal
through TLR4 such as those of E.coli and Salmonella (see Table 1.1). In fact, more
than 90% of all publications on endotoxin were done with endotoxins from
enterobacteriaceae (Dehus et ai, 2006). Whereas, this kind of investigation require at
least more than one LPS control to support the results from both classical and non-
classical LPSs. For example, one LPS as a TLR4 positive control and another as a
TLR2 positive control since the differences between various kind of LPSs from
different species are now considered to be the rule not the exception.
However, TLR4 is not a dedicated receptor for LPS. A recent study has shown that a
specific viral protein of Hepatitis C virus is recognised by TLR4 resulting in
production of p-Interferon and Interleukin-6 (Machida et al., 2006). Other PAMPs of
different structure that have been found to be recognized by TLR4 include the plant
diterpene paclitaxel and the fusion protein of respiratory syncytial virus (RSV) (Kurt-
Jones et al., 2000; Akira et al., 2006). In addition, TLR4 has been shown to be a
signal transducer for endogenous ligands such as heat shock proteins (HSP60 and
HSP70), the extra domain A of fibronectins and oligosaccharides of hyaluronic acid,
heparan sulfate and fibrinogen (Takeda and Akira, 2005). However, all of these
endogenous ligands need exceedingly high concentrations of TLR4 to be activated
(Takeda and Akira, 2005). These findings need to be appraised carefully since it is
well known that LPS is a very potent immuno-inducer, and therefore, TLR4 can be
activated by a very minute amount of contaminating LPS, that might be present in
endogenous ligand preparations (Takeda and Akira, 2005).
Most recently, two interesting studies have demonstrated further clarification about
the functional role ofTLR4. One of them showed for the first time that TLR4 plays a
role in the induction of fever in mice (Steiner et al., 2006). The other study also
demonstrated for the first time that TLR4 is expressed on both human and murine
platelets (Aslam et al., 2006).
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Tablel.l Examples of LPS preparations used in different studies
Study Type of lipopolysaccharide No of
citations
1 (Kirschning et al., 1998) Escherichia coli 0111 :B4 488
2 (Poltorak et al., 1998a) Unknown LPS 2348
3 (Chow et al., 1999) Unknown LPS 670
4 (Heine et al., 1999) Salmonella minnesota R595 178
5 (Hoshino et al., 1999) E. coli 055:B5 & 5. minnesota R595 875
6 (Takeuchi et al., 1999) E. coli 055:B5 & S. minnesota R595 1137
7 (Yang et al., 1999) E. coli 165
8 (Faure et al., 2000) E. coli K235 210
9 (Hirschfeld et al., 2000) E. coli 0111:B4, J5 , andK12 405
10 (Lien et al., 2000) S. minnesota R595 340
11 (Muzio et al., 2000) E. coli 005:B5 304
12 (Poltorak et al., 2000) E. coli 0127:B8 238
13 (Tapping et al., 2000) E. coli & S. minnesota 135
14 (Naik et al., 2001a) E. coli 0111:B4 61
15 (Gioannini et al., 2004) Neisseria meningitides & E. coli 15
16 (Dehus et al., 2006) E. coli & Salmonella sp. 1
17 (Edclman et al., 2006) E. coli 0
18 (Hirschfeld et al., 2001) E. coli & Porphyromonas gingivalis 226
19 (Pulendran et al., 2001) E. coli & P. gingivalis 156
20 (Hajjar et al., 2002) E. coli & Pseudomonas aeruginosa 122
21 (Lorenz et al., 2002b) E. coli & Bacteroidesfragilis 8
22 (Toshchakov et al., 2002) E. coli & P. gingivalis 256
23 (Erridge et al., 2004b)
E .coli , Yersinia pestis, P. gingivalis,
B. fragilis, Chlamydia trachomatis,
Ps. aeruginosa
27
24 (Mancuso et al., 2005) B. fragilis & Salmonella enterica 4
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1.2.6 Myeloid differentiation protein 2 (MD2)
Myeloid differentiation protein 2 (MD-2) is a homologue of MD-1, a specific
secretory protein found in B-cells (Janssens and Beyaert, 2003). It is a small
cysteine-rich glycoprotein which is known to join with the ectodomain of TLR4.
TLR4 does not have the capacity to transduce LPS signalling unless it is attached to
MD-2 (Shimazu et al., 1999a). It has also been revealed that if MD-2 gene
expression is disrupted in mice, it leads to abolish the LPS signalling thus proving
the importance of MD-2 for the function of TLR4 (Schromm et al., 2001; Nagai et
al., 2002b; Nagai et al., 2002a). Moreover, MD-2 mice were found to be
hyporesponsive to LPS (Nagai et al., 2002a)
To this end, it is widely believed that cellular activation by LPS necessitates the
consequential linkage of a trimeric receptor complex containing mCD14, TLR4, and
the accessory adapter protein MD-2. This protein complex stimulates an intracellular
signalling pathway via kinase cascades and the transcription factor NF-kB to induce
the transcription of several hundred genes that express the phenotype of the
consequential systemic inflammatory response (Akashi et al., 2000; Kennedy et al.,
2004; Marshall, 2005). The idea of close proximity between LPS and the three
proteins complex CD14/TLR4/MD2 is supported by the finding that attachment to
CD 14 exclusively equips LPS to be linked to the TLR4-MD2 complex (da Silva
Correia et al., 2001). It was also found that neither the transfection with TLR4 alone
nor MD-2 alone can contribute to the LPS signalling. MD-2, which is an
extracellular protein without transmembrane domain, stays attached to the surface of
the cell and to the extracellular domain of TLR4 at the same time (Aderem and
Ulevitch, 2000; Akira et al., 2001; Erridgc et al., 2002). Furthermore, the
engagement of LPS/TLR4/MD-2 was found to be in a direct interaction (Akashi et
al., 2003). This was revealed by an approach in which the presence of detergent was
found to interrupt LPS interaction with CD 14 but not with TLR4-MD-2. Moreover, a
lipid A antagonist, E5531, was also found to block LPS interaction with TLR4-MD-2
at a concentration 100 times lower than that necessary for blocking LPS interaction
with CD 14 (Akashi et al., 2003).
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Recent study used LPS forms of wild-type and R-mutants of Salmonella and E. coll,
to show that S-form and R-form of LPS stimulate mouse cells in different ways. The
R-form activates cell signalling instantly via TLR4/MD2 complex, whereas the S-
form activates the same cells via TLR4/MD2 complex with the involvement of LBP
and CD14 (Huber et al., 2006). A recent interesting study showed that human, but
not murine, TLR4/MD2 complex is able to distinguish between the two types of
Lipid A which can be produced by bacterial species like Pseudomonas aeruginosa
which has the ability to vary between hexa- and penta-acylated Lipid A.
Consequently, hexa but not penta-acylated Lipid A, stimulate inflammatory response
through human TLR4-MD2 (Hajjar et al., 2002). Furthermore, it was revealed by
many investigators that MD-2 has the capacity to distinguish between TLR4 agonists
and antagonists (Gioannini et al., 2004). A recent report provides evidence that both
a tetra-acylated P. gingivalis LPS preparation as well as mutant penta-acylated LPS
of E. coli antagonise a hexa-acylated E. coll LPS at the TLR4 signalling complex of
human endothelial cells in a competing manner (Coats et al., 2003) in which MD-2
plays the principal role (Coats et al., 2005).
MD-2 also has a species dependent discrimination activity similar to that of TLR4.
One recent study demonstrated that MD-2 can discriminate between E. coli and
Salmonella Lipid A molecules (Muroi et al., 2002). It was also found that only the
expression of the following murine complexes either CD14/TLR4/MD2 or
TLR4/MD2 allowed THP-1 cells to response to Salmonella Lipid A, but neither
singular expression of the previous molecules, CD14/TLR4, nor CD14/MD-2 confer
the responsiveness to the same Lipid A (Muroi et al., 2002). Moreover, lipid IVa is a
useful tool to study the differences between mouse and human in LPS signalling
since mouse TLR4/MD-2, but not human TLR4/MD-2, transduce lipid IVa
signalling. In light of this, mouse TLR4/human MD-2 (mTLR4/hMD-2) responded
to Lipid A from Salmonella minnesota but not lipid IVa. Findings of this nature
attribute species-specific discrimination activity for hMD-2 as well and demonstrates
that hMD-2 has the capacity to regulate the specificity of TLR4. Not only that, but
lipid IVa operates as a Lipid A antagonist on mTLR4/hMD-2. This situation needs a
physical contact between mTLR4/hMD-2, Lipid A and Lipid IVa (Akashi et al.,
2001).
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In support of the previous finding, another molecule, Taxol which is an antitumor
agent purified from the bark of the Western yew, Taxus brevifolia, can signal
mTLR4/MD-2, but not hTLR4/MD-2. However, it is found that the HEK293 human
cell line transfected with mTLR4/hMD-2 does respond to LPS but not Taxol,
although mTLR4/mMD-2 respond to both LPS and Taxol (Kawasaki et al., 2001).
Additionally, an active form of soluble MD-2 (sMD-2) was observed to be secreted
by primary cells like immature dendritic cells and also by MD-2-transfected cell
lines. sMD-2 seems to have a capacity to bind TLR4 on MD-2 deficient cells and
convert these cells to be responsiveness to LPS (Kennedy et al., 2004). Furthermore,
a recent study demonstrated that the activity of sMD-2 is diminished within 24-h at
physiological temperature unless it is stabilized by LPS treatment in CD 14 dependent
process. sMD-2/LPS complex was then able to stimulate TLR4 on cells like
epithelial cells, which express TLR4 but not MD-2 (Kennedy et al., 2004). It was
also found that sMD-2/LPS binding is vastly augmented by molecules such as LBP
(Viriyakosol et al., 2001; Kennedy et al., 2004).
Many investigators currently propose that MD-2 has a function similar to that of
Spaetzle, the endogenous ligand in Drosophila that attaches to Toll and stimulates
antimicrobial peptide production. In parallel with this, MD-2 is assumed to go
through conformational alteration after binding LPS. This alteration permits MD-2 to
activate TLR4 (Gioannini et al., 2004; Visintin et al., 2005).
Another study found that MD-2 can also act with TLR2 to enhance its
responsiveness to a wide range of LPS molecules, lipoteichoic acid, Gram-negative
bacteria, Gram-positive bacteria and in particular peptidoglycan which does not
signal through TLR4/MD-2. The attachment between TLR2 and MD-2 is weaker
than that between TLR4 and MD-2 (Dziarski et al., 2001).
Most recently, another novel regulatory protein (PRAT4A or PRAT4B) has been
elucidated to be linked with immature form of TLR4, but not MD-2 nor TLR-2. It is
thought to regulate the TLR-4 cell surface expression and it is found that PRAT4A
knockout eliminated the LPS signalling in cells expressing TLR4/MD-2 (Konno et
al., 2006; Wakabayashi et al., 2006).
38
1.2.7 Intracellular receptors for LPS recognition
A number of the processes in the TLR signalling cascade are similar to that of the IL-
1 Receptor (IL-1R) since they share the conserved Toll-like/IL-1 receptor (TIR)
domain in their intracellular regions (O'Neill et al., 2003; Akira and Takeda, 2004;
Kaisho and Akira, 2006; Pandey and Agrawal, 2006). Obviously, the other part of
LPS signalling story is started in that TIR domain as a point of contact which is
shared by both the receptor and adaptor molecules and it is located intracellularly
inside the cytoplasm (Dunne and O'Neill, 2005; Lasker and Nair, 2006). TIR
domains are crucial for TLR signalling processes since a single point mutation in the
TIR domain of murine TLR4 eliminates LPS signalling completely (Poltorak et al.,
1998a).
To date, there are five adaptor proteins known to be recruited to the TIR domain of
TLR: the myeloid differentiation factor 88 (MyD88), MyD88 adaptor-like or TIR-
associated protein (MAL/TIRAP), TIR related activator of interfcron-P (TRIF), Trif
related adaptor molecule (TRAM) and SAM and ARM protein (SARM) (Beutler,
2004a; McGettrick and O'Neill, 2004; O'Neill, 2006). All of these adaptor proteins
act as a transducers of signals from the TIR domains downstream to reach the
transcription factors that cause inflammatory responses (Beutler, 2004a).
It has been demonstrated that MyD88-deficient mice are hyporesponsive to
endotoxin (Lasker and Nair, 2006). Moreover, one study showed that macrophages
and splenocytes from MyD88-deficient mice are entirely hyporesponsive to a wide
range of Gram-negative, Gram-positive and Mycobacterium cell wall components.
These results demonstrated that MyD88 is indispensable for the cellular response to
bacterial cell wall components (Takeuchi et al., 2000). When MyD88 is being
stimulated, it utilizes its amino-terminal death domain to attach the death domain-
containing serine-threonine kinases of the IL-1 receptor associated protein kinase 4
(IRAK4) (Akira et al., 2001; Heumann and Roger, 2002; Lasker and Nair, 2006).
After activation of IRAK-4, it phosphorylates IRAK-1 which consequently detached
from the receptor complex and combine with tumor necrosis factor (TNF) receptor-
activated factor 6 (TRAF6). This process eventually leads to activation of nuclear
factor (NF-kB) which controls the expression of several genes involved in organizing
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the inflammatory response (Athman and Philpott, 2004; Lasker and Nair, 2006;
O'Neill, 2006).
The nuclear factor-KB (NF-kB) family is a key participant in regulating both innate
and adaptive immunity. They control the expression of cytokines, growth factors,
and effector enzymes in response to many receptors involved in immunity such as T-
cell receptors (TCRs), B-cell receptors (BCRs) and Toll/IL-IR family molecules
(Ghosh and Karin, 2002; Hayden and Ghosh, 2004). In the cytoplasm, NF-kB
proteins are found in connection with dedicated inhibitory proteins ofNF-kB (IkBs).
After stimulation, the IkB proteins are degraded to allow NF-kB proteins to
translocate to the nucleus and bind their related DNA binding sites to stimulate the
transcription of a large number of genes, including antimicrobial peptides, cytokines,
chemokines, stress-response proteins and anti-apoptotic proteins (Li and Verma,
2002).
The cytokines released include pro-inflammatory cytokines (TNF-a, IL-1, IL-6) and
chemokines (IL-8) which provoke fever and up-regulate the acute phase response
with the production of complement, C-reactive protein and other molecules (Basset
et al., 2003). Of these cytokines, TNF-a is considered to be the most fundamental
one since the inhibition of TNF activity leads to significant reduction of LPS toxicity
(Beutler et al., 1985). On the other hand, it was found that direct administration of
TNF-a provokes similar effects to LPS toxicity in normal animals (Tracey et al.,
1986). That is why some investigators believe that TNF-a acts as an endogenous
mediator of endotoxicity (Beutler and Rietschel, 2003). Subsequently, these
cytokines stimulate neighbouring cells to produce chemokines and adhesion
molecules in order to attract a range of inflammatory cells into the infection focus.
Subsequent responsive cells like macrophages or neutrophils are then stimulated and
engulf pathogens via internalizing PRRs. As a result, pathogens are killed by the
production of molecules like nitric oxide, reactive oxygen species or defensins.
Hence, the inflammatory immune response represents a critical local response to
resolve infection. On the other hand, inflammation is a double edged sword since
when cytokines are produced in excessive quantity, they cause fatal effect and that is
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exactly what happens in endotoxic shock (Weber et al., 2003; Kaisho and Akira,
2006).
All TLR, except TLR3, utilize the MyD88-dcpendent pathway (Hoebe et al., 2003a;
O'Neill et al., 2003; Akira and Takeda, 2004; Kaisho and Akira, 2006; Pandey and
Agrawal, 2006). Moreover, genetic investigations utilizing MyD88-deficient mice
proved that this factor is vital for the NF-KB-dependent stimulation of the genes
responsible for the production of the cytokines TNF-a and 1L-6 in response to TLR
agonists (Imler and Zheng, 2004).
Furthermore, IRAK4 is central for the responses to IL-1 and ligands that signal
different TLRs. IRAK4-knockout animals are entirely insensitive to lethal doses of
LPS and are severely weakened in their abilities to resist microbial challenges.
Moreover, both deficiency and mutations associated with IRAK4 have been reported
in patients suffering from repeated pyogenic bacterial infections (Athman and
Philpott, 2004).
Other adaptor proteins, like MAL, revealed its importance since Mai-deficient mice
are hyporesponsive to TLR2 and TLR4 stimulation but have normal responses to
other TLRs. Additionally, TRIF adaptor protein is considered to be responsible for
the induction of IFN-p by the virtue of TLR3 and TLR4 signalling but not TLR2
(O'Neill, 2006).
Figure 1.3 summarises the common steps in inflammatory immune response.
1.2.8 Other immune response against LPS
Either in health or disease, endotoxin is in continuous dialogue with the host which
has developed several machanisms to deal with various amounts of LPS depending
on different approaches with the aim of diminishing or removing LPS effects. Trying
to understand each individual strategy in isolation from the others is problematical
since they evidently overlap, whether they take place extracellularly or intracellularly
(Elsbach, 2000) The signalling approach was explained in detail in the previous
section. Other approaches will be summarized here.
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Figure 1.3 Common steps in inflammatory immune response
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Natural antibodies plays a role in LPS clearance from the circulation as revealed by
studies on recombinase-activating gene-2 (RAG-2"/")-deflcient mice and Bruton's
tyrosine kinase (Btk~")-dcficicnt mice, which lack serum antibodies and are known to
be highly sensitive to endotoxin. In RAG-2" ~ mice, both survival and clearance of
endotoxin is improved when RAG-2 " mice are inoculated with sera from normal
mice. Btk_/" mice have reduced levels of IgG3 and IgM and demonstrated a
significant increase in their capacity to clear endotoxin when they were reconstituted
with purified normal mouse IgM (Reid et al., 1997).
Another kind of innate response which may lead to a signalling pathway is the
complement system which may have the capability to differentiate between LPSs of
various bacteria. In the absence of specific antibodies, complement receptors present
on monocytes/macrophages and dendritic cells could be stimulated via opsonization
of bacteria. During scenarios of this nature, the classical complement pathway is
stimulated by Lipid A and rough LPS, whereas the alternative pathway is stimulated
by O-antigen polysaccharide. Moreover, CD14, complement receptor type 3
(CDllb/CD18) and TLR 4 have been shown to work together as LPS recognition
and/or signalling receptors in macrophages (Caroff et al., 2002). Nevertheless, it is
revealed that monocytes and macrophages isolated from CD18-deficient patients
show normal levels of TNF-a and IL-1, which indicating that CD18 in particular is
not critical for LPS signalling (Wright et al., 1990a). Moreover, it is also found that
leukocytes which are treated by an antibody against CD 18 do not show decreased
level ofTNF-a after challenging with LPS (Wright et al., 1990b).
Although the binding between LPS and lipoprotein by itself contributes to the
decreased LPS bioactivity, lipoprotein also participates as a key molecule in LPS
elimination. It enhances the LPS clearance from the blood stream and delivery to the
liver which is considered as the main organ responsible for the removal of endotoxin
from the body (van Oosten et al., 1998; Elsbach, 2000; Su, 2002). High-density
lipoprotein (HDL) is known to act as one of main transport proteins of LPS in
plasma. It has the capacity to bind fractions of LPS released when Gram-negative
bacteria are incubated with plasma. Low-density lipoprotein (LDL) also has similar
LPS binding properties. They both have a potential significant role in endotoxin
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clearance since septic shock patients are found to have notably reduced plasma levels
ofHDL and LDL (Freudenberg et al., 2001).
Another LPS-binding molecule is the bactericidal/permeability-increasing protein
(BPI) which could differentiate between different LPS types and cause a decline in
the LPS-dependent production of TNF-a and other cytokines in whole blood
experiments. Furthermore, recombinant forms of BPI are demonstrated to protect
animals against the fatal effects of LPS (Diks et al., 2001).
The macrophage scavenger receptor (SR) class A type of receptors is another
example of LPS-binding protein which is proposed to inhibit the inflammatory
response by binding and eradicating LPS from the circulation. Indeed, the scavenger
receptor conceals LPS from the host's immune system rather than initiating
signalling. In parallel with this, the scavenger receptor is found to compete for LPS
with the CD 14 molecule. Moreover, studies show that the scavenger receptor play an
essential role in ingestion of pathogenic structures for antigen presentation (Nicoletti
et al., 1999; Yamamoto et al., 1999; Diks et al., 2001).
The liver acts as a last barrier to prevent gastrointestinal bacteria and bacterial
products, such as LPS, from entering the systemic blood stream. In this regard,
Kupffer cells, and less significant endothelial cells and liver parenchymal cells, are
the liver cells involved (van Oosten et al., 1998). Experimental animals provide
evidence of quick LPS clearance from the circulation within a few minutes of
intravenous injection, most of it via the liver. The crucial function of the liver in LPS
clearance can be verified in patients with liver failure, like cirrhosis, since they
repeatedly suffer from endotoxaemia, not only that but the worse the liver failure the
higher the endotoxaemia (Su, 2002). However, it is obvious that this approach does
not contain cell signalling machinery in a way that leads to an inflammatory response
(Heumann and Roger, 2002).
Acyloxyacyl hydrolase (AOAH) is a unique lipolytic leukocyte enzyme that has
LPS-detoxification properties through its capacity to remove the secondary acyl
chains of Lipid A (Munford and Hall, 1989; Erwin and Munford, 1990; Su, 2002).
This partial deacylation mechanism eliminates the bioactivity of LPS, in addition to
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creating such a reaction product which inhibits signalling by intact LPS in a
competitive manner (Su, 2002).
1.3 The systemic inflammatory response syndrome
In healthy individuals, the normal plasma values of endotoxin are small and vary
between 3 to 10 pg/ml (-0.1 EU/ml) as detected by standard Limulus amoebocyte
lysate (LAL) assay techniques. On the contrary, systemic endotoxin levels reach high
concentrations in patients suffering from severe sepsis or septic shock with plasma
concentrations of more than 300 pg/ml (Alexander and Rietschel, 2001). It is
observed that most patients in intensive care units have, on the day of admission, an
elevated level of endotoxin which is related to both nonspecific illness severity, and
infection of both Gram-negative and Gram-positive origin (Marshall, 2005).
Furthermore, many investigators have shown that regardless of the origin of the
infecting microorganism, the presence of endotoxin is frequent in the blood
circulation in sepsis cases (Danner et al., 1991; Hurley, 1994; Hurley, 1995a; Opal et
al., 1999). On the other hand, several studies that involved intensive care patients
with sepsis or septic shock found that endotoxaemia was established in only 20 to
40% of those patients. Although these result were linked to LAL-positivity, they give
an indication that endotoxin is not always detected in the blood of septic patients
(Cohen, 2000). Furthermore, it is also difficult to conclude that whenever
endotoxaemia exist it must indicate the presence of Gram-negative infection.
Nevertheless, it is noticeable that endotoxaemia and Gram-negative bacteraemia arc
not synonymous; patients may suffer from bacteracmia due to either Gram-negative
or Gram-positive bacteria without any indication for the presence of free endotoxin
in the blood. Similarly, endotoxaemic patients are not inevitably bacteraemic nor
have an infection focus elsewhere. So, as a conclusion, endotoxaemia by itself is not
linked to an identified Gram-negative infection or bacteraemia (Cohen, 2000).
Of special interest, the relationship between high mortality and the presence of
endotoxin is not readily explicable in older patients. Although endotoxin challenge
studies in aged animals demonstrated that they do not tolerate endotoxin as well as
younger animals. This may, in some way, be due to the variation in the metabolic
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response to endotoxin among different age groups which eventually effect sensitivity
to endotoxin (Opal et al., 1999).
In a relatively homogeneous population, like patients with meningococcal disease, it
is observed that patients with meningococcal meningitis have both an absent or low
levels of endotoxin in the blood and low mortality rate. However, meningococcaemia
endotoxaemia patients have the opposite situation with a positive quantitative
association between the level of endotoxin in the blood and the outcome (Brandtzaeg
et al., 1989). This relationship is by far much more complicated to disclose in a
heterogeneous ICU population. Nevertheless, analysis of 11 studies concluded that
the presence of both Gram-negative bacteraemia and endotoxaemia did define a
subcategory of patients at higher risk of dying (Hurley, 1995b). In light of this
notion, some investigators introduced the idea of a "sepsis score" by which they
consider the levels of endotoxin, TNF-a, IL-1 and IL-6. These studies found a
significant correspondence between the higher scores and poor outcome (Casey et
al., 1993). This may indicate that endotoxaemia is not the only indicator for mortality
rate in ICU patients. However, several studies support the observation that patients
with endotoxaemia, and in particular those with elevated levels of endotoxin, are
expected to be more severely ill (Cohen, 2000).
It is clear now that Gram-positive bacteria are one of the main causes of sepsis and
septic shock (Horn et al., 2000). This suggests that new players, such as exotoxins,
peptidoglycans, lipotcichoic acid and prokaryotic DNA, rather than endotoxin are
involved (Heumann et al., 1994; Dziarski et al., 1998; Schromm et al., 1999).
However a recent study demonstrated that endotoxin was detected in the patients
who have no microbial growth on their sample culture at levels almost similar to
those patients who have reported infection from intra-abdominal, lung and blood
sites (Marshall et al., 2004). Such study supports the translocation hypothesis of
endotoxin from the gastrointestinal tract which is considered to contain approximate
25 grams of endotoxin (van Devcnter et al., 1988; Doig et al., 1998).
From this site, Gram-negative bacteria and their endogenous endotoxin are thought
to penetrate the disrupted permeability barrier of the colon due to the inflammation-
mediated mechanisms induced by even Gram-positive sepsis (Doig et al., 1998; Horn
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et al., 2000). Moreover, local hypoperfusion and mucosal ischaemia are assumed to
contribute to the endotoxin translocation from the intestine to the blood circulation
(Rocke et al., 1987; van Deventer et al., 1988; Hurley, 1995a). Additionally, it is
reported that sepsis and systemic inflammatory response syndrome are complications
after cardiovascular or vascular surgery because of the translocation of endotoxin
from the intestine (Martinez-Pellus et al., 1997; Sugita et al., 1998). Moreover,
different illnesses or even invasive procedures, varying from multiple trauma, ankle
fracture and colonoscopy, have been linked to systemic endotoxaemia. Such
examples support the hypothesis that the endotoxin is mainly derived from the gut
(Marshall, 2005).
Septic shock patients who have circulating endotoxin are found to suffer from severe
physiological changes and high mortality rate (Danner et al., 1991). Symptoms of
sepsis in human are similar in many ways to the pathophysiological events that
happened as a result of the administration of endotoxin to humans and experimental
animals (Horn et al., 2000; Hurley, 2003). In addition to fever, endotoxin can
contribute to multiple biological effects like leukocytosis, platelet aggregation,
thrombocytopenia, leukopenia, tachycardia, tachypnea, hypotension, disseminated
intravascular coagulation, and multi-organ failure (Hurley, 1995a; Schletter et al.,
1995b). Apparently, sepsis is an outcome of incapacity in the immune system to
overcome an immense bacterial load which outweigh the inhibition mechanisms that
control inflammation (Decker, 2004).
For almost a century, sepsis was defined as the systemic host response to an
infection. While the original definition of the sepsis was supposed to be linked to the
existence of bacteria in the blood (bacteraemia). Both of the terms "sepsis" and
"septicaemia" were repeatedly interchanged in their usage in the clinical situation.
Some investigators introduced another simple definition for the sepsis syndrome that
was a specific clinical manifestations including a known source of infection
(Riedemann et al., 2003).
Sepsis is linked to several terms and nomenclature, which indicate the level of
complexity to distinguish between many symptoms of inflammatory responses that
are assumed to be identical regardless of their causes. In 1991, the American College
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of Chest Physicians and the American Society ofCritical Care Medicine published a
new scheme of definitions for what they termed systemic inflammatory response
syndrome (SIRS) and sepsis. They tend to concern the way the cases were diagnosis
and the treatment method. Critically ill patients with different underlying illncses
such as trauma, bums, pancreatitis and infection, were shown to have a group of
inflammatory response variables including leucocytosis or severe leucopoenia,
hyperthermia or hypothermia, tachycardia and tachypnoea which are all termed
together as systemic inflammatory response syndrome (SIRS). This definition
highlights the magnitude of the inflammatory process itself, whether it is
accompanied by infection or not. Therefore, SIRS that is linked with suspected or
confirmed infection is designated by another term, sepsis. When evidence of organ
failure is detected, the patient transfers to another level which is called severe sepsis
in which several other signs are observed, such as hypoxaemia, oliguria, lactic
acidosis or altered cerebral function. Moreover, septic shock is reached when a case
of severe sepsis is accompanied by hypotension with systolic blood pressure less
than 90 mmHg even with sufficient fluid resuscitation. Additionally, sepsis and SIRS
may get worse if the failure of two or more organs are detected which is termed a
multiple organ failure (MOF) (Paterson and Webster, 2000). MOF is considered to
be the eventual cause of death in sepsis patients. Typically, patients will primary
suffer from a single organ failure like respiratory failure needing mechanical
ventilation and then if not treated, it will develop a multiple organ failure. There is a
close association between the severity of organ failure on admission day to an
intensive care unit and the likelihood of survival, and between the number of failed
organs and the threat of death. Four or five failed organs translates to a mortality of
more than 90%, regardless of treatment. The organ failure pathogenesis is not yet
fully understood due to the influence of multiple risk factors such as tissue
hypoperfusion and hypoxia (Cohen, 2002).
However, there are two ways to interpret these kinds of inflammatory response
complications. On the one hand, it is proposed that severe infection leads to a
reduced capacity of the immune system to generate an effective antimicrobial
response which ultimately results in prevalence of paralysis of the immune system.
On the other hand, it is assumed that specific microbial components, such as
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endotoxin, stimulate a powerful immune reaction that leads to an excessive
production of immune mediators that eventually gives rise to multiple organ failure
(Pfeffer, 2003).
From 1979 through to 1987, Gram-negative bacteria were considered to be the
leading organisms causing sepsis. Nevertheless, in 2002 Gram-positive bacteria were
shown to be the most important cause of sepsis with 52.1%, followed by Gram-
negative bacteria with 37.6%, polymicrobial infections with 4.7%, anaerobes with
1.0% and fungi with 4.6%. Organ failure had a deteriorating effect on the overall
outcome since the mortality rate among patients without organ failure is about 15% ,
while it is 70% among patients with three or more organ failures (Martin et al., 2003;
Riedemann et al., 2003). Nevertheless, other recent studies have demonstrated that
Gram-negative bacteria accounted for about 60% of sepsis cases, where Gram-
positive were responsible for the rest (Angus et al., 2001; Alberti et al., 2002). In
another regard, the immunopathogenesis of septic shock caused by Gram-positive
bacteria is considerably different from that observed in Gram-negative sepsis.(Horn
et al., 2000). Needless to say that both of them are different in the way they initiate
disease. Since Gram-positive bacteria usually depend on the production of powerful
exotoxins (sometimes superantigens) while Gram-negative bacteria depend on the
production of endotoxin. Moreover, they also differ in the origin site from which
sepsis arose. Gram-positive sepsis often arise from skin, wounds, soft-tissue
structures, and catheter sites whereas Gram-negative sepsis often arise from enteric
or genitourinary sources (Bone, 1994). Morevcr, there are differences in both the
nature and timing of the responses. Endotoxin induces a rapid response of
proinflammatory cytokines, primarily TNF-alpha, IL-1, IL-6, and IL-8. On the
contrary, the Gram-positive toxins induces a typical Th-l-typc cytokine response,
dominated by TNF-beta and interferon-gamma. TNF-alpha and IL-1 were produced
but less than in response to endotoxin. Furthermore, the rhythm of the cytokine
response to Gram-positive toxins is different from the Gram-negative response, with
peak response delayed to perhaps 50-75 hrs after the challenge, in contrast to the 1-5
hrs response to endotoxin (Andersson et al., 1992). Another study showed an
obvious difference in responses between Gram-negative endotoxin and Gram-
positive exotoxins when they both challenge human peripheral blood mononuclear
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cells. IL-8 was the most abundant cytokine produced in response to the exotoxins,
while endotoxin was most active in inducing IL-1, IL-6, and TNF-alpha (Muller-
Aloufetal., 1994).
Analysis of discharge data on approximately 750 million hospitalization in the
United States over a 22-year period recognized 10,319,418 cases of sepsis which
represent 1.3% of all hospitalizations. An annual increase in the incidence of sepsis is
noticed from about 164,000 cases (82.7 per 100,000 population) in 1979 to nearly
660,000 cases (240.4 per 100,000 population) in 2000. In the USA and Europe, the
estimated affected patients who suffer from sepsis vary between 400,000 to 500,000
on an annual basis (Guha and Mackman, 2001). Another study, derived from the US
data, revealed that the cases of severe sepsis that occurred in 1995 only were
751,000, from which the observed mortality rate was 28.6%, and this turns into about
215,000 deaths. As one of the leading causes of death in the US since 1950, sepsis
showed the largest increase in death rate which increased 38-fold, from 0.3 in 1950,
to 11.5 in 2000, per 100,000 (Russo and Johnson, 2003). Moreover, sepsis is
considered as an outcome related to the risk factors such as prolonged stay both in
intensive care unit (ICU) and in hospital (Granja et al., 2004). However, a recent
epidemiological study from North America indicated that the incidence of sepsis was
about 3.0 cases per 1,000 of US population, which means 750,000 cases annually.
The overall mortality was approximately 40%, varying from 30% in the elder
patients to 50% or higher in patients suffering from severe symptoms of septic shock
(Angus et al., 2001). Another study linked the mortality rate of 20-50% to septic
shock syndrome which results in annual numbers of 100,000 deaths in the USA
(Schletter et al., 1995b). A third conservative study showed that the annual resultant
deaths from sepsis were between 20,000 -50,000 only in the United States (Bone,
1991). Another study estimated that approximately 700,000 people suffered from
sepsis annually and the annually resultant deaths from sepsis are between 100,000 to
210,000 in the United States (Nogare, 1991; Riedemann et al., 2003). In view of that,
sepsis results in an estimated $16.7 billion per year as a costs to the US health care
system (Riedemann et al., 2003). Moreover, estimated cost of sepsis patient care is
about as $50,000 per patient. Sepsis is considered to be the second highest reason of
death among patients in non-coronary intensive care units and the tenth top reason of
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death in general in the United States. Furthermore, sepsis significantly contributes to
the low-quality life of the survival patients (Martin et al., 2003). In general, septic
patients stay in hospital for prolonged periods and they rarely depart the ICU before
2-3 weeks (Riedemann et al., 2003).
1.4 Aims of thesis
It becomes widely recognizable that different LPSs from different bacteria may
interact, signal in different way. It was, therefore, reasonable to choose structurally
and functionally different LPSs from different bacterial species that represent what
may happen inside the human host when bacteria or their LPS reach the blood stream
for instance in the case of sepsis. It is also rational to investigate how different
methods of extraction and purification will affect the signalling activity of LPS
quantitatively and qualitatively. Accordingly, three main aims for this study were
investigated
1) Investigating the effects of different LPS extraction methods on the activity
of different LPS preparations from four different bacteria (Escherichia coli
018K-, Pseudomonas aeruginosa Pa-Ol, Bacteroides fragilis NCTC 9343
and Rhodobacter sphaeroides NCIMB 8253) and their ability to produce
proinflammatory cytokines (TNF-a and IL-1 (3).
2) Investigating the effect of mixing different LPS preparations extracted by
different methods from three different bacteria (E. coli 018K-, B. fragilis
NCTC 9343 and R. sphaeroides NCIMB 8253) on producing
proinflammatory cytokines.
3) Investigating how LPS repurification method, different LPS extraction
methods of Bacteroides fragilis together with different heat killed B. fragilis
populations might affect the toll like receptor (TLR) specificity.
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CHAPTER 2: MATERIAL AND METHODS
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2.1 General chemicals
All chemicals used were of Analar grade, unless mentioned otherwise. Aqueous
solutions used in all lipopolysaccharide studies were made up in pyrogen free water
(PFW), others were made up in distilled water (Millipore, Billerica, MA, USA).
Phosphate buffered saline (PBS) was prepared in all experiments by dissolving one
tablet of PBS (Oxoid, Basingstoke, UK) per 100ml ofPFW and autoclaved prior use.
All other autoclavable chemicals were autoclaved before use.
2.2 Media for bacterial growth
The following media were used throughout this study.
2.2.1 Nutrient broth medium (NB)
Filter-sterilized nutrient broth was purchased from Gibco (Paisley, UK) and used for
aerobic growth of Escherichia coli and Pseudomonas aeruginosa strains.
2.2.2 Proteose Peptone Yeast Extract Medium (PPY medium)
PPY medium was used for an anaerobic growth of Bacteroides fragilis strains.
Proteose peptone (Oxoid) 20g, yeast extract (Oxoid) lOg, NaCl 5g, cysteine HC1
(3.75% w/v solution) 20ml, solution carbonate (2% w/v solution) 20ml,
hacmin(250|lg/ml)/mcnadione (50jlg/ml) were added to 940ml of PFW, autoclaved
at 121°C for 15min and stored at 4°C.
2.2.3 R8AH medium (modified ATCC 550 liquid medium)
Rhodobacter sphaeroides was grown on R8AH medium which is recommended by
the American Type Culture Collection (ATCC) according to the original work of
Drews (1965) and Weckesser et al.(1972) with a slight modification.
Trace element requirements of this medium were prepared separately at lOOx the
trace element concentration as indicated in Table 2.1
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Table 2.1 List of trace element used for R8AI1 medium
Trace element Concentration
Manganese chloride.4H20 (MnCl2.4H20) 20mg to 100ml PFW
Boric acid (H3B03) lOmg to 100ml PFW
Copper sulfate (CuS04.5H20) lOmg to 100ml PFW
Ammonium heptamolybdate ((NH4)6Mo7024.4H20) 20mg to 100ml PFW
Zinc sulfate(ZnS04) 1 Omg to 100ml PFW
Then, 300mg of ammonium ferric citrate, 63.7mg EDTA.Na2.2H2O and CaCl2.2H20
were dissolved in 95ml of PFW and 1ml of each of the lOOx trace elements
(Table2.1) were added. Vitamin solution at lOOx concentration was prepared by
adding 8mg to 10ml PFW. 20mg nicotinic acid, 20mg nicotinamide and 40mg
thiamine HC1 were dissolved in 99ml PFW and 1ml of lOOx biotin solution was then
added. All solutions were stored in 4°C.
Complete medium was prepared by dissolving malic acid in 900ml of PFW which
then neutralized with 1M NaOH. The remaining ingredients were added as stated in
Table 2.2. Finally the medium was autoclaved at 121 °C for 15min and stored at 4°C.
Table2.2 Ingredients of R8AH complete medium
Ingredients Weight or volume
Malic acid (C4H605) 2.5g
Yeast extract (BD 212750) l.Og
Ammonium sulfate ((NH4)2S04 ) 1.25g
Magnesium sulfate heptahydrate (MgS04-7H20) 0.2g
Calcium chloride (CaCl2) 0.07g
Ammonium ferric citrate (C6Hg07.nFe.nH3N) 0.0lg
Ethylenediaminetetraacetic acid (EDTA) (CioHi6N2Os) 0.02g
Potassium dihydrogen phosphate (KH2P04) 0.6g
Dipotassium phosphate (K2HP04) 0.9g
Trace elements (See above) 1.0ml




The KIT-system used in this study are listed in Table 2.3 .
Table 2.3 KIT-svstems used in this study
KIT-system Source
DuoSet® ELISA Development system for R&D, Abingdon,UK
measuring human TNF-oc/TNFSFIA (DY210)
DuoSet® ELISA Development system for R&D, Abingdon,UK
measuring human IL-p/IL-l F2 (DY201)
Pyrochrome LAL kit Associates ofCape Cod, Falmouth, MA,
USA
2.4 Cell lines
The cell lines used in this study are listed in Table 2.4 .
Table 2.4 Cell lines used in all experiments




Transformed from normal human
epithelial embryonic kidney cells
with sheared adenovirus 5 DNA,
Graham et al. (1977)








Derived from human male 1 year








Derived from normal subcutaneous
areolar and adipose tissue of 100







2.5 Maintenance of cell lines
2.5.1 L929 cell line
Cells were routinely sub-cultured using DMEM/10%FCS which was prepared by
adding 50ml of sterile filtered foetal calf serum (FCS, Sigma), 5ml of penicillin
streptomycin and glutamine (PSG, Gibco) to 500ml ofDMEM medium (Sigma). The
same medium formula was used for the adhering stage before TNF-a bioassay
except 25ml of FCS was added, (DMEM/5%FCS). For the TNF-a bioassay 50pl of
Actinomycin D (Stock of 5mg/ml in DMSO, Sigma) was added to the
DMEM/5%FCS (DMEM/5%FCS/ActD).
As an adherent cell line, L929 was washed using sterile PBS and disaggregated by a
solution which was prepared by adding 2ml of Trypsin-EDTA (Gibco) to 20ml of
sterile PBS.
10ml of freezing medium for L929 cell line contained 1 ml of dimethylsulphoxide
DMSO (Sigma) and 9 ml of FCS.
2.5.2 THP-1 cell line
Cells were grown in a start-up culture contained 30ml of RPMI-1640 medium
(Sigma), 6ml of FCS, 3ml of lOOmM autoclaved 4-(2-hydroxyethyl)-l-
piperazineethanesulfonic acid, (HEPES) (Gibco) (RPMI/20%FCS/I IEPES). For
routine growth, cells were sub-cultured using (RPME10%FCS/PS+G) which was
prepared by adding 50ml of FCS, 5ml of penicillin streptomycin and 15ml of
200mM Glutamine (Sigma) to 500ml ofRPMI medium. For the differentiation stage,
cells were grown using (RPMI/PSG) which was prepared by adding 5ml of PSG to
500ml of RPMI medium, cells were then stimulated by adding 2ml of lOOnM
Vitamin D3 (Sigma) to 20ml of the cell suspension. To maintain cell growth after
differentiation stage, cells were grown in (RPMI/10%FCS/PSG) which was prepared
by adding 50ml of FCS and 5ml of PSG to 500ml of RPMI medium. 10ml of




Cells were routinely sub-cultured using DMEM/10%FCS as mentioned above. Cells
were grown in DMEM medium plus PSG during transfection stage (DMEMO). For
sample stimulation stage, cells were grown using (DMEM/1%FCS) which was
prepared by adding 5ml FCS and 5ml ofPSG to 500ml ofDMEM.
2.5.4 Determination of cell viability
Viability of cell lines was determined using trypan blue dye (Sigma) assay which is
based on the exclusion of the dye from viable cells (Mishell and Shiigi, 1980). One
volume of cells harvested at lOOg for 5 min were added to an equal volume of trypan
blue dye and mixed well. Cells were then immediately observed under a microscope
using a dual-chamber haemocytometcr. Stained and unstained cells were recorded
separately and the viable cell ratio was calculated according to the following
equation:
(Number of unstained cells/Total number of cells) x 100 = Percent Viable Cells.
2.6 Bacterial strains
The bacterial strains which used during this study are listed in Table 2.5 .
Table 2.5 Bacterial strains used in all experiments
Species Strain
Escherichia coli 018K~ (MPRL 1275)
Pseudomonas aeruginosa PAOl (MPRL 664)
Bacteroides fragilis NCTC 9343 (MPRL 1669)
Rhodobacter sphaeroides NCIMB 8253(MPRL 4788)
Porphyromonas gingivalis NCTC 11834
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2.7 Reagents
The lipopolysaccharide preparations used in this study are listed in Table 2.6 .
2.7.1 Lipopolysaccharides





E. coli Triton /Proteinase K EC1 M. Al-hawi
E. coli Triton EC2 M. Al-hawi
E. coli Aqueous phenol EC3 M. Al-hawi
E. coli Boiling H20 /Proteinase K EC4 M. Al-hawi
P. aeruginosa Triton PA1 M. Al-hawi
P. aeruginosa Triton /Proteinase K PA2 M. Al-hawi
P. aeruginosa Aqueous phenol PA3 M. Al-hawi
P. aeruginosa Boiling H20 /Proteinase K PA4 M. Al-hawi
B. fragilis Triton BF1 M. Al-hawi
B. fragilis Triton /Proteinase K BF2 M. Al-hawi
B. fragilis PCP BF3 M. Al-hawi
B. fragilis Boiling H20 /Proteinase K BF4 M. Al-hawi
B. fragilis Aqueous phenol BF5 M. Al-hawi
R. sphaeroides Aqueous phenol RSI M. Al-hawi
R. sphaeroides PCP RS2 R. Brown
R. sphaeroides PCP RS3 R. Brown
R. sphaeroides PCP RS4 R. Brown
P. gingivalis Aqueous phenol PG Gift from C. Erridge
2.7.2 Heat killed bacteria
The heat killed bacteria preparations used in this study are listed in Table 2.6 .
Table 2.7 Heat killed bacteria used in all experiments
Species Description Abbrev, Source
B.fragilis Large capsule population HKLC Gift from Prof Sheila
B.fragilis Small capsule population HKSC UmVcrsity^effast
B. fragilis Electron dense layer population HKEDL Belfast,UK)
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2.8 Bacterial growth conditions
The purity of all cultures was checked by performing Gram stain films and a 48h
purity plate.
2.8.1 Anaerobic growth
Anaerobic conditions (10%H2, 10%Co2 + 80%N2) were used to culture B. fragilis
species in PPY broth medium at 37°C overnight in an anaerobic work station.
Bacterial cells were then harvested by centrifugation at 10,000g for 15min at 4°C
then washed once with wash buffer (depended on extraction method), centrifuged
again at 10,000g for lOmin at 4°C. Finally the bacterial pellets are washed for the last
time with PFW with same centrifugation settings. The bacterial pellet was frozen at
-20°C, freeze dried and weighed.
2.8.2 Aerobic growth
E. coli and P. aeruginosa were grown aerobically in NB medium at 37°C overnight,
shaken at 150 rpm. Bacterial species of R. sphaeroides was grown in ATCC 550
broth medium at 30°C overnight in the dark and shaken at 150 rpm. Bacterial cells
were then harvested by centrifugation at 10,000g for 15min at 4°C then washed once
with wash buffer (depended on extraction method), centrifuged again at 10,000g for
lOmin at 4°C. Finally the bacterial pellets are washed for the last time with PFW
with same centrifugation settings. The bacterial pellet was frozen at -20°C, freeze
dried and weighed.
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2.9 Extraction of lipopolysaccharide
Different preparations of LPS have been used in this study. LPSs were obtained by
extraction of lyophilized bacterial cell by different extraction methods.
2.9.1 Aqueous Phenol (API method
Wash buffer used prior to this method for harvesting bacteria was prepared by
dissolving 1.48g sodium dihydrogen phosphate (NaFfjPCL^FLO), 5.749g disodium
hydrogen orthophosphate (NaiHPCL) and 8.77g sodium chloride (NaCl) in 1 litre of
PFW.
LPSs were extracted from E. coli, P. aeruginosa, B. fragilis and R. sphaeroides using
the aqueous phenol method as described by Westphal and Luderitz (1954). Pre-
weighed, freeze-dried bacteria were ground-up and suspended to 5% w/v in PFW.
The preparation was heated in a waterbath at 67°C and an equal volume of preheated
(67°C) 90% w/w phenol solution was added. The well-mixed solution was incubated
at 67°C for 15min and then cooled in an ice bath to allow phases to separate. The
solution was centrifuged at 10,000g for 15min at 4°C. The resulting clear upper
aqueous layer containing LPS material was then carefully transferred to dialysis
tubing (Medical International Ltd, London). The centrigugation step was repeated
and the pooled aqueous layers were dialysed against tap water overnight. Dialysed
opalescent supernatant was concentrated under vacuum on a rotary evaporator then
ultracentrifuged at 100,000g for 3h at 4°C. The resulting pellet was resuspended in
PFW and ultracentrifuged again at the same previous settings. Finally, the LPS pellet
was resuspended in PFW and freeze-dried then stored at -20°C.
60
2.9.2 Phenol/chloroform/petroleum spirit (PCP) method
Wash buffer used prior to this method was the same as for aqueous phenol method.
PCP reagent was prepared by adding 90% w/w aqueous phenol, chloroform and
petroleum spirit in the ratio of 2:5:8 by volume. Diethyl ether was added to acetone
in the ratio of 1:5 by volume.
PCP method was implemented according to the work of Galanos et al. (1969) in
addition to the further procedure of using diethyl ether/acetone mixture proposed by
Qureshi et a/.(1982) for extraction of rough LPS from B. fragilis. Pre-weighed,
freeze-dried bacteria were ground-up and suspended as one part of bacterial pellet in
at least 12 parts of PCP extraction mixture until a fine suspension was obtained. This
preparations was centrifuged twice at 10,000g for 15min at 4°C. The resulting
supernatant was filtered through Whatman No. 1 filter paper. The bacterial residue
was extracted once more as above and the filtered supernatant was added to the first
one. The filtered supernatant was then rotary evaporated to be followed by mixing of
one volume of LPS-containing phenol solution with six volume of diethyl
ether/acetone mixture at room temperature for lh. Next centrifugation step was
carried out at 5000g for lOmin at room temperature. The resultant pellet was
resuspcnded in the previous mixture and centrifuged for three times. LPS was then
dried in a vacuum desiccator and resuspended again in PFW to be ultracentrifuged
for the last time at 100,000g for 4h at 4°C. Finally, the LPS pellet was resuspended in
PFW and freeze dried then stored at -20°C.
2.9.3 Triton/magnesium chloride (TM/TMP) method
Wash buffer used prior to this method for harvesting bacteria was prepared by
dissolving 7.57g Tris (hydroxymethyl) methylamine (NFLQCFLOFl^) in 1000ml
PFW, pH was then adjusted to 6.8 with 1M HC1 and 8.77g sodium chloride (NaCl)
was then added. Solutions for different methods were prepared as outlined in Table
2.8.
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Table 2.8 Solutions used in Triton/magnesium chloride method
Solution Components Preparation
TS1 lOOmM Tris/HCl, pH 8.0 6.055g Tris in 500ml PFW
TS2 1M MgCl2.6H20 40.662g magnesium chloride in 200ml PFW
TS3 0.5M MgCl2.6H20 10.166g magnesium chloride in 100ml PFW
TS4 8% (v/v) Triton X-100 40ml Triton X-100 in 460ml PFW
TS5 0.2M EDTA, pH 8.0 18.613g EDTA in 250ml PFW




100ml of TS1 and 10ml TS2 to 890ml PFW
LPSs were extracted from E. coli, P. aeruginosa and B. fragilis using the
Triton/magnesium chloride method with (TMP) and without (TM) Proteinase K
treatment according to the work of Uchida and Mizushima (1987). This method
consists of three parts. At the end of the first part an insoluble form of LPS was
collected as a pellet after one gram freeze-dried bacteria was ground-up and
suspended in 22ml PFW followed by successively adding 4ml TS1, 4ml TS3, 10ml
TS4 and 10ml ethanol (EtOH) . This mixture then boiled in a vigorously boiling bath
for 20min, cooled, centrifuged at 20,000g for 20min. Then pellet was resuspended in
40ml TS7 and finally centrifuged at 100,000g for 90 min at room temperature.
In the second part, the washed precipitate was mixed well with sequence adding of
10ml PFW, 10ml TS5, 10ml TS6 and 10ml TS4 , incubated in a shaking waterbath at
37°C for 60min then centrifuged at 20,000g for 25min at room temperature. The
resulting supernatant containing the LPS was centrifuged again to ensure complete
removal of insoluble materials.
In part three, 4ml TS2 was added to the supernatant, to precipitate the LPS, and the
mixture incubated at 37°C for 60min. The LPS was collected by ultra-centrifugation
at 100,000g for 90min at room temperature. At this stage, the optional Proteinase K
treatment was implemented. After rcsuspending the resulting clear precipitate in
PFW, the solution was treated with Proteinase K (20|ig/ml) at 37°C for 2h.
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Then, the Proteinase K - or non treated material were washed once in 40ml TS7,
ultra-centrifuged at 100,000g for 90min at room temperature. Finally, the LPS pellet
was resuspended in PFW and freeze dried then stored at -20°C.
2.9.4 Boiling water/ Proteinase K treatment (BWP) method
Wash buffer containing 20mM Tris-FICl, 0.15M NaCl, lOmM MgCl2 at pFI 7.4 was
used prior to this method for harvesting bacteria according to the method of
Yoshimura et al.(1984).
LPSs were extracted from E. coli, P. aeruginosa and B. fragilis using a rapid boiling
water/ Proteinase K treatment method as proposed by Eidhin and Mouton (1993).
Freeze-dried bacteria of 25mg were suspended in 1ml of PFW and boiled in a water
bath for 15min with vortexing at 5min intervals. The mixture was then centrifuged at
12000g for 5min. The resulting supernatant was collected, treated with Proteinase K
(lmg/50pl PFW) and incubated at 60°C for lh before being transferred to a boiling
water bath for 5min to precipitate any residual Proteinase K and centrifuged as
before. The resulting supernatant was then subjected to an overnight dialysis against
water and subjected to a second round of precipitation and centrifugation. Finally,
the resulting supernatant was freeze-dried and stored at -20°C.
2.10 Depigmentation ofR. sphaeroides method
Prior to LPS extraction, freeze-dried R. sphaeroides were subjected to a
depigmentation procedure to remove red pigment which is known to interfere with
the extraction of LPS according to the work of Strittmatter et al. (1983). Freeze-dried
cells (2.8g) were suspended in 200ml of PFW and centrifuged at 10,000g for lOmin
at 4°C. The pink freeze-dried cells turned green after being treated three times with
100ml butan-l-ol containing 1% acetic acid and centrifuged at 10,000g for lOmin at
4°C. The resulting pellet was then treated three times with 100ml EtOH and
centrifuged at 10,000g for lOmin at 4°C when it turned brown in colour.
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Bacterial cells then turned orange-red after being treated three times with 100ml
acetone and centrifiiged at 10,000g for lOmin at 4°C. The colourless pellet was
achieved after treated bacterial cells were washed three times with 100ml ether,
centrifiiged at 10,000g for lOmin at 4°C and finally dried in-vacuum. LPS was then
extracted by the methods outlined above.
2.11 Re-purification of LPS
All LPSs extracted by the different methods were subjected to repurification to
eliminate possible protein contaminants, that are active in signalling via TLR2 on
C3H/HeJ macrophages (Manthey et al., 1994), according to the work of Manthey
and Vogel (1994) that was detailed further by Hirschfeld et al.(2000). LPS (5mg)
was dissolved in 1ml PFW containing 0.2% triethylamine (TEA) at room
temperature. A 500(0.1 volume of this preparation was added to 100|il of 3% sodium
deoxycholate solution and briefly mixed. Water-saturated phenol (600(tl:WSP)
solution was then added to the mixture which was intermittently vortexed for 5min at
room temperature. The phases were allowed to separate for a further 5min at room
temperature before being placed in an ice-bath for 5min and then centrifugcd at
10,000g for 2min at 4°C. After the top aqueous layer was transferred to another tube,
the lower phenol phase was re-extracted with 600pl of 0.2% TEA/0.5% sodium
deoxycholate solution as above. Again the top aqueous layer was transferred and
pooled with the other top aqueous layer previously collected. The aqueous phases
were re-extracted with 600(il ofWSP as above. The top aqueous phase was collected,
and adjusted to 75% EtOH/ 30mM sodium acetate, allowed to precipitate at -20°C
for lh and then ccntrifugcd at 10,000g for lOmin at 4°C. The resulting precipitate
was washed in 1ml cold 100% EtOH and the precipitate dried at room temperature.
Almost one hundred percent of LPS was assumed to be recovered from this
procedure.
To enhance LPS solubility, triethylamine (TEA) was added to all crude or repurified
LPS preparations as lmg of LPS/lml of PFW/l(tl ofTEA and frozen at -20 °C.
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2.12 LPS and protein analysis
2.12.1 Preparation samples for polyacrylamide gel electrophoresis (PAGE)
LPS samples extracted by the four different methods were suspended in PFW at
lmg/ml. Just prior to loading onto gels samples were mixed with an equal volume of
double strength PAGE sample buffer, boiled for 3min and then allowed to cool to
room temperature. Double strength PAGE sample buffer (0.125M Tris/HCl pH6.8,
20% glycerol, 2% 2-mercaptoethanol, 0.002% bromophenol blue) was prepared by
dissolving 1.514g Tris, 25.2g glycerol, 2ml 2-mercaptoethanol, 4ml bromophenol
blue in 100ml PFW.
2.12.2 PAGE
Analysis of LPS preparations was performed using the buffer system proposed by
Laemmli (1970). PAGE of LPS samples was performed omitting sodium dodecyl
sulfate from both separating and stacking buffers (non-SDS PAGE). Double strength
separating gel buffer (0.75M Tris/HCl pH8.8) was prepared by dissolving 22.72g
Tris in 250ml PFW. Double strength stacking gel buffer (0.25M Tris/HCl pH8.8)
was prepared by dissolving 7.571 g Tris in 250ml PFW. Both separating and stacking
gels were prepared as outlined in Table 2.9 and deaerated under vacuum prior to
adding TEMED (NNN'N-tetramethyl-l,2-diaminoethane, BDH) and ammonium
persulphate (BDH). A 40% w/v aqueous acrylamide/ methylenebisaccrylamide
solution was prepared by dissolving lOOg acrylamide, 2.7g methylenebisacrylamide
in 250ml PFW.
The separating gel was loaded between two assembled glass plates which had been
cleaned with methylated spirit and sealed with molten Vaseline. The gel was covered
with a thin layer of water-saturated butan-2-ol (BDH) and allowed to polymerize.
After the butan-2-ol was removed, a 4% stacking gel was poured onto the separating
gel. A comb was fitted and the gel allowed to polymerize. After the comb was
removed, the gel was placed into an electrophoresis tank (Jencons Scientific Ltd,
Beds.). Finally, electrode buffer (0.025M Tris, 0.192M glycine, 0.1%SDS, pH8.3)
was added.
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LPS samples or an equal volume of single strength PAGE sample buffer were then
loaded into the wells of the stacking gel. The samples were run through the stacking
gel at constant voltage of 60V and through the separating gel at 150V. After
electrophoresis, LPS samples were examined by silver stain method (section 2.12.3)
and the protein contaminants detected by colloidal gold total protein stain (section
2.12.5) after the gel was transferred to nitrocellulose (section 2.12.4).
Table 2.9 Preparation of separating and stacking PAGE gels
Reagent: 12% Separating gel 4% Stacking gel
Distilled Water 5.2ml 3.5ml
Separating buffer 17.5ml
Stacking buffer 5.0ml
Acrylamide solution (40%) 10.5ml 1.0ml
TEMED (Sigma) 50pl 20pl
Ammonium persulphate w/v (15mg/ml) 1.75ml 0.5ml
2.12.3 Silver stain of PAGE gel for LPS
LPS samples were visualized on PAGE gel according to the method proposed by
Tsai and Frasch (1982) and modified by Hancock and Poxton (1988). PAGE gel was
transferred into a tray containing fixative (25% propan-2-ol, 7% acetic acid) and left
overnight at room temperature. The fixative was then discarded and the oxidiser
(0.7% periodic acid in dilute fixative: 1.05g periodic acid, 4ml fixative and 150ml
distilled water) was added for 15min at room temperature with slow agitation on a
platform (used for all of the following steps). Oxidiser was discarded and gel was
then washed in four changes of 200ml distilled water over 4h. Freshly prepared silver
stain solution was prepared by adding 21ml 0.36% NaOH and 1.4ml 0.88 SG
ammonia solution to 100ml distilled water, 4ml 19.4% silver nitrate solution was
then added dropwise. Silver stain solution was added for 15min and then discarded.
The gel was washed in four changes of 200ml distilled water over 40min. Samples
were visualised using freshly prepared developer solution (0.005% citric acid in
0.019% formaldehyde solution) to achieve the required staining intensity. The
developer was then discarded and the gel washed repeatedly in large volume of
distilled water and finally scanned digitally.
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2.12.4 Transferring gel to nitrocellulose
Components present in the gel after electrophoresis were transferred to a
nitrocellulose membrane in a plastic cassette which was placed into electrophoresis
tank. The electrode buffer was then poured into cover the whole of the cassette. A
constant voltage of 40mA overnight at 4°C was used.
2.12.5 Colloidal gold total protein stain
For detecting protein contaminants bound to LPS samples, the method as described
by Rohringer and Holden (1985) was used. The nitrocellulose membrane was
transferred to an incubation vessel and washed three times, each for 20min, with
100ml of Tween Tris buffered saline (TTBS) ( 0.02M Tris/HCl, 0.5M NaCl pH 7.5,
0.025% Tween 20). The TTBS was then discarded and the membrane was washed
three times, each for 2min, with 100ml of PFW. LPS protein bands were visualized
after 50 ml of colloidal gold total protein stain (Bio-Rad) was added to the
membrane. Once the desired staining intensity had been obtained the membrane was
washed repeatedly in water, allowed to dry, digital scanned and recorded.
2.12.6 Limulus amoeboevte lysate assay (LAL assay)
The endotoxic activity of lyophilized preparation of different LPSs was determined
by an endpoint method of LAL-assay using the Pyrochrome LAL kit (see section
2.3) which is based on the original work of Levin and Bang (1964). As described in
the manufacturers instructions, Pyrochrome reagent was resuspended in 3.2ml of
Pyrochromc buffer and kept in ice. To achieve a 1.0 EU/ml concentration, 2ml of
LAL reagent water (LRW) was added to a vial containing 0.2ng of control
endotoxin of E.coli. Applying doubling dilutions from 1.0 EU/ml (O.lng/m)
downwards, a 7 points standard curve was created. Samples of LPS preparations
(lOpg/ml and lOOpg/ml) resuspended in LRW were then added at 50pl per well in a
96 well plate. PFW was included as a control.
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A 50jll1 volume of reconstituted Pyrochrome reagent was then added to each sample
or control and the plate was shaken gently, incubated at 37°C for 30 min. A 25pi
volume of 50% acetic acid in PFW was then added to each well in order to stop the
reaction. Absorbance values were read at 405nm on an Anthos 2001 automated plate
reader.
2.13 Preparation of human monocytes for the bioassav
2.13.1 Media and reagents
Medium used to maintain human monocytes was prepared by adding 5 ml of human
serum (HS:Sigma) to 50 ml of RPMI 1640 medium (RPMI/10%HS). White cell
diluting fluid, WCDF was prepared by mixing 0.01% of Gentian Violet in 1% acetic
acid. Crystal violet for TNF-oc bioassay was prepared by mixing 0.5% Crystal Violet
in 20% methanol in PFW and filtered through Whatman no.l paper. Stocks of LPS
samples were prepared at lmg/ml by adding 5mg to 5ml of PFW then adding 5pi of
triethlyamine (TEA) to completely dissolve the LPS. Human recombinant TNF-a for
a standard curve control was purchased from NIBSC, (Hertfordshire, UK).
2.13.2 Separation of peripheral blood mononuclear cells (PBMC1 from blood
Whole venous blood samples were obtained aseptically from healthy volunteers and
placed in sterile heparinised tubes. One volume of blood sample was added to 3
volumes of sterile PBS. The mixture was then smoothly layered onto 10ml of pre-
warmed Histopaque-1077 (Sigma) at 37°C. Red blood cells and granulocytes were
separated from the PBMC following centrifugation at 300g for 30min at room
temperature. The interface layer containing PBMC was carefully transferred by a
sterile plastic pipette to a centrifuge tube and washed once with PBS and then RPMI
1640 medium at 300g for 7min. Finally PBMC was then resuspended in appropriate
medium at the required concentration.
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2.13.3 Counting of white blood cells
Pelleted PBMC were resuspended in 10ml of RPMI/10%HS. Of this suspension,
10(il was added to 90|ol of WCDF. One chamber of an assembled haemocytometer
(Hawksley, London) was then filled with a portion of the sample. Only monocytes
cells which are characterised by an irregular nucleus and a prominent extended
cytoplasm were counted for the purpose ofmonocytes plating experiment.
2.13.4 Separation of monocytes from PBMC
PBMC were resuspended at 2xl05 monocytes per ml, plated at lOOjol per well of a 96
well plate (Iwaki, Stone, UK) and incubated at 37°C for lh in order to allow adhering
of monocytes. Non-adherent cells were then removed with moderate shaking. Cells
were then washed 3-4 times with sterile PBS and then resuspended in a medium as
outlined in section 2.16.
2.14 Preparation of THP-1 cell line for bioassay
The human THP-1 cell line was used in parallel with human PBMC to measure the
cytokine responses. After confluency was reached, THP-1 cells were resuspended at
5xl05 cells/ml in RPMI/10%FCS. Untreated suspension was seeded at 1 OOpl in each
well of a 96-well tissue culture plate and cells were permitted to adhere by
incubation at 37°C, 5% CO2 overnight. For pre-trcatcd suspension, 2ml of working
concentration (=1 pM) of Vitamin D3 (1,25-dihydroxyvitamin D3, Sigma) were add
to every 20ml of the cell suspension (final concentration = 0.1 pM) in order to
differentiate THP-1 cells into the macrophage-like lineage. lOOpl of this suspension
was added to each well of 96-wcll tissue culture plate, incubated for 72h at 37°C and
5% CO2. After incubation, medium was gently removed from both untreated and pre-
treated cells, and directly replaced by lOOpl of serial dilutions of LPS samples (see
section 2.17)
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2.15 Preparation of LPS dilutions
In a new 24-well culture plate, 10 fold x 7 times serial dilutions were created in
RPMI/10%HS medium. Defrosted stock of LPS (lOpl) at lmg/ml were added to
990pl of the medium to achieve lOpg/ml, from which, 30|il were added to 270pl of
the medium to achieve 1 pg/ml (=1000ng/ml) as a starter concentration. The previous
step was repeated across the plate to achieve the rest of six decreasing concentrations
(lOOOng, lOOng, lOng, lng, 0.1ng and 0.01 ng).
A cocktail of LPSs experiment in which a constant concentration of 200ng/ml from
one type of LPS (i.e LPS1) mixed with serial dilutions of another type of LPS (i.e
LPS2) were also done. Defrosted stock of LPS (10pl) at lmg/ml were added to 990pl
of the medium to achieve lOpg/ml then 20pl of this were added to 980|ll of the
medium to get the final concentration of 200ng/ml .
The serial dilution of LPS2 were achieved by adding lOfxl of defrosted stock of LPS2
at lmg/ml to 990pl of the medium to achieve 10|lg/ml. From this, 50jll1 were added
to 250ul of the medium to achieve 2pg/ml (=2000ng/ml) as a starter concentration.
The previous step was repeated across the plate to achieve the rest of six decreasing
concentrations (2000ng, 200ng, 20ng, 2ng, 0.2ng and 0.02ng).
When cocktail experiment was attempted 50pl of constant concentration of LPS1
were added to 50pl of the corresponding dilution of LPS2 so that all concentrations
were decreased by half.
The constant concentration of LPS 1 alone was also tried by adding 10pl of defrosted
stock of LPS 1 at lmg/ml to 990pl of the medium to achieve lOjig/ml. From this lOjil
were added to 990|il of the medium to achieve lOOng/ml. lOOftl volume from this
concentration was examined with each cocktail experiment plate.
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2.16 Challenging ofmonocytes or THP-1 cells with LPS
A 100|il volume of the series of six LPS dilutions described in the previous section
were added to the plated human monocytes or THP-1 cells prepared as in sections
2.13.4 and 2.14 respectively. Cell culture plates were then incubated at 37°C for 4h.
Some wells were left with medium alone as a control. Finally, supernatants were
collected and cytokine levels measured .
2.17 Cytokines detecting assays
2.17.1 L929 bioassav
L929 cells were used in a bioassay since they are sensitive to the cytotoxic effect of
bioactive TNF-a. A method based on the work of Delahooke et a/.(1995) was
applied. Sub-confluent monolayers of L929 cells were trypsinized using the
trypsin/EDTA method (section 2.5.1) and resuspended at 4xl06 cells/ml in
DMEM/5%FCS. Aliquots of 1 OOpl of the cell suspension were then seeded in each
well of 96-well tissue culture plate and cells were permitted to adhere for 3-4h of
incubation.
Supernatants were then carefully aspirated from each well and replaced with 90|ll
(sample wells) or lOOpl (standard curve wells) of DMEM/5%FCS/Act. The standard
curve was created by removing 1 Ojil ofmedium from well number one and replaced
with lOpl of 100,000 IU/ml recombinant human TNF-a in PBS (NIBSC,
Hertfordshire, UK) to make the concentration in the first wall of 10,000 IU/ml. A 3.2
fold serial dilutions arise from well number one was made along the standard curve
across the plate by taking 45pl along and mixing into the lOOpl already present. The
final 45|il was removed from the last well in the row. For sample measurement, lOpl
of fresh supernatant from challenged cells was transferred to the 90|il of
DMEM/5%FCS/Act already present in each sample measurement well. Plates were
then incubated at 37°C, 5% CO2 overnight.
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The next day, medium was discarded by inverting the plates. Viable cells were then
stained with 50)0.1 of L929 assay crystal violet which was added to each well and left
for 3-4min, subsequently washed thoroughly under the tap, and briefly dried on
tissue to remove the excess water. 50jol of L929 assay acetic acid (20% acetic acid in
distilled water) was then added to each well to solubilise the stained cells. Optical
density was measured with an automated microplate reader (Anthos 2001) at 540nm
and all values were reported as the mean of triplicate measurements and compared to
the standard curve.
2.17.2 Enzyme linked immunosorbent assay ( ELISA)
Sandwich enzyme-linked immunosorbent assay of DuoSet system from R&D
(Abingdon,UK) was used to detect the immuno-reactive TNF-a or IL-lp levels
according to the manufacturer's instructions. A 100p.l of working concentration
(4pg/'ml for both TNF-a and IL-1 (3) of capture antibody were added to each well of
96-well tissue culture plate, sealed and incubated overnight at room temperature. The
plate was then aspirated, washed three times with wash buffer (0.05% Tween 20 in
sterile PBS) at 400pl/well and inverted against clean paper towels to remove any
remaining wash buffer. A 300p,l of Blocking buffer (1% Bovine serum albumin,
BSA (Sigma) in sterile PBS) was then applied for a minimum of lh at room
temperature and additional aspiration/wash step was then repeated.
Fresh sample supernatants (100pl per well) from challenged cells (see section 2.16)
were transferred to the plate in addition to two internal standard curves which were
included in every plate to measure the concentration ofTNF-a or IL-1 (3 in sample.
The internal standard curve for TNF-a ELISA assay was achieved by reconstituting
290ng/ml of ELISA recombinant human TNF-a with 0.5ml of filtered reagent
diluent (1% bovine serum albumin, BSA (Sigma) in sterile PBS). From which, 10pl
was added to 2900pl of filtered reagent diluent to achieve the working concentration
of lng/ml.
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The standard curve wells were filled by 600|il of filtered reagent diluent and 2-fold
serial dilutions were achieved by transfer and well mix 600fil from the working
concentration of recombinant human TNF-a along seven wells of this standard
curve. The highest standard curve concentration of lng/ml was included followed by
500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml, 31.25pg/ml and 15.625pg/ml.
The internal standard curve for IL-1 (3 ELISA assay was achieved by reconstituting
1 lOng/ml ofELISA recombinant human IL-1 p with 0.5ml of filtered reagent diluent.
From which, 6|il was added to 2640pl of filtered reagent diluent to achieve the
working concentration of 250pg/ml. The standard curve wells were filled by 600|_ll of
filtered reagent diluent and 2-fold serial dilutions were achieved by transfer and well
mix 600|_ll from the working concentration of recombinant human IL-1 (3 along seven
wells of this standard curve. The highest standard curve concentration of 250pg/ml
was included followed by 125pg/ml, 62.5pg/ml, 31.25pg/ml, 15.625pg/ml,
7.8125pg/ml and 3.90625pg/ml.
The plate was then covered, incubated for 2h at room temperature and a third
aspiration/wash step was then followed. A lOOpl volume ofworking concentration of
detection antibody (75ng/ml for TNF-a and lOOng/ml for IL-1 (3) was applied to
each well of the plate, sealed and incubated for 2h at room temperature and a fourth
aspiration/wash step was then followed. Avoiding direct light for the rest of the
assay, 100|il of working cone (50|al in 10ml of reagent diluent) of Streptavidin-HRP
were added to each well of the plate, incubated for 20min at room temperature and a
final aspiration/wash step was then followed. lOOpl of a complete substrate solution
(1 tablet TMB (Sigma) dissolved in 10ml citrate phosphate buffer and 2pl of
30%H2O2) were then added to each well of the plate, incubated for 20min at room
temperature and finally the colour reaction was stopped by adding 50prl of Stop
solution (1M H2SO4) to each well, the plate was tapped to ensure thorough mixing.
Absorbance optical density was measured with an automated microplate reader
(Anthos 2001) at 450nm, all values were reported as the mean of triplicate
measurements and compared to standard curve.
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2.18 Toll like receptor assay
2.18.1 Plasmids
The following expression plasmids were a kind gift from Dr Clett Erridge
(University of Strathclyde, Glasgow, UK):
1) pELAM stands for NF-kB dependent endothelial leukocyte adhesion molecule 1
promoter Luciferase, it is also called NF- kB dependent E-selectin promoter
(Schindler and Baichwal, 1994; Chow et al., 1999; Erridge et al., 2007b).
2) The pRL plasmid is designed to express renilla luciferase driven by a
cytomegalovirus promoter and was used as an internal control for efficiency of
transfection.
3) The pCMV plasmid acts as a co-transfectant to maintain the quantity of DNA
constant between transfections.
4) pCD14 expresses human cDNA for CD 14
5) pTLR2 expresses human cDNA for TLR2
6) pTLR4 expresses human cDNA for both TLR4 and MD2
2.18.2 Transient transfection of HEK-293 cell line
To give 60-70% confluence at the day of transfection, HEK-293 cells were grown at
an initial density of 8x104 cells per ml, plated at lOOpl per well of 96-wcll plate and
incubated at 37°C, 5% CO2 the night prior to transfection. The following day, 168pl
ofDMEM/0% FCS were added to three sterile eppendorf tubes labelled TLR2, TLR4
and CD 14. 6.3pl ofGeneJuice transfection reagent (Novagen) were then added to the
three tubes, briefly vortexed and allowed to sit for 5min at room temperature.
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Plasmid constructs were then defrosted, added to the three tubes as outlined in Table
2.9, smoothly mixed and allowed to sit for lOmin at room temperature. Carefully,
5.6|il from each tube were added to 24 wells of 96-well plated HEK-293 cells and
incubated again at the same conditions for 48-72h.




pELAM (lOng) 0.9(ll 0.9(0.1 0.9(0.1
pCD14 (30ng) 1.6(0.1 1.6|ol 1.6(01
pCMV 1.8|ol 2.7(il
pRL 2.4(0,1 2.4|ol 2.4(ol
pTLR2 (10ng) 3.3|il
pTLR4 (30ng) 5.4(il
2.18.3 Stimulation of transfected HEK-293 cell
LPS and heat killed bacteria (HKB) samples were made up in DMEM/1% FCS. The
medium was then removed from the transfected cell culture plates (previous section)
and quickly replaced by 120jll per well of either LPS or HKB samples. One row was
left with medium alone, another with E. coli LPS as a TLR4 positive control and a
third lane with P. gingivalis LPS as TLR2 positive control. The plate was then
returned to the incubator at 37°C, 5% CO2 overnight.
2.18.4 Luciferase assay
Two Luciferase assays were applied, firefly luciferase which is a 61kDa protein
isolated from beetles (Photinus pyralis) and Renilla luciferase which is a 36kDa
protein from sea pansy (Renilla reniformis) that was used to normalize and control
the transfection process in the firefly luciferase assay (Matijasevic et al., 2001;
Nieuwenhuijsen et al., 2003).
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The following day after stimulation of transfected HEK-293 cell, 10ml per plate of
lysis buffer were defrosted. This lysis buffer was prepared by adding 168 ml distilled
water to 25 mM Tris (605 mg), 8 mM MgCl2.6H20 (325 mg), 1 mM DTT (30.8 mg),
1% Triton X-100 (2 ml) and 30ml glycerol. The pH was then adjusted to 7.8.with
phosphoric acid.
A sufficient amount of luminescent reagent, either for firefly luciferase or Renilla
luciferase was also defrosted. Firefly luciferase luminescent reagent buffer was
prepared by adding 1 mM ATP (36.5 mg), 0.25 mM Lucferin (5 mg) (Sigma), 1%
BSA (662 mg) to 66.2ml of lysis buffer. Rcnilla luciferase luminescent reagent
buffer was prepared by dissolving Coelenterazine to lmg/ml in absolute EtOH then
aliquoted into foil wrapped eppendorfs then stored desiccated at -80°C. It was then
diluted 1:500 in room temperature PBS just before use.
Plated cells were washed with 120|il per well of PBS, then lysed by adding 1 OOjllI per
well of lysis buffer. Using a multichannel pipette, wells were then scratched several
times in a circular motion, pipetted up and down several times to ensure all cells
were lysed. A 40|il sample from each well was then transferred to a white
luminometer plate and either one of the previous luminescent reagent buffers was set
up to inject 40pl per well. Finally, the plate was placed in a BMG Lumistar Galaxy
and read according to manufacturer's instructions
The fold expression was presented in the graph and calculated as counts from
pELAM expression divided by counts from pRL which gives raw promoter
expression (RPE). Fold induction is the RPE for treated cells divided by the RPE
value for cells cultured in medium alone.
2.19 Statistical analysis
The results depicted in section 3.2 to section 3.7 are expressed as means +/- SEM of
at least three independent experiments and analysed by student t-test. P values of





LPS preparations were extracted by 4 different extraction methods and all of them
were further repurified by the method described in (section 2.11).
All of the 4 methods have been successfully applied to E. coli, B. fragilis, Ps.
aeruginosa. LPS extracted by PCP method from B. fragilis showed the least yield
and the hardest to solubilise. R. sphaeroides LPS has been extracted by two methods,
PCP and PW.. As shown in Table 3.1, yields of LPSs extracted by these methods and
the percentage of the extracted LPS from the dry weight of the bacterial cell varied
between methods. The highest LPS yield seems to be that extracted by BW method
from E. coli, B. fragilis and Ps. aeruginosa. The lowest LPS yield seems to be that
extracted by TM/TMP method from E. coli. The next lowest LPS yield seems to be
that extracted by PCP method from B. fragilis.
The structural morphology of the investigated LPS preparations were analysed by
non-SDS PAGE:
3.1.1 Electrophoretic analysis of is. coli 018K LPS preparations
Three different methods were used to extract LPS form E. coli: TM/TMP, AP and
BWP methods (Fig 3.1A, B). Four extracted LPS preparations were further repurified
to remove any possible protein contaminants (Fig 3.1C).
The LPS preparations used in (Fig 3.1A) were submitted to non-SDS PAGE in which
the LPS components travel in the gel according to their molecular weights, and LPSs
were visualized by silver staining. An overall view of the E.coli LPS profiles
demonstrated in Fig 3.1 A, which represent the unpurified LPS preparations (EClu,
EC2u, EC3u and EC4u), reveals some differences between these four chcmotypes
which are resultant from different extraction methods as mentioned above. EClu,
EC2u, EC3u, which were extracted by TMP, TM and AP respectively, show an
almost equal intensity in the low-molecular mass of Lipid A regions seen in the base
line of the gel (labeled R), EC3u shows the most intense one. On the other hand,
EC4u, which was extracted by BWP, seems to be faint in that low-molecular mass
region compared with the other three profiles. Nevertheless, all of this fast-migrating
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material of the 4 LPS profiles are discernible as a doublet of bands. Similarly,
common antigen (CA) band, which is present behind the main front band, has almost
the same intensity in EClu, EC2u and EC3u but it is very faint in EC4u.
Table 3.1 Yields of different LPSs obtained by different extraction methods

















AP 5.4g 64.5mg 1.2% 3.3g 12.9mg 0.4% - - -
TM 2g l.lmg 0.06% 2g 36mg 1.8% 2g 15.1mg 0.76%
TMP 2g 2.9mg 0.15% 2g 19.1mg 0.96% 2g 27.3mg 1.37%
BW 180mg 18.1mg 10.1% 200mg 20.3mg 10.15% 250mg 12.8mg 5.12%
PCP - - - - - - 3.6g 8.1mg 0.23%
(AP) = aqueous phenol method, (TM) = Triton/magnesium chloride method, (TMP) =
Triton/magnesium chloride plus proteinase K treatment method, (BW) = Boiling water/ Proteinase K
treatment method, (PCP) = Phenol/chloroform/petroleum spirit method, (cell dw) = dry weight of the
bacterial cell before LPS extraction, (LPS dw) = dry weight of the specific LPS, (%) = percentage of
the extracted LPS from the bacterial cell dry weight.
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Figure 3.1 Analysis of E. coli 018K- LPS preparations by non-SDS PAGE and colloidal gold total
protein
(A) = non-SDS PAGE for unpurified LPSs, (B) = colloidal gold stain for unpurified LPSs, (C) = non-
SDS PAGE for unpurified and purified LPSs, (EClu) = unpurified E. coli LPS extracted by TMP,
(EClp) = purified EClu LPS, (EC2u) = unpurified E. coli LPS extracted by TM, (EC2p) = purified
EC2u LPS, (EC3u) = unpurified E. coli LPS extracted by AP, (EC3p) = purified EC3u LPS, (EC4u) =
unpurified E. coli LPS extracted by BWP, (EC4p) = purified EC4u LPS, (R) = rough LPS at gel front,
(CA) = common antigen, (S) = ladder pattern of smooth LPS.
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All of these four chemotypes yielded the classical ladder-like O-antigenic domain
profiles of smooth LPS. Moreover, the migration pattern of these high-molecular
weight bands are almost identical. In this stage of LPS analysis, EClu and EC3u
demonstrate the much similar patterns to the classical LPS.
The LPS preparations were submitted to non-SDS PAGE transferred to nitrocellulose
membrane and subjected to colloidal gold staining to detect any protein contaminants
(Fig 3.IB). For the rough type regions, since EC4u has the most faint rough region in
Fig 3.1 A, it obviously shows the most rough domain free from protein contaminants
followed by EClu and EC2u as they both have same protein materials in the rough
type regions. Parallel to the level of intensity of the rough type region shown in Fig
3.1A, EC4u also shows the most rough type region that contains most attached
protein materials to both rough type and common antigen regions as well. The
clearest CA region from protein is EC4u since it is the most faint one in PAGE gel
followed by EC2u then EClu (Fig 3.IB). However, the main difference in the
content of protein material is demonstrated in the high-molecular weight bands.
EC3u seems to have the cleanest smooth type that is almost free from protein
followed by EClu which is extracted by TMP. On the other hand EC2u has higher
protein contaminants since it was extracted by TM only. Although EC4u LPS was
extracted by BWP which is include proteinase K treatment, it contains the most
protein materials in the smooth type regions.
The LPS preparations were submitted to non-SDS PAGE, and LPSs were visualized
by silver staining (Fig 3.1C). An overall view of the E.coli LPS profiles
demonstrated the unpurified and purified LPS preparations (EClu, EClp, EC2u,
EC2p, EC3u, EC3p, EC4u, and EC4p), directly reveals a noticeable drop in protein
contents after applying the repurification method to eliminate the protein
contaminants except between LPS profiles extracted by TMP and AP respectively
(EClu, EClp, EC3u, and EC3p) which arc nearly identical in the gel before and after
repurification. EC4p appears to be the LPS that contains the least protein followed by
EClp. Although EC2p demonstrates a more protein free profile than EC2u, it still
shows a clear band just under the ladder pattern region that is probably protein in
nature.
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3.1.2 Electrophoretic analysis ofB. fraeilis LPS preparations
Four different methods were used to extract LPS form B. fragilis: TM/TMP, PCP,
BWP and AP (Fig 3.2A, B). Five extracted LPS preparations were further repurified
to remove any possible protein contaminants (Fig 3.2C).
The LPS preparations were subjected to non-SDS PAGE and the LPS visualized by
silver staining (Fig 3.2A). LPS profiles which represent the unpurified LPS
preparations (BFlu, BF2u, BF3u and BF4u), reveals also some differences between
these four chemotypes which are a result of the different extraction methods as
mentioned above. BFlu, BF2u and BF3u which were extracted by TM, TMP and
PCP respectively, show an almost equal intensity in the low-molecular mass of Lipid
A regions seen in the base line of gel (labeled R) with the most intense pattern in
BF2u. On the other hand, BF4u, which was extracted by BWP, seems to be faint in
that low-molecular mass region compared with the other three profiles. The high
molecular weight bands were more defined in BFlu and BF2u. While BF3u show
major diffuse material located just behind the fast-migrating band. To a lesser extent,
the appearance ofBF4u profile is similar to that ofBF3u in this region.
The LPS preparations used in Fig 3.2B were submitted to non-SDS PAGE
transferred to nitrocellulose membrane and proteins present visualized by colloidal
gold staining. BFlu and BF4u showed a rough region almost clear from protein
material. The rough type area of BF2u appeared to have very little protein associated
with it while BF3u shows a little protein material in its rough region. The main
differences were concentrated in the higher molecular weight bands, in which BF2u
shows the clearest profile among not only B. fragilis LPS profiles but also among all
examined LPS profiles before the repurification method was applied. BFlu and
BF4u show some protein contaminated bands in their high-molecular weight regions.
But the worst scene is shown in BF3u profile which contains high level of protein
contaminants diffused along its high-molecular weight region.
A comparison between unpurified LPS preparations (BFlu, BF2u, BF3u, BF4u and
BF5u) and repurified LPS preparations (BFlp, BF2p, BF3p, BF4p and BF5p) is seen
in Fig 3.2C. It considerably demonstrates clear profiles of repurified LPS
preparations after the repurification procedure was applied.
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Figure 3.2 Analysis of B. fragilis NCTC 9343 LPS preparations by non-SDS PAGE and colloidal gold
total protein
(A) = non-SDS PAGE for unpurified LPSs, (B) = colloidal gold stain for unpurified LPSs, (C) = non-
SDS PAGE for unpurified and purified LPSs, (BFlu) = unpurified B. fragilis LPS extracted by TM,
(BFlp) = purified BFlu LPS, (BF2u) = unpurified B. fragilis LPS extracted by TMP, (BF2p) =
purified BF2u LPS, (BF3u) = unpurified B. fragilis LPS extracted by PCP, (BF3p) = purified BF3u
LPS, (BF4u) = unpurified B. fragilis LPS extracted by BWP, (BF4p) = purified BF4u LPS, (BF5u) =
unpurified B. fragilis LPS extracted by AP, (BF5p) = purified BF5u LPS, (R) = rough LPS at gel
front, (H) =high molecular weight region.
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3.1.3 Electrophoretic analysis of Ps. aeruginosa PA-01 L and R. sphaeroides LPS
preparations
Three different methods were used to extract LPS form Ps. aeruginosa: TM/TMP,
AP and BWP methods (Fig 3.3A, B). AP and PCP methods were used to extract
LPS from R. sphaeroides and Fig 3.3C shows R. sphaeroides LPS which was
extracted by AP method. The Ps. aeruginosa LPS preparations were subjected to
non-SDS PAGE and the LPSs were visualized by silver staining (Fig 3.3A). An
overall view of the Ps. aeruginosa LPS profiles demonstrated in Fig 3.3A, which
represent the unpurified LPS preparations (PAlu, PA2u, PA3u and PA4u), reveals
some differences between these four chemotypes which are a result of the different
extraction methods used. PAlu, PA2u and PA3u which were extracted by TM, TMP
and AP respectively, show an almost equal intensity in the low-molecular mass Lipid
A regions seen in the base line the of gel with most intense pattern in PA2u. On the
other hand, PA4u, which was extracted by BWP, seems to have only a faint profile in
that low-molecular mass region compared with the other three profiles. The ladder
pattern of smooth type region is seen in the four LPS profiles with a classical and
distinguished appearance in PAlu and PA2u. PA3u and PA4u exhibit a closely
spaced smooth type regions.
The LPS preparations used in (Fig 3.3B) were submitted to non-SDS PAGE
transferred to nitrocellulose membrane and proteins present visualized by colloidal
gold staining. There are very little differences between PAlu, PA2u and PA3u in the
protein contaminants in their rough regions. They also have a protein contaminants in
their common antigen regions. PA4u shows the least protein material not only in
both rough and common antigen regions, but also in its smooth type regions. PA3u
has the most contamination of the smooth type region with protein material whereas
the proteinase K treatment does not make a noticeable difference between PAlu and
PA2u in their high-molecular weight regions since the later was subjected to such
treatment.
R. sphaeroides LPS was a difficult LPS to extract and many extraction methods were
used. These methods included PCP with applying both further procedures of
ether/acetone and water and TM procedures.
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Figure 3.3 Analysis of Ps. aeruginosa PA-01 and R. svhaeroides LPS preparations by non-SDS PAGE
and colloidal gold total protein
(A) = non-SDS PAGE for unpurified Ps. aeruginosa LPSs, (B) = colloidal gold stain for unpurified
Ps. aeruginosa LPSs, (C) = non-SDS PAGE for unpurified and purified R. sphaeroides LPSs, (PAlu)
= unpurified Ps. aeruginosa LPS extracted by TM, (PAlp) = purified PAlu LPS, (PA2u) = unpurified
Ps. aeruginosa LPS extracted by TMP, (PA2p) = purified PA2u LPS, (PA3u) = unpurified Ps.
aeruginosa LPS extracted by AP, (PA3p) = purified PA3u LPS, (PA4u) = unpurified Ps. aeruginosa
LPS extracted by BWP, (PA4p) = purified PA4u LPS, (RSlu) = unpurified R. sphaeroides LPS
extracted by AP, (RSlp) = purified RSlu LPS.
85
The only success of extracting this kind of LPS was when applying the AP procedure
after a full depigmentation process (Fig 3.3C). However the author was given three
previous small LPS stocks of this species most kindly extracted by Mr Robert Brown
and Mr Fraser Pike. Fig 3.3C shows that there are not many differences between
RSlu and RSlp and in addition they both exhibit a faint appearance.
3.2 Activity of LPS preparations in LAL assay
The endotoxic activity of all crude LPS preparations was measured by an endpoint
method of LAL assay. All of E. coli LPS preparations reveal different levels of LAL
activity as shown in Fig 3.4A either at O.lng/ml or O.Olng/ml concentrations. EC3u
which was extracted by AP method reveals the most active preparations at O.lng/ml
that was significantly higher than all other four E. coli LPS preparations (p< 0.05) at
O.lng/ml concentration. Nevertheless, EC3u was not statistically significant at
O.Olng/ml (p< 0.05). While EClu which was extracted by TMP shows the least LAL
activity. Also obvious is the huge differences in the LAL activity between O.lng/ml
and O.Olng/ml concentrations for all E. coli LPS preparations.
An almost identical scenario is repeated by Ps. aeruginosa LPS preparations which
demonstrate different levels of LAL activity as shown in Fig 3.4A either at O.lng/ml
or O.Olng/ml concentrations. However, there is no much difference between PAlu
and PA2u in their LAL activities. PA4u which was extracted by BWP method
reveals the most active preparations among all Ps. aeruginosa LPS preparations at
O.lng/ml concentrations but it was significantly higher when compared to PA3u only
(p< 0.05). Again a large differences in the LAL activity between O.lng/ml and
O.Olng/ml concentrations for all Ps. aeruginosa LPS preparations is observed. EClu,
EC2u, EC3u, EC4u and PA4u showed a significant differences between O.lng/ml
and O.Olng/ml (p< 0.05).
B. fragilis crude and purified LPSs were tested again as shown in Fig 3.4B. It is
obvious from Fig 3.4A that the LAL activity ofmost B. fragilis LPSs is much lower
than the activity of other tested LPSs. However, BF5u is approximately fivefold
more active than other B. fragilis LPSs at the concentration of O.lng/ml of LPS (Fig
3.4B). It also showed a significant statistical difference among all other B. fragilis
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Figure 3.4 The LAL activity of different LPS preparations
(A) = LAL activity ofunpurified LPSs, (B) = LAL activity ofunpurified and purified B. fragilis LPSs,
(BFlu) = unpurified B. fragilis LPS extracted by TM, (BFlp) = purified BFlu LPS, (BF2u) =
unpurified B. fragilis LPS extracted by TMP, (BF2p) = purified BF2u LPS, (BF3u) = unpurified B.
fragilis LPS extracted by PCP, (BF3p) = purified BF3u LPS, (BF4u) = unpurified B. fragilis LPS
extracted by BWP, (BF4p) = purified BF4u LPS, (BF5u) = unpurified B. fragilis LPS extracted by
AP, (BF5p) = purified BF5u LPS, (BF EDL) = Fieat killed bacteria of B. fragilis of electronic dense
layer population, (BF SC) = Heat killed bacteria of B. fragilis of small capsule population, (BF LC) =
Heat killed bacteria ofB. fragilis of large capsule population, (HPW1) = Injection pyrogen free water,
(FIPW2) = Highly purified water 1, (IIPW3) = Highly purified water 2, (BLANK) = Empty wells,
Results represent the means +/- SEM for at least two experiments. ' Indicates data point represent a
statistical difference from other data points (p<0.05).
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crude and purified LPSs (p< 0.05) at O.lng/ml but not at O.Olng/ml. Although BFlu
and BF3u show a considerable higher activity in the data depicted in Fig 3.4A at the
same concentration, these results probably reflect inconsistence readings from three
experiments (0.06-0.066-0.39) and (0.07-0.052-0.28) for BFlu and BF3u
respectively. There are no much differences between the activity of all B. fragilis
LPSs at the concentration ofO.Olng/ml of LPS.
It is also reasonable that heat killed bacteria of B. fragilis from three different
populations of different capsular polysaccharide all significantly showed high LAL
activity compared to other LPS samples except BF5u (p< 0.05).
3.3 Different LPS preparations of the same bacterial species stimulated TNF-a
production by human PBMC
3.3.1 Different LPSs ofE. coli stimulated TNF-a production measured by L929
cell line
E. coli LPS preparations were picked to measure their ability to produce TNF-a from
human PBMC isolated from five healthy volunteers and then measured by L929 cells
which are sensitive to the cytotoxic effect of this specific cytokine (Fig 3.5). General
view of these TNF-a responses show that there are reasonable differences at two
higher concentrations (1 Opg/ml and 1 pg/ml) among all these E. coli LPSs.
EClu which was extracted by TMP reveals the highest ability to induce TNF-a
production especially at lOpg/ml and lpg/ml concentrations followed by EC3u
which was extracted by AP. At 10jig/ml EClu and EC3u were significantly higher
than both EC2u and EC4u (p< 0.05). At lpg/ml EClu was significantly higher than
all other E. coli LPS preparations whereas EC3u was significantly higher than EC4u
only (p< 0.05). Furthermore, EC2u reveals low TNF-a production comparing with
other E. coli LPSs and especially EClu. EClu and EC2u were extracted with the
same method with the only difference being proteinase K treatment applied to the
former.
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concentrations from different E. coli LPSs and measuring by L929
(EClu) = unpurified E. coli LPS extracted by TMP, (EC2u) = unpurified E. coli LPS extracted by
TM, (EC3u) = unpurified E. coli LPS extracted by AP, (EC4u) = unpurified E. coli LPS extracted by
BWP. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
Figure 3.6 TNFoc production (IU/mP after 4 h by human PBMC after stimulation with different
concentrations from different E. coli LPSs and measuring by ELISA
(EClu) = unpurified E. coli LPS extracted by TMP, (EC2u) = unpurified E. coli LPS extracted by
TM, (EC3u) = unpurified E. coli LPS extracted by AP, (EC4u) = unpurified E. coli LPS extracted by
BWP. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
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3.3.2 Different LPSs of E. coli stimulated TNF-a production measured by
ELISA
The same approach was used to measure the ability of E. coli LPS preparations to
produce TNF-a via human PBMC but then measured by ELISA assay (Fig 3.6).
Again EClu and EC3u stimulated the most TNF-a production at the higher
concentration of 10(ig/ml and lpg/ml. At 10|ig/ml EClu and EC3u were again
significantly higher than both EC2u and EC4u (p< 0.05). But both of EClu and
EC3u were not significantly higher than EC2u and EC4u at l|lg/ml (p< 0.05).
There was a marked difference between the levels of TNF-a production ofEClu and
EC2u despite the fact they are both extracted with the same method TM/TMP apart
from proteinase K treatment in the latter. Once again EC4u exhibited the least
amount ofTNF-a production at the higher concentration of 10|tg/ml and l|_lg/ml (Fig
3.6). Both Fig 3.5 and Fig 3.6 demonstrate that TMP and AP methods produced
LPSs that induce high TNF-a response compared to that ofTM and BWP.
3.3.3 Different LPSs of B. fragilis stimulated TNF-a production measured by
ELISA
B. fragilis LPS preparations were also chosen to compare their ability to produce
TNF-a from human PBMC and then measured by ELISA (Fig 3.7). BF4u which was
extracted by the mild method of BW showed the most significant TNF-a production
at 10pg/ml LPS concentration compared to BF2u and BF3u but not BFlu. BFlu in
turn showed a significant higher TNF-a production compared to BF3u but not BF2u
(p< 0.05). At 1 jag/ml, BF4u showed a significant higher TNF-a production compared
to other three B. fragilis LPS preparations. Moreover, TNF-a production in response
to BFlu remained significantly higher at lower concentrations 0.1 pg/ml and
O.Olpg/ml compared to BF3u and BF4u; and BF3u respectively. While BF3u which
was extracted by the PCP method produced the least amount of that cytokine at the
same concentration. Moreover, there was little difference between all of these B.
fragilis LPSs at the concentration of lpg/ml. Again BF3u which was extracted by
PCP method demonstrated the least ability to produce such a TNF-a response at the
lower concentrations of 0.1pg/ml, O.OljXg/ml, 0.001|lg/ml, 0.000lpg/ml (Fig 3.7).
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Figure 3.7 TNFa production (IU/mll after 4 h by human PBMC after stimulation with different
concentrations from different B. fraeilis LPSs and measuring by ELISA
(BFlu) = unpurified B.fragilis LPS extracted by TM, (BF2u) = unpurified B. fragilis LPS extracted
by TMP, (BF3u) = unpurified B. fragilis LPS extracted by PCP, (BF4u) = unpurified B. fragilis LPS
extracted by BWP. Results represent the means +/- SEM for at least three experiments. * Indicates data
point represent a statistical difference from other data points (p<0.05).
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3.4 Interactions between different LPSs from various bacterial species in
stimulation TNF-oc production by human PBMC
3.4.1 Interactions between E. coli and B. fraeilis LPSs
Using the ELISA assay to measure the TNF-a production after challenging human
PBMC cells, with mixture ofE. coli LPS preparations extracted by different methods
with their equivalent B. fragilis LPS preparations (Fig 3.8, Fig 3.9, Fig 3.10, Fig
3.11).
In parts A of these figures, comparisons between various concentrations ofB. fragilis
LPS alone and various concentrations of B. fragilis LPS plus a constant
concentration of E. coli LPS (lOOng/ml) are displayed. The effect of a maximum E.
coli concentration (lOOng/ml) alone is also included. While parts B demonstrated the
opposite approach in which comparisons were made between various concentrations
of E. coli LPS alone and various concentrations of E. coli LPS plus a constant
concentration of B. fragilis LPS (lOOng/ml). The effect of B. fragilis LPS at
concentration of lOOng/ml is also included. The third approach is depicted in parts C
in which comparisons were made between concentrations of E. coli LPS alone,
concentrations of B. fragilis LPS alone and equal concentrations of E. coli and B.
fragilis LPSs included together the same time. An overall view of parts A in these
figures gives the initial impression that B. fragilis LPS preparations exert a lowering
and masking effect on TNF-a stimulation by the different E. coli LPS preparations
especially at the higher concentrations of lOOOng/ml and lOOng/ml. In parts B, the
ability of constant concentration (lOOng/ml) of different B. fragilis LPS preparations
to lower that of E. coli LPS preparations was clearly demonstrated with EClu/BFlu
at the lower concentrations of EClu LPS (lOng/ml, lng/ml, O.lng/ml). This B.
fragilis LPSs lowering effect was started at much lower concentration of lng/ml with
EC3u/BF3u. On the other hand, it was started at higher concentration of lOOng/ml
with EC4u/BF4u and EC2u/BF2u. However, in parts C, no uniformity of such
lowering effect ofB. fragilis LPSs could be deduced.
In Fig 3.8A, the lowering effect was significant when BFlu+constEClu was
compared to maxEClu at lOOOng, lOng, lng and O.lng (p<0.05). In Fig 3.8B,
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EClu+constBFlu was significantly higher than maxBFlu at only the first two higher
concentrations whereas it was significantly lower than EClu at lower concentrations
of 10, 1 and O.lngs (p<0.05). In Fig 3.11C, EClu/BFlu was significantly higher than
BFlu at all concentrations (p<0.05).
Fig 3.9A showed more significant lowering effect than it was shown in Fig 3.8A. In
Fig 3.9B, EC2u+constBF2u was significantly higher than maxBF2u at the first four
higher concentrations while it was significantly lower than EC2u at only lOOng and
lOng (p<0.05). In Fig 3.11C, EC2u/BF2u was significantly higher than BF2u at all
concentrations while it was significantly lower than EC2u at only 100 and lOngs
(p<0.05).
Fig 3.1 OA shows the least significant lowering effect of its type. In fact,
BF3u+constEC3u was significantly lower than maxEC3u at only lOOOng and lOOng
(p<0.05). In Fig 3.1 OB, EC3u+constBF3u was significantly higher than maxBF3u at
the first three higher concentrations while there was no significant differences
between EC3u+constBF3u and EC3u at any concentration. In Fig 3.10C, EC3u/BF3u
was significantly higher than BF3u at 1000, 100, 1 and O.Olngs (p<0.05), while there
was no significant differences between EC3u/BF3u and EC3u at any concentration.
In Fig 3.11 A, the lowering effect was so representative in such dose-dependent style
with EC4u/BF4u which were both extracted by BW method. In fact
BF4u+constEC4u was statistically significant from maxEC4u at lOOOng, lOOng, lng
and O.lng. In Fig 3.1 IB, EC4u+constBF4u was significantly higher than maxBF4u at
all concentrations while it was significantly lower than EC4u at only lng and O.lng.
In Fig 3.11C, EC4u/BF4u was significantly higher than BF4u at all concentrations
while it was significantly lower than EC4u at only lOOOng (p<0.05).
3.4.2 Interactions between different LPSs and /?. sphaeroides LPS preparations
R. sphaeroides LPS was difficult to extract and RSlu represent the LPS preparation
of this bacteria which was fully depigmented and then extracted by AP method. The
effect of interactions between RSlu and LPSs from different bacterial species in
production ofTNF-a is demonstrated in Fig 3.12. As shown in Fig 3.12A, RSI LPS
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Figure 3.8 TNFa production (m/mll by human 1'BMC after interactions between EClu and BFlu in
different combinations and measured by ELISA
(A) Comparing between various concentrations of BFlu LPS alone and various concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). (B) Comparing between various
concentrations of EClu LPS alone and various concentration of EClu LPS plus constant
concentration of BFlu (lOOng/ml). (C) Comparing between various concentration of EC1 u LPS alone,
various concentrations of BFlu LPS alone and various mixtures of equal concentrations of EClu and
BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).




Figure 3.9 TNFq production (IU/mll by human PBMC after interactions between EC2u and BF2u in
different combinations and measured by EL1SA
(A) Comparing between various concentrations of BF2u LPS alone and various concentrations of
BF2u LPS plus constant concentration of EC2u (lOOng/ml). (B) Comparing between various
concentrations of EC2u LPS alone and various concentration of EC2u LPS plus constant
concentration of BF2u (lOOng/ml). (C) Comparing between various concentration ofEC2u LPS alone,
various concentrations of BF2u LPS alone and various mixtures of equal concentrations of EC2u and
BF2u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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different combinations and measured by ELISA
(A) Comparing between various concentrations of BF3u LPS alone and various concentrations of
BF3u LPS plus constant concentration of EC3u (lOOng/ml). (B) Comparing between various
concentrations of EC3u LPS alone and various concentration of EC3u LPS plus constant
concentration of BF3u (lOOng/ml). (C) Comparing between various concentration of EC3u LPS alone,
various concentrations of BF3u LPS alone and various mixtures of equal concentrations of EC3u and
BF3u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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different combinations and measured by EL1SA
(A) Comparing between various concentrations of BF4u LPS alone and various concentrations of
BF4u LPS plus constant concentration of EC4u (lOOng/ml). (B) Comparing between various
concentrations of EC4u LPS alone and various concentration of EC4u LPS plus constant
concentration of BF4u (lOOng/ml). (C) Comparing between various concentration of EC4u LPS alone,
various concentrations of BF4u LPS alone and various mixtures of equal concentrations of EC4u and
BF4u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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was able to exert a lowering effect against all of the E. coli LPS preparations to the
extent of half of the TNF-a produced by lp,g/ml of EClu, EC2u and EC4u LPSs
alone although they were statistically significant with EClu and EC4u LPSs. It also
exerted a significant lowering effect against EC3u LPS when it went beyond this low
level to almost a third of the amount produce by EC3u LPS alone. The effect of RS1
LPS against B. fragilis LPS preparations (Fig3.12B) was not to the same level
compared with E.coli LPSs. There is very small non-significant lowering effect by
RSI against all except BF3u and BF2u. However, Fig 3.12C shows a noticeable
lowering effect of RSI LPS against all of the Ps. aeruginosa LPS preparations and it
was significant with PAlu and PA3u LPSs which in presence of RSI LPS produced
third and halfof the amount ofTNF-a respectively.
Preparations of a small stock of R. sphaeroides LPSs were given by Mr R. Brown
and Mr F. Pike. These LPS preparations were then examined for their ability to
stimulate TNF-a producion and interact with one preparation of E.coli LPS (Fig
3.13). RS2 LPS was fully depigmented and extracted by PCP method with water,
RS3 LPS was partially depigmented and extracted by PCP method with water and
RS4 was not depigmented and extracted by PCP method with water. Fig 3.13A
shows the TNF-a production after interactions between RS2, RS3 and RS4 at two
concentrations, 10pg/ml and lOOjlg/ml, with EClu at lpg/ml after immediate
mixing. As a rule, significant lowering effects of all of these different preparations of
RS2, RS3 and RS4 were demonstrated with nothing much to distinguish between the
two different concentrations of each of them except with RS4/EClu in which the
higher concentration of 1 OOpg/ml led to a greater lowering effect against EClu. Fig
3.13B shows the TNF-a production after interactions between RS2, RS3 and RS4 at
two concentrations, 10pg/ml and 100p,g/ml, which were added to the cells 2 hour
before adding EClu at lpg/ml. Again significant lowering effect was also noticed





Figure 3.12 TNFq production (IU/ml) by human PBMC after interactions between different LPSs
from different bacterial species and RS1 LPS and measured by L929 cells
(A) TNF-oc production from different E. coli LPSs at 1 pg/ml alone and mixed with R. sphaeroides
LPS at lOOpg/ml. (B) TNF-oc production from different B. fragilis LPSs at I pg/ml alone and mixed
with R. sphaeroides LPS at 1 OOpg/ml. (C) TNF-a production from different Ps. aeruginosa LPSs at
1 pg/ml alone and mixed with R. sphaeroides LPS at 1 OOpg/ml. (RSI) R. sphaeroides LPS fully
depigmented and extracted by AP method. Results represent the means +/- SEM for at least three
experiments. * Indicates data point represent a statistical difference from other data points (p<0.05).
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L929 cytotoxicity bioassay (immediate mixing)
I 25.0
□ 1 ug/ml EC1 u + 10ug/ml RS
m 1 ug/ml EC1u + 100ug/ml RS
RS2/EC1 u RS3/EC1 u RS4/EC1 u EC1u alone






L929 cytotoxicity bioassay ( 2h pretreatment with RSs)
n 1 ug/ml EC1u + 10ug/ml RS
m 1 ug/ml EC1u + 100ug/ml RS
RS2/EC1 u RS3/EC1 u RS4/EC1u EC1u alone
Escherichia coti LPS (1 ug/ml)
Media alone
Figure 3.13 TNFq production (IU/ml) by human PBMC after interactions between different R.
sphaeroides LPS preparations and E. coli LPS extracted by TMP method
(A) TNF-a production from different R. sphaeroides LPS preparations at two concentrations 10pg/ml
and I OOug/rnl mixed immediately with E. coli LPS of EClu at 1 pig/ml. (B) TNF-a production from
different R. sphaeroides LPS preparations at two concentrations 10|ig/ml and lOOpg/ml which added
first to the human PBMC alone and after 2 hour of pre-treatment an E. coli LPS of EClu at 1 pg/ml
were then mixed with. The TNFa production was measured by L929 cells. (RS2) R. sphaeroides LPS
fully depigmented and extracted by PCP method. (RS3) R. sphaeroides LPS partially depigmented
and extracted by PCP method (RS4) R. sphaeroides LPS not depigmented and extracted by PCP
method. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
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3.5 Interactions between different LPSs from different bacterial species in
stimulation TNF-g production by THP-1 cell line
All the time, at least two plates of Vitamin D3 treated and untreated THP-1 cells
were prepared for the interactions experiment.
3.5.1 Interactions between EClu and BFlu LPSs on TNF-g production and
measured by L929 cell cytotoxicity assay
Using the L929 assay to measure the TNF-a production after challenging THP-1
cells, interaction approaches were done between EClu and BFlu LPSs in the manner
identical to that described in Section 3.4.1. Fig3.14 represented THP-1 without
treatment of Vitamin D3. Fig 3.14 A shows the lowering effect of the various
concentrations of BFlu against a constant concentration of EClu, lOOng/ml, at all
concentrations except the lowest one of BFlu. This lowering effect was statistically
significant at 100, 10, 1 and O.lngs. In Fig 3.14B, EClu+constBFlu was
significantly higher than maxBF2u at the first three higher concentrations while there
was no significant differences between EClu+constBFlu and EClu at any
concentration. Again Fig 3.14C shows no significant differences between
EClu/BFlu and EClu at any concentration although TNF-a production in response
to EClu/BFlu was significantly higher than that ofBFlu alone (p<0.05).
Where Vitamin D3 was included in the incubation with THP-1 cells (Fig 3.15) the
BFlu still inhibited TNF-a production at the three highest concentrations used but
this lowering effect was statistically significant only at lOOng as shown in Fig3.15A.
Fig 3.14A shows more significant lowering effect than it was shown in Fig 3.15A.
When the conditions are reversed, using constant concentration of BFlu LPS at
lOOng/ml as shown in Fig 3.15B, no significant differences was calculated at any
concentrations. However, EClu+constBFlu was significantly higher than maxBFlu
at the first three higher concentrations. The general lowering effect is again
demonstrated although the effect is less marked. In Fig3.15C, no significant
differences were calculated between EClu/BFlu and EClu. Nevertheless,
EC 1 u/BF 1 u was significantly higher than BF1 u (p<0.05).
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Figure 3.14 TNFa production (lU/mlt by THP-1 cell without VD3 treatment after interactions
between EClu and BFlu in different combinations and measured by L929
(A) Comparing between various concentrations of BFlu LPS alone and various concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). (B) Comparing between various
concentrations of EClu LPS alone and various concentration of EClu LPS plus constant
concentration ofBFlu (lOOng/ml). (C) Comparing between various concentration of EClu LPS alone,
various concentrations of BFlu LPS alone and various mixtures of equal concentrations of EClu and
BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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Figure 3.15 TNFa production dU/mO by TIIP-1 cell with VD3 treatment after interactions between
EClu and BFlu in different combinations and measured by L929
(A) Comparing between various concentrations of BFlu LPS alone and various concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). (B) Comparing between various
concentrations of EClu LPS alone and various concentration of EClu LPS plus constant
concentration of BFlu (1 OOng/ml). (C) Comparing between various concentration ofEC! u LPS alone,
various concentrations of BFlu LPS alone and various mixtures of equal concentrations of EClu and
BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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3.5.2 Interactions between EC2u and BF2u LPSs on TNF-g production and
measured by L929 cell cytotoxicity assay
Fig 3.16A and Fig3.17A demonstrate the lowering effect of BF2u LPS against
constant concentration ofEC2u LPS at lOOng/ml. This effect is totally reduced at the
two lowest concentrations O.lng/ml and O.Olng/ml. In Fig 3.16A, the lowering effect
ofBF2u LPS was statistically significant compared to constant EC2u at the first three
higher concentrations. Although there was no significant differences between EC2u
and EC2u+constBF2u at any concentration (Fig 3.16B), TNF-a response by
EC2u+constBF2u was significantly higher than that of maxBF2u. In Fig 3.16C,
EC2u/BF2u shows significant differences compared to BF2u at the first three higher
concentrations. EC2u/BF2u also showed significant differences compared to EC2u at
the three lower concentrations (p<0.05).
Similar to what shown in Fig 3.16A, significant lowering effect was noticed at 100,
10 and lngs of BF2u+constEC2u compared to maxEC2u inFig3.17A where THP-1
cells were treated by Vitamin D3. In Fig 3.17B, no significant differences was shown
between EC2u+const BF2u and EC2u except at O.Olng. On the other hand, TNF-a
response by EC2u+const BF2u was significantly higher than that of maxBF2u at the
first three higher concentrations. Fig3.17C shows no significant differences between
EC2u/BF2u and EC2u at any concentration. Although the same figure shows
significant differences between EC2u/BF2u and BF2u at all concentrations (p<0.05).
3.5.3 Interactions between EC3u and BF3u LPSs on TNF-q production and
measured by L929 cell cytotoxicity assay
Fig 3.18A demonstrates a slightly fluctuating lowering effect of BF3u LPS against
constant concentration of EC3u LPS at lOOng/ml. This effect was significant at 1000
and lOng/ml but it almost non-existent at lng/ml and O.lng/ml concentrations. No
significant differences between different combinations were noticed either in Fig
3.18B or in Fig3.18C.
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between EC2u and BF2u in different combinations and measured by L929
(A) Comparing between various concentrations of BF2u LPS alone and various concentrations of
BF2u LPS plus constant concentration of EC2u (lOOng/ml). (B) Comparing between various
concentrations of EC2u LPS alone and various concentration of EC2u LPS plus constant
concentration of BF2u (lOOng/ml). (C) Comparing between various concentration of EC2u LPS alone,
various concentrations of BF2u LPS alone and various mixtures of equal concentrations of EC2u and
BF2u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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Figure 3.17 TNFa production llU/mO by THP-1 cell with VD3 treatment after interactions between
EC2u and BF2u in different combinations and measured by L929
(A) Comparing between various concentrations of BF2u LPS alone and various concentrations of
BF2u LPS plus constant concentration of EC2u (lOOng/ml). (B) Comparing between various
concentrations of EC2u LPS alone and various concentration of EC2u LPS plus constant
concentration of BF2u (lOOng/ml). (C) Comparing between various concentration of EC2u LPS alone,
various concentrations of BF2u LPS alone and various mixtures of equal concentrations of EC2u and
BF2u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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On the other hand, when Vitamin D3 treatment was included Fig 3.19A shows a
dose-dependent lowering effect that completely vanished at the two lowest
concentrations O.lng/ml and O.Olng/ml. Although it was statistically significant only
at the two higher concentrations. Fig 3.19B shows an obvious lowering effect of
constant BF3u LPSs at all concentrations of EC3u LPS although it was significant
only at 100 and lngs. No steady patterm can be deduced from the combinations
shown in Fig3.19C (p<0.05).
3.5.4 Interactions between EC4u and BF4u LPSs on TNF-q production and
measured by L929 cell cytotoxicity assay
Fig 3.20A revealed an obvious lowering effect of BF4u LPS against constant EC4u
LPS at the two highest concentrations and two lower concentrations but not that
much at lOng/ml and lng/ml of BF4u LPS. This lowering effect was statistically
significant at 1000, 0.1 and O.Olngs. When TFIP-1 cells were treated by Vitamin D3,
Fig 3.21A shows a fluctuating lowering effect of BF4u LPS against constant
concentration of EC4u LPS. Although this effect is significant at 1000, 10 and lngs,
it was not observed at O.lng/ml and O.Olng/ml. Although Fig 3.20B and Fig 3.21B
demonstrate a slight lowering effect exerted by constant amount of BF4u, no
statistical differences were noticed in both figures. In Fig 3.20C, EC4u/BF4u showed
a significant difference compared to both EC4u and BF4u. While Fig 3.21C shows
no significant difference except between EC4u/BF4u and BF4u at the three higher
concentrations (p<0.05).
3.5.5 Interactions between EClu and BFlu LPSs on TNF-q production and
measured by ELISA
Fig 3.22A shows a significant lowering effect of BFlu LPS against constant EClu
LPS at the three highest concentrations. This lowering effect was not seen at the
three lowest concentrations. Significant differences were neither shown between
EClu+constBFlu and EClu (Fig 3.22B) nor between EClu/BFlu and EClu at any
concentrations (p<0.05).
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Figure 3.18 TNFa production (IU/mO by THP-1 cell without VD3 treatment after interactions
between EC3u and BF3u in different combinations and measured by L929
(A) Comparing between various concentrations of BF3u LPS alone and various concentrations of
BF3u LPS plus constant concentration of EC3u (lOOng/ml). (B) Comparing between various
concentrations of EC3u LPS alone and various concentration of EC3u LPS plus constant
concentration of BF3u (lOOng/ml). (C) Comparing between various concentration ofEC3u LPS alone,
various concentrations of BF3u LPS alone and various mixtures of equal concentrations of EC3u and
BF3u. Results represent the means +/- SEM for at least three experiments. " Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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EC3u
■X — maxBF3u (100ng)
•EC3u+const.BF3u
■medium
Figure 3.19 TNFa production (IU/ml) bv THP-1 cell with VD3 treatment after interactions between
EC3u and BF3u in different combinations and measured by L929
(A) Comparing between various concentrations of BF3u LPS alone and various concentrations of
BF3u LPS plus constant concentration of EC3u (lOOng/ml). (B) Comparing between various
concentrations of EC3u LPS alone and various concentration of EC3u LPS plus constant
concentration of BF3u (lOOng/ml). (C) Comparing between various concentration ofEC3u LPS alone,
various concentrations of BF3u LPS alone and various mixtures of equal concentrations of EC3u and
BF3u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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Figure 3.20 TNFa production (TU/mO by THP-1 cell without VD3 treatment after interactions
between EC4u and BF4u in different combinations and measured by L929
(A) Comparing between various concentrations of BF4u LPS alone and various concentrations of
BF4u LPS plus constant concentration of EC4u (lOOng/ml). (B) Comparing between various
concentrations of EC4u LPS alone and various concentration of EC4u LPS plus constant
concentration of BF4u (lOOng/ml). (C) Comparing between various concentration of EC4u LPS alone,
various concentrations of BF4u LPS alone and various mixtures of equal concentrations of EC4u and
BF4u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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EC4u and BF4u in different combinations and measured by L929
(A) Comparing between various concentrations of BF4u LPS alone and various concentrations of
BF4u LPS plus constant concentration of EC4u (lOOng/ml). (B) Comparing between various
concentrations of EC4u LPS alone and various concentration of EC4u LPS plus constant
concentration of BF4u (lOOng/ml). (C) Comparing between various concentration ofEC4u LPS alone,
various concentrations of BF4u LPS alone and various mixtures of equal concentrations of EC4u and
BF4u. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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between EClu and BFlu in different combinations and measured by ELISA
(A) Comparing between various concentrations of BFlu LPS alone and various concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). (B) Comparing between various
concentrations of EClu LPS alone and various concentration of EClu LPS plus constant
concentration ofBFlu (lOOng/ml). (C) Comparing between various concentration of EClu LPS alone,
various concentrations of BFlu LPS alone and various mixtures of equal concentrations of EClu and
BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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Figure 3.23 TNFa production (lU/mD by T1IP-1 cell with VD3 treatment after interactions between
EClu and BFlu in different combinations and measured by ELISA
(A) Comparing between various concentrations of BFlu LPS alone and various concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). (B) Comparing between various
concentrations of EClu LPS alone and various concentration of EClu LPS plus constant
concentration of BFlu (lOOng/ml). (C) Comparing between various concentration ofEClu LPS alone,
various concentrations of BFlu LPS alone and various mixtures of equal concentrations of EClu and
BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates data point
represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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Fig 3.23A demonstrates a substantial lowering effect that goes even below the values
for the two highest BFlu LPS concentrations and continues in a dose-dependent style
to the lowest concentration of BFlu. This effect is statistically significant at the first
four concentrations. A slight fluctuating lowering effect is demonstrated in Fig 3.23B
and it is significant at 1000 and lOOngs. Fig3.23C also shows a significant
differences between EClu/BFlu and EClu at 1000 and lOOngs (p<0.05).
3.6 Interactions between different LPSs from various bacterial species in
stimulation IL-B production
3.6.1 Interactions between EClu and BFlu LPSs on IL-B production by human
PBMC and measured by ELISA
Using an ELISA to measure IL-p production after challenging human PBMC, an
interaction investigation was done between EClu and BFlu LPSs in the manner
identical to that shown in Section 3.4.1. Fig 3.24A shows a slight lowering effect of
BFlu LPS against a constant concentration of lOOng/ml of EClu in most
concentrations by a range of ten to twenty IL-p units compared to the constant EClu
response. The effect is significant at the two highest concentrations of BFlu. Fig
3.24B shows also a slight lowering effect exerted by constant BFlu and becomes
significant at the lower concentrations of 10, 1, O.lngs. Fig 3.24C demonstrated no
significant differences between different concentrations except between EClu/BFlu
and BFlu at the first three highest concentrations (p<0.05).
3.6.2 Interactions between EC2u and BF2u LPSs on IL-B production by human
PBMC and measured by ELISA
Fig 3.25A demonstrates a non-significant lowering effect of BF2u LPS on the
constant amount of EC2u LPS . The highest lowering effects are at lOOOng/ml and
lng/ml of BF2u LPS. Although it is non-significant, Fig 3.25B shows an obvious
lowering effect of lOOng/ml BF2u against EC2u LPS stimulated IL-p production at
concentrations of 100, 10, 1, 0.1 ng/ml ofEC2u LPS.
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different combinations and measured by ELISA
(A) Comparing between different concentrations of BFlu LPS alone and different concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). maximum ofEClu concentration alone at
lOOng/ml. (B) Comparing between different concentrations of EClu LPS alone and different
concentration of EClu LPS plus constant concentration of BFlu (lOOng/ml). Maximum of BFlu
concentration alone at lOOng/ml. (C) Comparing between different concentration of EClu LPS alone,
different concentrations of BFlu LPS alone and different concentration of equal concentrations of
mixed EClu and BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates
data point represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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Figure 3.25 IL-ft production flU/ml) by human PBMC after interactions between EC2u and BF2u in
different combinations and measured by ELISA
(A) Comparing between different concentrations of BF2u LPS alone and different concentrations of
BF2u LPS plus constant concentration of EC2u (1 OOng/ml). Maximum ofEC2u concentration alone at
lOOng/ml. (B) Comparing between different concentrations of EC2u LPS alone and different
concentration of EC2u LPS plus constant concentration of BF2u (1 OOng/ml). Maximum of BF2u
concentration alone at 1OOng/ml. (C) Comparing between different concentration of EC2u LPS alone,
different concentrations of BF2u LPS alone and different concentration of equal concentrations of
mixed EC2u and BF2u. Results represent the means +/- SEM for at least three experiments. * Indicates
data point represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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3.6.3 Interactions between EC3u and BF3u LPSs on IL-B production by human
PBMC and measured by ELISA
Fig 3.26A shows an almost non-significant constant lowering effect of BF3u LPS
against IL-(3 production by a constant EC3u LPS. Moreover, Fig 3.26B does not
demonstrate a significant lowering effect of the constant BF3u against EC3u LPS.
3.6.4 Interactions between EC4u and BF4u LPSs on IL-B production by human
PBMC and measured by ELISA
Fig 3.27A indicates an obvious example of fluctuating lowering effect which reach
the most and significant effect at 100 and 0.1 ng/ml of BF4u. A slight non-significant
lowering effect is also noticeable in Fig 3.27B starting from concentration of
lOOng/ml of EC4u LPS. An additive significant effect is seen when EC4u and BF4u
LPS is added together in equal amounts (Fig 3.27C) at 1000, 100, 10 and lngs
concentrations (p<0.05).
3.6.5 Interactions between EClu and BFlu LPSs on IL-B production by THP-1
cells and measured by ELISA
Using ELISA assay to measure the IL-J3 production after challenging TFIP-1 cells, an
interaction approaches were done between EClu and BFlu LPSs in the manner
identical to that shown in Section 3.4.1. Fig 3.28A shows the lowering effect of the
different BFlu against constant concentration of lOOng/ml of EClu in dose-
dependent style and it is statistically significant just for the two higher concentrations
of BFlu. This effect is totally reduced starting from lOng/ml of BFlu. Significant
lowering effect is observed in Fig 3.29A at concentrations of 10 and lng/ml of BFlu.
Fig 3.28B shows a slight significant lowering effect at lng/ml of EClu. While Fig
3.29B shows non-significant differences between EClu+constBFlu and EClu.
EClu/BFlu shows significant differences against EClu at some lower concentrations
as shown in both Fig 3.28C and Fig3.29C (p<0.05).
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(A) Comparing between different concentrations of BF3u LPS alone and different concentrations of
BF3u LPS plus constant concentration of EC3u (lOOng/ml). Maximum ofEC3u concentration alone at
lOOng/ml. (B) Comparing between different concentrations of EC3u LPS alone and different
concentration of EC3u LPS plus constant concentration of BF3u (lOOng/ml). Maximum of BF3u
concentration alone at lOOng/ml. (C) Comparing between different concentration of EC3u LPS alone,
different concentrations of BF3u LPS alone and different concentration of equal concentrations of
mixed EC3u and BF3u. Results represent the means +/- SEM for at least three experiments. * Indicates
data point represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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different combinations and measured by ELISA
(A) Comparing between different concentrations of BF4u LPS alone and different concentrations of
BF4u LPS plus constant concentration of EC4u (lOOng/ml). maximum of EC4u concentration alone at
lOOng/ml. (B) Comparing between different concentrations of EC4u LPS alone and different
concentration of EC4u LPS plus constant concentration of BF4u (lOOng/ml). maximum of BF4u
concentration alone at lOOng/ml. (C) Comparing between different concentration of EC4u LPS alone,
different concentrations of BF4u LPS alone and different concentration of equal concentrations of
mixed EC4u and BF4u. Results represent the means +/- SEM for at least three experiments. * Indicates
data point represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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EClu and BFlu in different combinations and measured by ELISA
(A) Comparing between different concentrations of BFlu LPS alone and different concentrations of
BFlu LPS plus constant concentration ofEClu (lOOng/ml). maximum ofEClu concentration alone at
lOOng/ml. (B) Comparing between different concentrations of EClu LPS alone and different
concentration of EClu LPS plus constant concentration of BFlu (lOOng/ml). Maximum of BFlu
concentration alone at lOOng/ml. (C) Comparing between different concentration of EClu LPS alone,
different concentrations of BFlu LPS alone and different concentration of equal concentrations of
mixed EClu and BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates
data point represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.0 lng/ml.
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EClu and BFlu in different combinations and measured by ELISA
(A) Comparing between different concentrations of BFlu LPS alone and different concentrations of
BFlu LPS plus constant concentration of EClu (lOOng/ml). maximum of EClu concentration alone at
lOOng/ml. (B) Comparing between different concentrations of EClu LPS alone and different
concentration of EClu LPS plus constant concentration of BFlu (lOOng/ml). Maximum of BFlu
concentration alone at lOOng/ml. (C) Comparing between different concentration of EClu LPS alone,
different concentrations of BFlu LPS alone and different concentration of equal concentrations of
mixed EClu and BFlu. Results represent the means +/- SEM for at least three experiments. * Indicates
data point represent a statistical difference from other data points (p<0.05).
1= lOOOng/ml, 2=100ng/ml, 3=10ng/ml, 4=lng/ml, 5=0.1ng/ml, 6=0.01ng/ml.
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3.7 Toll like receptor assay
Using a transient transfection of TL4/MD2, TLR2, CD 14 receptors into HEK-293
cells, comparison experiments were done for five unpurified and five purified B.
fragilis LPS preparations extracted by different methods in addition to unpurified and
purified R. sphaeroides LPS. Heat killed B. fragilis from three different populations
of different polysaccharide capsules were also examined for toll like receptor
specificity. These experiments were done with and without transfection efficiency
control.
3.7.1 Toll like receptor specificity of unpurified B. frasilis LPSs
Fig 3.30A and B clearly demonstrate the TLR2 high specificity of all five unpurified
B. fragilis LPS preparations. All of them show stronger TLR2 specificity than the
TLR2 positive control LPS except BF3u which show an equal TLR2 specificity to
that of the TLR2 positive control LPS. BFlu LPS shows the strongest TLR2
specificity among all others. Non of the five unpurified B. fragilis LPS preparations
demonstrate a TLR4 specificity comparing with the TLR4 positive control LPS. No
considerable differences between running a transfection assay with or without the
transfection efficiency control were observed. All TLR2 specificity of five unpurified
B. fragilis LPS preparations show a significant difference compared to the values of
TLR4/MD2 and CD 14 with or without using transfection efficiency assay. BFlu
shows significant difference compared to BF3u when the transfection efficiency
assay was done (Fig 3.30B).
3.7.2 Toll like receptor specificity of purified B. frasilis LPSs
Fig 3.31A and B clearly demonstrate the TLR2 high specificity of BFlp, BF4p and
BF5p LPSs and reasonable TLR2 specificity with BF2p and BF3p which were
extracted by TMP and PCP respectively. The specificity of TLR2 positive control
LPS is stronger than all five purified B. fragilis LPS preparations. BF5p LPS shows
the strongest TLR2 specificity among all others followed by BFlp and BF4p.
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Figure 3.30 Toll like receptor specificity of five unpurified B. frasilis LPS preparations
(A) HEK-293 transfection assay without transfection efficiency control (B) HEK-293 transfection
assay with transfection efficiency control. (EC LPS) TLR4/MD2 positive control of E. coli LPS (PG
LPS) TLR2 positive control of P. gingivalis LPS. Results represent the means +/- SEM for three
experiments including the transfection efficiency control experiment. * Indicates data point represent a
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Figure 3.31 Toll like receptor specificity of five purified B. frasilis LPS preparations
(A) HEK-293 transfection assay without transfection efficiency control (B) HEK-293 transfection
assay with transfection efficiency control. (EC LPS) TLR4/MD2 positive control of E. coli LPS (PG
LPS) TLR2 positive control of P. gingivalis LPS. Results represent the means +/- SEM for three
experiments including the transfection efficiency control experiment. * Indicates data point represent a
statistical difference from other data points (p<0.05).
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None of the five purified B. fragilis LPS preparations demonstrate a TLR4 specificity
compared with the TLR4 positive control LPS. All TLR2 specificity of five purified
B. fragilis LPS preparations show a significant difference compared to the values of
TLR4/MD2 and CD 14 only with using the transfection efficiency assay. BFlp and
BF5p show significant difference compared to BF2p and BF3p when the transfection
efficiency assay was done (Fig 3.31B).
3.7.3 Toll like receptor specificity of heat killed B. fraeilis and R. sphaeroides
LPSs
Fig 3.32A and B clearly demonstrate the TLR2 high specificity ofHK EDL, HK SC
and FIK LC heat killed B. fragilis populations. All of these heat killed populations
are stronger than TLR2 positive control LPS in their TLR2 specificities. In the same
time, none of them demonstrate TLR4 specificity comparing with the TLR4/MD2
positive control LPS. R. sphaeroides LPSs show weak TLR2 specificity in
transfection assay without efficiency control and show much weaker TLR2
specificity in transfection assay with efficiency control. Nevertheless all TLR2
specificity of three heat killed B. fragilis populations and two samples of R.
sphaeroides LPSs show a significant differences compared to the values of
TLR4/MD2 and CD 14 only with using transfection efficiency assay.
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Figure 3.32 Toll like receptor specificity of heat killed B. fragilis and R. sphaeroides LPSs
(A) HEK-293 transfection assay without transfection efficiency control (B) HEK-293 transfection
assay with transfection efficiency control. (EC LPS) TLR4/MD2 positive control of E. coli LPS (PG
LPS) TLR2 positive control of P. gingivalis LPS (HK EDL) heat killed B. fragilis of electron density
layer (HK SC) heat killed B. fragilis of small capsule (HK LC) heat killed B. fragilis of large capsule
(RSlu) unpurified R. sphaeroides LPS (RSlp) purified R. sphaeroides LPS. Results represent the
means +/- SEM for three experiments including the transfection efficiency control experiment.




4.1 Lipopolysaccharide extraction and analysis
The actual dialogue which is taking place between the innate immune mechanisms
and different PAMP molecules is far from being completely elucidated especially
when it is comes to Gram-negative bacteria. Although it is crucial to identify the
detailed interactions between the focal inflammatory inducer, endotoxin and the
innate immune mechanisms, it is not possible to isolate these interactions from
possible interactions with other cell wall related PAMPs such as capsular
polysaccharide, lipoprotein and peptidoglycan. In addition, it is fundamental to try to
mimic the bacterial behaviour inside the host as much as possible to make the
investigation approach more reliable. Studies have used different extraction and
purification methods which make comparisons difficult. These different techniques
affect the purity, solubility and efficacy of the LPS preparations that are to be worked
with. In this context, it is observed that LPS activity can differ significantly
according to the type of organism, method of cultivation and the technique by which
the LPS is extracted (Fukushi et al., 1964; Morrison and Leive, 1975). Moreover,
although LPS activity is particularly associated with the Lipid A moiety it can also
be affected by other materials which can be present in the final preparation such as
outer membrane proteins (Morrison et al., 1976), the specific O-antigen subunit
(Vukajlovich and Morrison, 1985) and the O-antigen carbohydrates (Morrison et al.,
1987). The associated material is not always of protein in nature. It is assumed that
the contaminants of B. fragilis LPS are not of protein origin (Mancuso et al., 2005).
A previous study found that there are non-protein components present in
enterobacterial preparation that have LPS-like activities (Muroi et al., 2003).
Moreover, one early study using purified capsular polysaccharide of B. fragilis
showed that these molecules have the capacity to induce IL-8 production from
human monocytes or polymorphonuclear leukocytes (Gibson et al., 1996).
Furthermore, LPS in itself is a particularly difficult ligand to work with because of its
amphipathicity which neither make it easily soluble nor allow the forming of LPS
monomers in aqueous suspension (Lien et al., 2000).
In this study four different extraction methods were chosen to produce different
forms of LPS; mainly smooth, high molecular weight material is extracted by
aqueous phenol (AP) method. With Phenol, Chloroform, Petroleum spirit (PCP)
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method, rough, low molecular weight material predominates. Using the last two
extraction methods: Triton/magnesium chloride with and without Protienase K
treatment(TM/TMP) method and Boiling water with Proteinase K treatment (BWP)
method which are much milder than the first two methods as proposed by Poxton and
Edmond (1995). LPS yields from all methods with all tested bacteria, except of R.
sphaeroides, were reasonable. For example, the percentage of LPS yield, extracted
by AP method from E. coli was 1.2% of the bacterial cell dry weight (Table 3.1)
which is in agreement with previous studies that reported the percentage of LPS yield
extracted by the same method from the same organism to be from 1 to 4% (Luderitz
el al., 1971) However, the yield and solubility of B. fragilis LPS extracted by PCP
were much lower compared to others. It is reported that applying the PCP method to
extract LPS from B. fragilis dry bacteria results in only a trace amount of the LPS
(Kasper, 1976; Hofstad et al., 1977). This possibly happens because of the effect of
the capsular polysaccharide which makes the cell envelope more hydrophilic to the
extent it becomes insoluble in the hydrophobic PCP mixture (Weintraub et al., 1985).
It is also generally recognised that the solubility of rough LPS in water is poor
(Hellman et al., 2003). If it comes to choosing a common method that has an ability
to extract smooth and rough LPS in the same time, then TM/TMP will be the
preferable choice since in addition to its mild nature, the LPS preparations extracted
by this method showed a high level of purity especially after applying proteinase K
treatment. The AP method is considered to be the most common LPS extraction
method (Yi and Hackett, 2000) and showed high level of cleanness with LPS
extracted from E. coli (Fig 3.1A). This was also documented with this extraction
method which usually results in a pure LPS preparation of the smooth type (Darveau
and Hancock, 1983). Furthermore, although PCP method was documented to be
more effective in extraction of rough type LPS than the AP method (Darveau and
Hancock, 1983), it does not seem to produce a cleanness of appearance when it was
applied to B. fragilis (BF3u in Fig 3.2) compared with the appearance of the LPS
preparation of the same organism extracted by TM/TMP or AP methods (BFlu,
BF2u and BF5u in Fig 3.2).
It is widely believed that highly purified LPS is essential for studying its biological
activity in vitro (Kutuzova et al., 2001). Although it is not an easy task to approach
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since it was early demonstrated (1960s) that during extraction, when LPS is
subjected to denaturing steps many of the contaminating protein and other substances
become tightly bound to the LPS molecule and cannot be detached completely
(Rudbach and Proctor, 2001). So, use of a repurification procedure to prepare LPS
preparation in highly purified form has been one of the important goals in the LPS
research field especially when it is intended to investigate the specific signalling
activity of the LPS (i.e. the TLR specificity). For example, procedures of using gel
filtration (Gu and Tsai, 1991), repeating ultra centrifugation step (Yi and Hackett,
2000), digestion with proteinase-K (Chart and Rowe, 1991), using silica cartridge
(Qureshi et al., 1991) or even repeating the extraction procedure (Perez Perez and
Blaser, 1985; Yi and Hackett, 2000) are used to achieve highly purified LPS. The
repurification method of Manthey and Vogel (1994) which was used in this study
was tried by many investigators until Hirschfeld and his colleagues (2000) gave this
method another dimension since it was used to verify the actual TLR specificity of
LPS through eliminating the protein contaminants which are usually associated with
LPS preparations. Application of this repurification method has a noticeable effect
on the appearance of some LPS preparations tested in this study which is obvious
when comparing samples like BF3u and BF3p which were extracted by PCP method,
BF4u and BF4p which were extracted by BWP method, EC2u and EC2p which were
extracted by TM method and EC4u and EC4p which were extracted by BWP method
(Fig 3.1 and 3.2). Controversially, this seem to favour using lower concentration of
proteinase K treatment in the TMP method but against the use of higher
concentration of proteinase K treatment in BWP method when it is purposed to
eliminate the protein contaminants from LPS preparation by using proteinase K
treatment. This was illustrated further by the comparison between the appearance of
EClu and EC2p which were extracted by the TMP method as showed in Fig 3.1C.
Moreover, the effect of using the repurification method was very much noticeable
when BFlu, BF2u, BF3u, BF4u and BF5u were compared with BFlp, BF2p, BF3p,
BF4p and BF5p in term of their intensity ofTLR2 specificity as demonstrated by Fig
3.30 and Fig 3.31. On the other hand, it is totally unreasonable to consider that the
non-purified LPS is without its uses since it is still a powerful tool for studying an
immune inflammatory response against LPS. After all these non-purified LPS
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preparations more closely mimic the LPS that would be encountered by host cells
infected with either whole bacteria or released LPS molecules. For the same reason,
different heat killed bacteria populations were involved in the TLR assay (discussed
later). In fact one study supports this notion since it reported that fluorescein labelled
E. coli was able to pass across the rat intestinal epithelium but fluorescein conjugated
E. coli LPS was unable to do so even after disruption of the intestinal epithelium
with a potent mucolytic agent which did not result in significant increase in
transmucosal passage of E. coli LPS (Benoit et al., 1998). The ability to penetrating
the intestinal barrier when it is happen, expreses LPS directly to immune cells such
as monocytes which were used in this study. As a conclusion, using both LPS
extraction methods and an extra technique to repurify LPS contributed much to this
study in terms of comparing different LPS preparations of different levels of purity.
SDS-PAGE analysis is often used to differentiate between rough and smooth types of
LPS. However, this method of LPS analysis does not identify every immunoreactive
material (Fomsgaard et al., 1990). The smooth LPS with a ladder-like pattern on
SDS-PAGE analysis of both E. coli and Ps. aeruginosa (Fig3.1 and Fig3.3) is
something widely recognised in the literature. As a rule, smooth LPS shows a high
degree of heterogenicity and demonstrates LPS molecules with different numbers of
repeating oligosaccharide units (Fomsgaard et al., 1990). SDS-PAGE analysis of B.
fragilis LPS usually consists of two deeply stained bands constituting the core
regions. One study reported that most B. fragilis strains have a rough LPS style
which runs at the gel front followed by a common antigen and a ladder pattern bands
of smooth LPS (Poxton and Brown, 1986). Other investigators did not demonstrate
such a smooth LPS in any of the 17 strains examined including NCTC 9343 strain
(Weintraub et al., 1985). The findings of this study did not show an obvious ladder
pattern in any of B. fragilis LPSs. Nevertheless, PCP and to lesser extent BWP
methods produced an intense LPS material along the gel which seems to be kind of a
strong ladder pattern as demonstrated in Fig3.2A. Moreover, the high molecular
weight material observed distinctively in this study with B. fragilis LPS preparations
that were extracted by TM and TMP methods (Fig3.2A, BFlu & BF2u) are similar to
that found by another study of the same strain, B. fragilis NCTC 9343 (Poxton and
Edmond, 1995). It was also reported in the same study that the proteinase K
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treatment itselfwas not responsible for any biological activity (Poxton and Edmond,
1995).
An overall view of the protein content of the LPS preparations which were analysed
by colloidal gold stain showed that BWP extraction method is effective in
eliminating protein even before applying the repurification method as demonstrated
by Fig3.1B, EC4u; Fig3.2B, BF4u and Fig3.3B, PA4u. This may be because this
method includes a treatment with proteinase K at relatively high concentration. The
TMP method showed a similar effective protein elimination before applying
repurification with B. fragilis only (Fig3.2B, BF2u). It has been reported that the
sensitive colloidal gold stain can detect as little as lng of protein so if no bands
appeared in any of the LPS preparation tested it means that the protein contaminants
is always under 0.02% (Mancuso et al., 2005).
Another approach to analyse the LPS content was done by applying the LAL assay.
This analysis is widely recognised as an official test to substitute for the rabbit
pyrogen test. The LAL assay is one of the most sensitive and highly specific methods
for detecting the existence of endotoxin and comparing the endotoxin intensity
between different LPS preparations (Nakagawa et al., 2002). However, it is not
known if LPS activity in this assay is linked to the ability of LPS to induce
inflammatory immune responses for reasons like the obvious phylogenic distance
between the horseshoe crab and human cells (Nakagawa et al., 2002). In fact, one
previous study reported that there is not a strong relationship between LAL activity
of specific LPS and its in vitro TNF-a induction effect (Luchi and Morrison, 2000).
4.2 Production and detection of TNF-q and IL-lB cytokines
Two different cell types were used to study cytokines induced by LPS: human
monocytes isolated from healthy volunteers and the THP-1 cell line. Using fresh
blood sample is the most reliable way to mimic what happens inside the host, while
using the THP-1 cell line overcomes donor variations and availability. Although cell
lines of transformed origin have an ease of use advantage over the human
macrophages which although are easily cultured in vitro they have intrinsic
limitations in term of numbers, lifetime and heterogeneity in their responses between
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different donors (Witsell and Schook, 1991; Ravasi et al., 2002; Perkins and
Gilmore, 2006). However, it was reported that there are some differences in NF-kB
signalling between transformed and primary cells (Smith et al., 2001). Regarding the
use of THP-1 cells in particular, it has been reported in a recent article that LPS
stimulates an identical transcriptional response in both the THP-1 cell line and
human peripheral blood mononuclear cells (Sharif et al., 2007). This finding makes
the THP-1 cell line one of a preferred model system for studying the mechanisms of
LPS and NF-kB dependent gene expression (Sharif et al., 2007).
The result of cytokine production using THP-1 cell line are demonstrated in Fig 3.14
- 3.23, 3.28 and 3.29. These figures showed that untreated THP-1 cells produce more
cytokine than Vitamin D3-treated THP-1 cells which is unexpected since Vitamin D3
treatment is supposed to induce untreated THP-1 cells to mature into monocyte-like
cells. The reason for this discrepancy between the result of this study and result of
another study like that of Delahooke and others (1995) in the induction of THP-1 by
Vitamin D3 to be mature monocytes is unclear, but it may result from growth
conditions or cell passage number. For example the THP-1 cells used in this study
were from totally new THP-1 stock and not from an old passage. It is recognised that
Vitamin D3 is effective in stimulating the expression of CD 14 in THP-1 cells in
particular as one study showed that Vitamin D3-treated THP-1 cells expressed up to
380,000 molecules CD14/ccll compared to levels of 50 to 100,000 CD 14
molecules/monocyte and around 10,000 CD 14 molecules/cell on untreated THP-1
cells (Tobias et al., 1993). Nevertheless, another study indicated that the expression
of CD 14 is not fundamentally important. It was shown that although after adding
Vitamin D3, the level of CD 14 was increased slightly in THP-1 cells and strongly in
another kind of cell, Mono Mac 6 cells, the TNF-a response was much stronger in
THP-1 cells compared with Mono Mac 6 cells (Landmann et al., 1998). In the same
context, a previous study found that the untreated THP-1 cells expressed MD-2 and
TLR4 without any stimulation with molecules such as Vitamin D3 (Shimazu et al.,
1999b). Another study demonstrated that THP-1 cells endogenously express TLR2
(Kirschning et al., 1998). A third study showed that untreated THP-1 cells expressed
twice the level of TLR2 compared to Vitamin D3-treated THP-1 cells (Yang et al.,
2001). The same study also showed that there is no real differences in the TLR4
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expression between VD3-treated and untreated THP-1 cells (Yang et al., 2001).
Moreover, a recent study has also demonstrated that VD3 suppresses the expression
of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-
dependent manner (Sadeghi et al., 2006). Vitamin D3 was found to be the only agent
that induce CD 14 expression among those which induce phenotypic alterations in the
THP-1 cells, such as phorbol myristate acetate (PMA) (Fleit and Kobasiuk, 1991;
Zhang et al., 1994), It has also been found that Vitamin D3 induced CD 14 expression
on human monocytes (Sadeghi et al., 2006). Nevertheless, this unexpectedly resulted
in impaired TNF-a response, emphasizing the vital role of TLR in the stimulation of
inflammation (Sadeghi et al., 2006). Another study found that stimulation of THP-1
cells with Vitamin D3 did not induce a release of TNF-a and challenging both
Vitamin D3-differentiated THP-1 cells and PMA-differentiated THP-1 cells with
LPS resulted in much lower release of TNF-a from the former comparing with the
latter, ~500pg/106 and 7000pg/106 respectively (Schwende et al., 1996). On the other
hand, measuring cytokines was done either by L929 cytotoxicity bioassay for TNF-a
or by ELISA for TNF-a and IL-1(3. ELISA is favoured by many investigators as it
determines total TNF-a produced. While the L929 bioassay measures only biological
activity and does not detect receptor-bound TNF-a (Hutchison et al., 2000). Despite
the differences between these two methods in their ways of being sensitive, the
results demonstrated comparable styles.
4.3 Effects of interaction between different LPSs from different bacteria and
extracted by different methods
Four different Gram-negative species were chosen to represent LPSs with different
characteristics; E.coli as an ideal example of highly active enterobacterial LPS, B.
fragilis LPS as an example of low active LPS, Ps. aeruginosa as a member of non-
gut flora and R. sphaeroides LPS as a non toxic LPS. Investigation of the interaction
between different LPSs is an important approach because firstly it shows deeper
insight into the effect of endotoxins against host cells and the mechanism of
endotoxin bioactivity, and secondly it may lead to new strategies to control
endotoxin effects pharmacologically at a very early step (Rietschel et al., 1994).
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Choosing lOOng/ml to be the potential concentration for antagonism activity is based
on the fact that there is a considerable difference in the endotoxic activity between
highly active E.coli and low active B. fragilis LPSs. So it was useful to pick one
concentration which is reasonably high enough for the low active LPS and rational
for the high active LPS. Moreover, previous study showed that antagonistic effects
were observed when LPSs from both E. coli and P. gingivalis were each used at 100
ng/ml (Hajishengallis et al., 2002a). Choosing B. fragilis in particular to elucidate the
potential antagonism activity of their LPS against the classical kind of LPS such as
E. coli was a fundamental approach of this study. In general, Bacteriodes spp far
outnumber all other bacterial flora and account for 20-30% of the isolated species in
the gastrointestinal tract (Maier et al., 1972; Wannemuehler et al., 1984; Patrick,
1993; Neish, 2002). Particularly, it is estimated that Bacteroides species outnumber
the enterobacterial by 1,000-fold (Poxton and Edmond, 1995). Among anaerobic
species, B. fragilis represents about 1% of the bacterial flora in intestines (Moore and
Holdeman, 1974; Holdeman et al., 1976). Importantly, B. fragilis is found as a major
component of the mucosa-associated flora (Poxton et al., 1997; Ferreira et al., 2002).
It is also of utmost importance as an opportunistic pathogen since it is commonly
associated with bacteracmia, soft tissue infections, intra-abdominal infections and
abscesses (Gorbach and Bartlett, 1974; Polk and Kasper, 1977; Simon and Gorbach,
1984; Goldstein and Citron, 1988; Finegold, 1995; Redondo et al., 1995; Farthmann
and Schoffel, 1998; Brook and Frazier, 2000; Nguyen et al., 2000; Javaloyas et al.,
2002). Moreover, it is found that selective gut decontamination was unsuccessful in
decreasing the emergence of SIRS, to a certain extent because it just reduced aerobic
endotoxin sources but not B. fragilis a key contributor to endotoxaemia in the case of
translocation of the gut flora (Bennett-Guerrero et al., 2000; Bouter et al., 2002).
The findings of this study regarding the ability of B. fragilis LPS to induce
proinflammotory cytokines (Fig 3.7) are in keeping with previous results from others
who showed that, compared to E.coli and some other Gram-negative bacteria, B.
fragilis has a lower systemic endotoxicity (Sveen et al., 1977; O'Donnell et al., 1980;
Simon et al., 1985; Magnuson et al., 1989; Lindberg et al., 1990). LPS of B. fragilis
has structural differences which may contribute to its lower bioactivity when it is
compared with that of enterobacterial LPS (Hofstad et al., 1977; Weintraub et al.,
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1989; Erridge et al., 2002). However, another study indicated that different
extraction methods produce different B. fragilis LPSs in term of chemical
composition and biological activity (Poxton and Edmond, 1995). Nevertheless, the
differences in cytokine response between different B. fragilis LPSs, on the other
hand, emphasize the notion in the beginning of this chapter that different extraction
method produce different LPSs in term of chemical composition and biological
activity. The findings of the lowering effect exerted by B. fragilis LPSs against E.
coli LPSs are also consistent with that of Delahooke and others (1995). They found
that B. fragilis NCTC 9343 LPS at higher concentration can block the effects of E.
coli LPS on both human PMBC and VD3treated/untreated THP-1 cells (Delahooke
et al., 1995). Although it is acknowledged that the results obtained (Sections 3.4 and
3.5, previous chapter) are not of close relationship, Magnuson and others (1989)
found that B. fragilis LPS can inhibit the induction of endothelial adhesiveness by E.
coli LPS in a way that the more B. fragilis LPS concentration contribute to the more
increasing of the inhibition (Magnuson et al., 1989). Moreover, it was also shown
that partial deacylation (dLPS) inhibits the ability of LPS, but not other ligands, to
stimulate adhesion of neutrophils to human endothelial cells (Pohlman et al., 1987).
Like macrophages, vascular endothelial cell are consider to be a critical target for
LPS action (Morrison and Ryan, 1987; Cybulsky et al., 1988; Pober and Cotran,
1990; Heumann and Glauser, 1994; Mantovani et al., 1997).
In fact, the chemical and biological properties of B. fragilis LPS and its Lipid A are
identical to those of LPS from P. gingivalis, but different from those of classical
enterobacterial LPS such as E. coli (Weintraub et al., 1989; Hamada et al., 1990). B.
fragilis Lipid A is similar to that of P. gingivalis in many ways (Ogawa, 1993;
Kumada et al., 1995). They both lack phosphorus at position 4 of the disaccharide
domain and have five fatty acids chains of 15 to 17 carbon residues. However, the
position of the various fatty acids is different (Erridge et al., 2002). Moreover, it is
generally accepted that the toxicity of penta-acyl Lipid A is lower than that of hexa-
acyl Lipid A (Qureshi et al., 1991). Once again this points out the importance of the
notion that although different Lipid A components have an overall similar structures,
specific variations contribute to their different activities. Thus, the Lipid A of B.
fragilis LPS differs from that of E. coli in several aspects. 1) The fatty acids of B.
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fragilis Lipid A have chain lengths of 15 to 17 carbon atoms, whereas those of E.
coli have 12 to 14 carbons. This is noteworthy since it was shown that biologically
more active LPS usually contains shorter fatty acids with 10-14 carbon atoms. 2)
There are 4 to 5 fatty acids per diglucosamine residue in B. fragilis Lipid A, rather
than 6 in E. coli. In particular, B. fragilis NCTC 9343 Lipid A structure has a
considerable heterogenicity in this manner since it contains both tetra- and penta-
acyl chains. 3) There is only one (3-hydroxy fatty acid substituted with a
nonhydroxylated fatty acid in B. fragilis, whereas there are two in E. coli. 4) B.
fragilis Lipid A lacks a phosphate domain on the C4 of the non-reducing
glucosamine but it has a phosphate group on CI of the reducing amino sugar. 5) The
KDO domain in B. fragilis is most likely substituted by a phosphate group(s) not
present on E. coli KDO groups (Weintraub et al., 1989; Lindberg et al., 1990;
Patrick, 1993).
It is interesting to note that the same distribution of five fatty acids in B. fragilis
Lipid A are also found in the endotoxically non-active Lipid A of R. sphaeroides
(Weintraub et al., 1989). It is also found that tetraacyl structures of
lipopolysaccharide (LPS) and Lipid A act like LPS that has been partially
enzymatically deacylated (dLPS) by acyloxyacyl hydrolase. These compounds
antagonise other LPS structure such as hexa-acylated LPS at the surfaces of different
human cells such as monocyte, neutrophils, endothelial cells and whole blood human
cells (Loppnow et al., 1989; Kovach et al., 1990; Nogare and Yarbrough, 1990;
Riedo et al., 1990; Golenbock et al., 1991; Lynn et al., 1991; Feist et al., 1992;
Kitchens et al., 1992). Kitchens and Munford (1995) demonstrated that such dLPS
can antagonize LPS in three ways. 1) When the concentration of LBP in the medium
was suboptimal for stimulating LPS-CD14 binding, low concentrations of dLPS were
capable of competing with LPS for binding to LBP and inhibit the binding of LPS to
CD 14 competitively. 2) When LBP was present in excessive concentration, dLPS
could compete with LPS for binding CD14, but only at dLPS concentrations that
were at or above 100 ng/ml. 3) In contrast, low concentrations of dLPS (lng/ml)
inhibited LPS, at 3ng/ml, induction of interleukin-8 response without antagonizing
LPS binding to CD14. Underacylated LPS, such as penta- or tctra- acylated LPSs,
have been reported to have an antagonism activity against hexa-acylated LPS like
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those ofE.coli. Penta-acylated LPS isolated from R. sphaeroides displays the ability
to antagonize E. coli LPS (Golenbock et al., 1991). Mainly, tetra-acylated LPS of P.
gingivalis and the penta-acylated one also have such an antagonism property
(Bainbridge et al., 2002; Darveau et al., 2004b). Penta-acylated LPS of B. fragilis
has also this ability to antagonize E.coli LPS (Delahooke et al., 1995). A penta-
acylated form of mutant E. coli LPS can successfully antagonize the capability of
hexa-acylated E. coli LPS to activate human endothelial cells (Somerville et al.,
1996). In addition, the synthetic penta-acylated Lipid A-like compound, E5531, is
also considered as a potential therapeutic antagonist agent for LPS-dependent cell
activation and therefore stops septic shock development (Christ et al., 1995; Kawata
et al., 1999).
Fig 3.12 demonstrates that R. sphaeroides LPS is comparable to the cell culture
medium in producing almost no cytokine. This finding is consistent with a previous
study showing that when using RAW 264.7 cells and L929 cells as an indicator cell,
Lipid A from R. sphaeroides was not able to induce TNF-a (Takayama et al., 1989).
Moreover, another previous study reported that the LPS of R. sphaeroides ATCC
17023 is nontoxic (Strittmatter et al., 1983). Fig 3.12 also shows that R. sphaeroides
LPS managed to inhibit the effect of E. coli and Ps. aeruginosa LPSs (A and C).
However, there was no measurable differences between the TNF-a produced by
different B. fragilis LPSs by themselves and B. fragilis LPSs with 100|ag/ml of R.
sphaeroides LPS. This may indicate that R. sphaeroides LPS has no effective
antagonism activity on B. fragilis LPSs. In fact, a previous study demonstrated that
LPS from R. sphaeroides had no inhibition effect on cytokine responses induced by
repurified P. gingivalis, which has LPS structure identical to that of B. fragilis, or
Prevotella intermedia (Kirikae et al., 1999).
4.4 TLR specificity of B. frasilis and R. sphaeroides LPSs and heat killed B.
fragilis
Another main aim of this study was to elucidate the TLR specificity of different B.
fragilis LPS preparations extracted by different methods and different heat killed B.
fragilis populations as demonstrated in section 3.7. Although, TLR4, in particular, is
considered to be the main transducer of classic LPS activity (Poltorak et al., 1998a;
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Hoshino et al., 1999; Hirschfeld et al., 2000; Lien et al., 2000), there are
contradictory reports as to whether TLR2 (Erridge et al., 2004a; Erridge et al.,
2007a) or TLR4 (Mancuso et al., 2005) play a principal role in signalling of B.
fragilis LPS, as a non-classical lipopolysaccharide. A recent study has demonstrated
that penta-acylated and tetra-acylated LPSs like those of B. fragilis and P. gingivalis
functionally antagonize hexa-acylated LPS in its signalling via human TLR4 by
direct binding to the co-receptor human MD2. It has been shown that these
antagonistic LPSs can either directly compete with hexa-acylated LPSs, such as E.
coli LPS, for the same binding site on MD-2; or antagonistic LPS/MD2 complexes
can inhibit E. coli LPS/MD2 complexes signalling at TLR4 (Coats et al., 2007).
Comparison between Fig 3.30 and Fig 3.31 clearly demonstrated that the
repurification method made a huge difference in the intensity of the TLR signalling
but contributed nothing to the TLR specificity. The contribution of the repurification
method was clearly profound with all extraction methods and especially with TMP
and PCP methods. It is also possible to assume that although different extraction
methods may affect the conformational properties of Lipid A moieties of different B.
fragilis LPSs, this effect did not change the TLR specificity. That is the possible
reason why all 10 unpurified and purified B. fragilis LPSs, together with different
heat killed B. fragilis populations had an obvious TLR2 specificity through
transfection experiment. None of them produced an LPS structure that signalled
through TLR4 even after applying the rcpurification method (see Fig 3.30 and Fig
3.31). Using intact cells of B. fragilis in terms of heat killed bacteria of different
capsular polysaccharide populations was a further confirmation that B. fragilis does
not have a ligand that can signal through TLR4 although the intensity of TLR2
specificity by heat-killed B. fragilis (Fig 3.32) are comparable to their levels with the
unpurified B. fragilis LPSs demonstrated in Fig 3.30. Fig 3.32 showed that R.
sphaeroides LPS also has a notable TLR2 specificity. Probably this is due to the
presence of trace amounts of protein contaminants or lipoprotein even after the
repurification method. This is obvious when the TLR2 specificity of this LPS, which
is lower, is compared with purified RSlp than unpurified RSlu (Fig 3.32).
The method of repurification of LPS preparations to eliminate the protein
contaminants has shown notable differences in signalling through either TLR2 or
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TLR4. Recent studies have raised the issue of the diversity of these proteins and
indicate the need for investigations to clarify that a specific LPS preparation is free
from specific protein contaminants. These outer membrane proteins (OMP) include
molecules such as murein lipoprotein (MLP), peptidoglycan-associated lipoprotein
(PAL), and outer membrane protein A (OmpA) that are found to be present in LPS
from rough and smooth bacteria (Hellman et al., 2003). One relevant study also
identified two lipoproteins, Lip 19 and Lip 12 in LPS derived from Escherichia coli
K-12 strain LCD25 to be responsible for TLR2 signalling (Lee et al., 2002).
Moreover, one recent study revealed that PAL is biologically active and is released
into serum in close association with LPS. PAL alone or through synergistic action
with LPS can induce inflammation via TLR2 (Liang et al., 2005). Furthermore,
another study showed that PAL is released into the blood circulation in Gram-
negative sepsis and caused an inflammatory immune response that led to death in
mice (Hellman et al., 2002). Such findings are in a way supportive to our findings
since the TLR2 signalling through heat killed bacteria or unpurified B. fragilis LPSs
are higher than that of repurified LPSs. This may be in part due to other
proinflammatory OMP molecules without excluding the role of ligands such as
peptidoglycan which is known to signal via TLR2. Many experimental differences
between in vitro assays and in vivo human LPS models should be taken into
consideration when trying to understand what really happens inside the host. For
example, the in-vitro assay whatever its type, a fresh blood sample from volunteers
or cell line culture, are not subjected to the remarkable decrease in numbers, as
occurs in in-vivo model, of circulatory monocytes in particular and white blood cells
counts in general after LPS administration as shown by Richardson and others
(1989). One recent report gave such a difference in another dimension when it was
suggested that TLR2 and TLR4 are initially down-regulated on monocytes 2h after
the LPS in-vivo administration, and they were then up-regulated reaching a
significant level for TLR2 by 8 h (Marsik et al., 2003).
The reason for the inconsistency between this study's findings and Erridge and
others (2004a; 2007a) which all showed TLR2 specificity of B. fragilis LPS and heat
killed B. fragilis and those of Mancuso and his colleagues (2005) which showed
TLR4 specificity of B. fragilis LPS is unclear. However, this discrepancy may be due
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to culture conditions or even mixed bacterial cultures. In this regard, the findings of
the current study are preferred since it contains a diverse range of B. fragilis LPS
preparations together with different heat killed whole B. fragilis cells.
Although the TLR specificity of the classical LPS, such as those of E. coli, went
through a period of some controversy, nowadays it is general accepted that TLR4 is
an essential receptor for such a kind of LPS despite the fact that as yet there is no
clear evidence for the direct physical contact between TLR4 and LPS. This is not to
say, however, that TLR4 is the universal and the only receptor from the TLR
receptor family that detects LPS structures. In fact the majority of the studies
demonstrating TLR4 as an essential receptor for LPS signalling, have concluded this
by using enterobacterial LPS of a classical kind especially that extracted from E. coli
or Salmonella (see Table 1.1). This may have occurred because endotoxin
preparations from these bacteria are commercially available and the fact that the
structures of both are well characterised as mentioned by Erridge and others (2007a).
Accordingly, it seems inaccurate to conclude that TLR4-deficient mice do not
respond to LPS. It is more precise to say that they do not respond to the effect of
classical LPS such as those extracted from E. coli. Although a recent study by
Mancuso and others (2005) reported that repurified B. fragilis LPS failed to induce
TNF-a production in macrophages from LPS non-responder C3H/HeJ mice, which
have a point mutation in TLR4 that functions as a dominant-negative mutation. The
same preparation caused the release TNF-a from peritoneal macrophages from
TLR2-deficient mice. But this is not directly evident since there remains the strong
possibility that different species of animals use different TLR receptors in LPS
signalling as proposed by Takeuchi and others (1999). In fact, one of major
disadvantage of using a cell line from a dominant-negative TLR4 mouse strain is the
fact that binding of LPS to TLR4 is still taking place at normal levels. Since the
mutation point His712Pro is located in the intracellular domain of TLR4, this most
likely leaves the LPS binding properties of TLR4 unchanged (Lorenz et al., 2002b).
On the other hand, LPS non-responder C57BL/10ScNCr mice, which have a
complete deletion of the TLR4 gene, has the ability to produce the cytokine of
macrophage inflammatory protein-2 in the absence of TLR4 (Lorenz et al., 2002b).
Another study showed that mouse peritoneal macrophages appear not to be the key
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cells responsible for the overall host response during endotoxic shock. In fact, it was
suggested that the structural requirements for cells like human monocytes to
recognize LPS structures are more strict than those for murine cells (Matsuura et al.,
1999). Nevertheless, human cells broadly recognize more LPS-antagonist structures
compared to those recognized by murine cells (Matsuura et al., 1999). Such findings
emphasize the need to validate the association between in-vivo systems and in-vitro
systems when attributing specific functions to a cell type (Amura et al., 1998). In the
same context, it is found that P. gingivalis LPS, which is structurally related to B.
fragilis LPS, can act on TLR4 in a species-dependent manner since it does not signal
through mouse-TLR4 (Hirschfeld et al., 2001) or human-TLR4 (Martin et al., 2001;
Hajishengallis et al., 2002c) but shows the ability to signal a hamster-TLR4 and to be
an antagonist for human-TLR4 (Yoshimura et al., 2002). Another study found that
the same species-dependency for R. sphaeroides LPS which has the ability to act as
an antagonist for human and mouse TLR4 but as an agonist for hamster TLR4 (Lien
et al., 2000). It is probable that murine TLR4 is unable to distinguish between
conical and cylindrical conformation styles of Lipid A but human TLR4 is able to do
so. In fact a previous study reported that a molecule like Lipid IVa acts as an
antagonist for human MD-2, the essential co-receptor for TLR4, but acts as an
agonist with murine MD-2 (Akashi et al., 2001). The possible reason for the
difference between human and mouse TLR4 is probably the differences between
mouse and human microbial flora in a way the human immune system needs another
receptor to differentiate between "danger" and "non-danger" LPSs but the mouse
immune system does not need such an extra receptor since it considers all LPS
species as a "danger" signal.
It has been reported that P. gingivalis LPS, which was used as a TLR2 positive
control in this study, is highly heterogeneous since it contains more than one Lipid A
structure. This is why it is sometimes considered as a natural antagonist for E. coli
LPS and other oral bacteria and in term of TLR specificity it is also reported to be a
TLR4 antagonist in some cell types (Darveau et al., 2004b). However, P. gingivalis
LPS extracted from lipoprotein-deficient mutant showed a noticeable decline in
TLR2 signalling (Asai et al., 2005). Moreover, another study showed that
underacylated LPSs such as tetra- or penta-acylated LPSs produce reduced TLR4-
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dependent cell stimulation by shifting the interaction of the LPS/MD-2 complex with
TLR4 in a way that lessens receptor activation (Teghanemt et al., 2005).
Thus it could be hypothesized that different LPS species signal through different
TLR receptors. In fact it is tempting to speculate that TLR4 seems to be the essential
receptor for the "danger" LPS while other kinds of LPS which are known to be less
active than classical LPS in their ability to induce immune responses seem to be
detected via other member of TLR family such as TLR2. This may be conceivable in
the light of a large body of evidence that addresses the broad specificity ofTLR2 as a
receptor for a wide range of bacterial structures which are considered to be low
immune inducers compared with LPS from E. coli for example. Furthermore, many
studies observed that TLR2-transfected cells respond to a wide range of bacteria and
bacterial products, including Gram-positive bacteria, spirochaetes, mycoplasma and
mycobacteria (Kirschning et al., 1998; Yang et al., 1998; Brightbill et al., 1999;
Hirschfeld et al., 1999; Lien et al., 1999; Means et al., 1999a; Means et al., 1999b;
Schwandner et al., 1999; Yoshimura et al., 1999). This situation makes it difficult to
identify a common microbial pattern among all the ligands that are detected by a
single TLR2 molecule. Nevertheless, there is no clear evidence that TLR2 directly
binds any of these ligands (Lien et al., 1999). One study indicated that TLR2 tends to
form a functional complexes with TLR6 in order to increase its range of recognition
(Ozinsky et al., 2000). This complex formation may occur between either TLR2 and
other TLRs or other TLRs with each other.
From the genetic point of view, there is no reason to suppose that Tlr4 is the only
gene that makes up the core of signalling machinery since one recent study has
reported the presence of new locus, Lps2, which is required for TNF production in
response to LPS (Hoebe et al., 2003b). The Lps2 locus is similar in phenotypic effect
to Tlr4 and does not represent a novel allele of any of the genes that are known to
determine LPS signalling mechanism. Unlike Tlr4, the Lps2 locus does not exclude
signalling initiated by peptidoglycan or unmethylated DNA (Floebe et al., 2003a;
Hoebe et al., 2003b).
Moreover, new players have come on the scene and are currently attracting a
growing level of attention. This is a group of molecules that show a negative
143
regulation activity against TLRs and include SIGIRR, IRAK-M, MyD88s, Tollip,
ST2, Nod2 and Triad3A (Kobayashi et al., 2002; Zhang and Ghosh, 2002; Burns et
al., 2003; Wald et al., 2003; Chuang and Ulevitch, 2004; Watanabe et al., 2004). Of
much interest is RP105 which was originally considered as a B cell specific molecule
capable of controlling B cell proliferation (Miyake et al., 1994; Miyake et al., 1995).
One recent study has shown that RP105 is a specific homologue of TLR4 and is not
only found on B cells. Moreover, a complex of RP105/MD-1 directly interacts with
TLR4/MD-2 to inhibit its ability to bind LPS in a dose-dependent manner in a
HEK293 cells assay. Compared to wild-type mice, RP105-deficient mice produced
notably more TNF-a in response to a low dose ofE.coli LPS while a high dose of the
same LPS stimulated an augmented and accelerated endotoxicity. This strongly
implicates RP105 as a physiological negative regulator of TLR4 responses
(Divanovic et al., 2005). Such findings add another level of competition to LPS
signalling since it raises the possibility of negative regulation molecules for other
TLRs or even multiple negative regulatory activities for a molecule such as RP105.
4.5 Proposed scenario for non-classical LPS community in the gut and their
signalling receptor
The intention of this section is to try to summarize our understanding on two fronts,
the role of gut flora as the main source of endotoxin in septicaemia and the role of
TLR2 as a potential receptor for non-classical LPS. Innate immune mechanisms,
such as epithelial production of a-defensins, mucins and secretory immunoglobulin
A contribute to the prevention of bacteria from crossing the mucosal barrier (Hooper
and Gordon, 2001). Moreover, non-pathogenic bacteria may directly enhance the
capacity of intestinal epithelium to limit the immune response. In fact, one study
showed that an avirulent Salmonella strain abolished the induction of inflammatory
cytokines in human intestinal epithelial cells by interacting with human epithelia to
inhibit the NF-kB activation pathway by stopping IkB-oc degradation, which
eventually prevents subsequent activation of NF-kB dimmer (Neish et al., 2000).
Additionally, commensals like Bacteroides thetaiotaomicron are found to antagonise
transcription factor NF-kB selectively (Kelly et al., 2004). These findings suggest a
144
kind of tolerance mechanism is involved by the commensals that protect against
potential proinflammatory stimuli (Neish et al., 2000). Furthermore, the presence of
anaerobic bacteria prevent the enteric colonization of exogenous bacteria via
"colonization resistance" processes (van der Waaij et al., 1972). These bacteria also
appeared to play a role in preventing the translocation of indigenous gut bacteria.
One previous study showed that the administration of metronidazole, which
selectively eliminates gut anaerobic bacteria, to mice significantly contributed to
increased rates of dissemination of intestinal bacteria into mesenteric lymph nodes.
This kind of bacterial dissemination did not occur when mice were pretreated with
streptomycin, which selectively eliminate gut facultative Gram-negative bacilli. This
finding suggests that the absence of anaerobic bacteria facilitated the translocation of
the intestinal facultative anaerobic bacteria (Wells et al., 1987). This may explain the
observation that facultative anaerobic gut flora are the most common translocated
organism that cross the intestinal barrier in cases of sepsis when these
ecological/immunological barriers are no longer effective. In fact, one previous study
reported that E. coli was the translocated organism identified in 54% of cases
(O'Boyle et al., 1998)
In the gut environment, intestinal epithelial cells are considered as an essential
barrier that prevent the translocation of the gut flora or its products to the blood
circulation. These cells are non-responsive to LPS and other bacterial products since
they either express low levels or do not express CD14, TLR2 and TLR4 molecules
and the co-receptor MD-2 (Cario and Podolsky, 2000; Abreu et al., 2001; Melmed et
al., 2003; Fischer et al., 2006). However, another study showed that TLR2 mRNA
was detected in human intestinal epithelium whereas TLR4 mRNA was not (Naik et
al., 2001b). At mucosal surfaces, epithelial cells have the capacity to respond to
pathogens by secreting chcmokines that recruit circulating polymorphonuclear cells
and monocytes (Kagnoff and Eckmann, 1997; Mahida and Johal, 2001). Such
findings seem to be scientifically logical as the intestinal epithelium should stay
immunologically inert in response to gut flora and their LPS, but must retain its
capability to express TLR4 when "danger" LPS (i.e. TLR4 agonist) is sensed (Abreu
et al., 2002)
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Other potential factors came from one recent study which has demonstrated that
although TLR2 surface expression is unaffected by aging, it has been shown that
there was a highly significant defect in TLRl/2-induced TNF-a and IL-6 production
from peripheral blood monocytes of older adults (>65 years) compared with young
controls (21-30 years) (van Duin et al., 2007). This finding may shed some light on
findings from another study that showed that microbial translocation of gut origin
flora significantly increases with elderly patient (>70 years) (O'Boyle et ah, 1998).
On the other hand, monocyte mRNA and cell-surface receptor expression of TLR4
were increased 2.4-fold (P < 0.05) versus 1.7-fold (P < 0.02) in patients compared
with normal controls respectively(Calvano et al., 2003).
In the light of these findings, one can propose a scenario relating to what happens in
the gut when endotoxin is translocated to the blood circulation to start the events of
sepsis. In this case, it has been proposed that B. fragilis LPS has a protective role if it
is assumed as "non-danger" LPS which may inhibit classical kind of LPS which is
proposed to be kind of "danger" LPS. On the other hand, the ability of B. fragilis
LPS to induce low cytokine production such as TNF-a, is something that might keep
the immune response alert or might contribute to the immune tolerance against LPS.
This protective role might be dramatically changed in the case of disruption of the
permeability barrier of the large bowel by means of inflammation-mediated
mechanisms. Huge amounts of LPS from the gut flora, with anaerobic bacteria
representing the main species, may translocate to the blood circulation leading to the
probable over stimulation of TLR2 which may contribute to septic shock with other
kinds of LPS acting as TLR4-agonists. In fact, B. fragilis has the antigenic variation
capacity that may contribute to both its proposed protective role as a member of the
normal intestinal flora and its pathogenic mode as an opportunistic pathogen (Patrick
et al., 1999; Sears, 2005).
Another potential way to evaluate the role of TLR2 in signalling the so called "non-
danger" LPS came from a study reporting that blood cells from farmers' children
express significantly higher amounts of CD 14 and TLR2 on their surfaces than those
from non-farmers' children (Lauener et al., 2002). These findings suggested that
TLR2 with specificity towards "non-danger" ligands is also affected by the
environment. It is proposed that the farm environment contains higher concentrations
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of the bacterial cell wall component lipopolysaccharide (endotoxin) than those of
non-farming environments. This environmental situation which exerts a relatively
high "endotoxic pressure" on the immune system might change some "danger" LPS
to be "non-danger" in term of how the immune system deals with it. The more
simple interpretation is that TLR2 plays a central role in LPS tolerance dependent on
both the kind of LPS and quantity of it. Actually, in-vivo studies on intestinal
epithelial cell lines have revealed that extended exposure to LPS or lipoteichoic acid
leads to both tolerance and cross-tolerance to other ligands by mechanism which
include a decrease in TLR surface expression (Abreu et al., 2005)
4.6 Future directions
There is still much to be addressed in the field of LPS signalling and interactions
between different kinds of LPS. Based on the findings from this study, many
questions have been brought up that, if answered, would shed more light on the
activity of non-classical LPS preparations and its signalling machinery.
1) The interaction between different LPSs that signal different TLR receptor is a
direct approach to investigate these kinds of interactions at the TLR level
bearing in mind the bacterial species that inhabit the gut use more than one
cell system such as human monocytes and intestinal epithelial cells
2) The interactions between different LPSs that propose to have either identical
or very similar LPS activities such as different species of Bacteroides spp and
P. gingivalis, or antagonistic LPS activity such as that from R. sphaeroides
3) The current findings with others that both TLR4 and TLR2 appeared to be
involved in LPS signalling process raise the question as to whether they act
independently in a gut environment in particular, or whether they cooperate
together to keep the normal balance between "danger" and "non-danger"
LPSs in that specific environment.
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